Polymorphisms associated with hypertension

ABSTRACT

The invention discloses a collection of polymorphic sites in genes know or suspected to have a role in hypertension. The invention provides nucleic acids including such polymorphic sites. The nucleic acids can be used as probes or primers or for expressing variant proteins. The invention also provide methods of analyzing the polymorphic forms occupying the polymorphic sites.

CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims the benefit of the U.S. provisional ApplicationNo. 60/084,641, filed May 7, 1998, which is incorporated by reference inits entirety for all purposes.

The work described in this application was funded, in part, by a grantfrom the National Heart, Lung & Blood Institute (U10 HL54466), which mayhave certain rights in this invention.

BACKGROUND OF THE INVENTION

Hypertension, or high blood pressure, is a common disease affecting 50million Americans and contributing to over 200,000 deaths annually fromstroke, myocardial infarction, and end-stage renal disease. The diseaseis multifactorial and numerous genetic and nongenetic components, suchas salt intake, age, diet, and body mass, are suspected to contribute. Aspecific cause of hypertension can typically be identified in only asmall percentage of patients. Other patients with abnormally high bloodpressure of unknown cause are said to have essential hypertension.

The existence of a genetic component to hypertension is known from twinstudies, which have revealed a greater concordance of blood pressure inmonozygotic twins that in dizygotic twins. Similarly, biologicalsiblings have show greater concordance of blood pressure than adoptivesiblings raised in the same household. Such studies have suggested thatup to about 40% of the variations in blood pressure in the populationare genetically determined.

There is a substantial pool of candidate genes that may contribute tothe genetic component of hypertension. Because blood pressure isdetermined by the product of cardiac output and vascular resistance,candidate genes may act through either pathway. Physiologic pathwayswhich are know to influence these parameters include therenin-angiotensin-aldosterone system, which contributes to determinationof both cardiac output and vascular resistance. In this pathway,angiotensinogen, a hormone produced in the liver, is cleaved by anenzyme called renin to angiotensin I, which then undergoes furthercleavage by angiotensin I-converting enzyme (ACE) to produce the activehormone angiotensin II (AII). All acts through specific AT1 receptorspresent on vascular and adrenal cells. Receptors present on vascularcells cause vasoconstriction of blood vessels. Receptors present onadrenal cells cause release of the hormone aldosterone by the adrenalgland. This hormone acts on the mineralocorticoid receptor to causeincrease sodium reabsorption largely through a renal epithelial sodiumlocation. Other candidate genes are those of peripheral and centraladrenergic pathways, which have dominant effects on cardiac iontropy,heart rate and vascular resistance; a variety of renal ion channels andtransporters, which determine net sodium absorption and henceintravascular volume; calcium channels and exchangers and nitric oxidepathways, whose activity influences vascular tone. Another candidategene encodes atrial natriuretic factor precursor, which is cleaved toatrial natriuretic peptides, found in the heart atrium, an endocrineorgan controlling blood pressure and organ volume.

For some of the above candidate genes, variant forms have beenidentified that occur with increased frequency in individuals withhypertension. For example, a number of the polymorphisms have beenreported in the angiotensinogen gene (AGT). In one of these, an M/Tsubstitution at position 235, the T allele occurs more frequently inindividuals with hypertension suggesting that this polymorphic form is acause of hypertension or in equilibrium dislinkage with anotherpolymorphism that is a cause. Jeunmaitre et al., Am. J. Hum. Genet. 60,1448-1460 (1997). Two other genes within therenin-angiotensin-aldosterone system also have variant forms correlatedwith specific forms of hypertension, that is, aldosterone synthase geneand the gene encoding the β-subunit of the epithelial sodium channelinduced by the mineralocorticoid receptor. Lifton et al., Proc. Natl.Acad. Sci. USA 92, 8548-8551(1995).

Despite these developments, only a minute proportion of the totalrepository of polymorphisms in candidate genes for hypertension has beenidentified, and the primary genetic determinants of hypertension remainunknown in most affected subjects, as does the nature of the interactionbetween different genetic determinants. The paucity of polymorphismshitherto identified is due to the large amount of work required fortheir detection by conventional methods. For example, a conventionalapproach to identifying polymorphisms might be to sequence the samestretch of oligonucleotides in a population of individuals by dideoxysequencing. In this type of approach, the amount of work increases inproportion to both the length of sequence and the number of individualsin a population and becomes impractical for large stretches of DNA orlarge numbers of persons.

SUMMARY OF THE INVENTION

The invention provides nucleic acids of between 10 and 100 basescomprising at least 10 contiguous nucleotides including a polymorphicsite from a sequence shown in Table 1, column 8 or the complementthereof. The nucleic acids can be DNA or RNA. Some nucleic acids arebetween 10 and 50 bases and some are between 20 and 50 bases. The baseoccupying the polymorphic site in such nucleic acids can be either areference base shown in Table 1, column 3 or an alternative base shownin Table 1, column 5. In the some nucleic acids, the polymorphic site isoccupied by a base that correlates with hypertension or susceptibilitythereto. Some nucleic acids contain a polymorphic site having twopolymorphic forms giving rise two different amino acids specified by thetwo codons in which the polymorphic site occurs in the two polymorphicforms.

The invention further provides allele-specific oligonucleotides thathybridize to a nucleic acid segment shown in Table 1, column 8 or itscomplement, including the polymorphic site. Such oligonucleotides areuseful as probes or primers.

The invention further provides methods of analyzing a nucleic acidsequence. Such methods entail obtaining the nucleic acid from anindividual; and determining a base occupying any one of the polymorphicsites shown in Table 1 or other polymorphic sites in equilibriumdislinkage therewith. Some methods determine a set of bases occupying aset of the polymorphic sites shown in Table 1. In some methods, thenucleic acid is obtained from a plurality of individuals, and a baseoccupying one of the polymorphic positions is determined in each of theindividuals. Each individual is then tested for the presence of adisease phenotype, and correlating the presence of the disease phenotypewith the base, particularly hypertension.

In another aspect, the invention provides nucleic acids comprising anisolated nucleic acid sequence of Table 1, column 8 or the complementthereof, wherein the polymorphic site within the sequence or itscomplement is occupied by a base other than the reference base show inTable 1, column 3. Such nucleic acids are useful, for example, inexpression of variant proteins or production of transgenic animals.

The invention further provides methods of diagnosing a phenotype. Suchmethods entail determining which polymorphic form(s) are present in asample from a subject at one or more polymorphic sites shown in Table 1,and diagnosing the presence of a phenotype correlated with the form(s)in the subject.

The invention also provides methods of screening polymorphic siteslinked to polymorphic sites shown in Table 1 for suitability fordiagnosing a phenotype. Such methods entail identifying a polymorphicsite linked to a polymorphic site shown in Table 1, wherein apolymorphic form of the polymorphic site shown in Table 1 has beencorrelated with a phenotype. One then determines haplotypes in apopulation of individuals to indicate whether the linked polymorphicsite has a polymorphic form in equlibrium dislinkage with thepolymorphic form correlated with the phenotype.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A and 1B depict computer systems suitable for storing andtransmitting information relating to the polymorphisms of the invention.

DEFINITIONS

A nucleic acid can be DNA or RNA, and single- or double-stranded.Oligonucleotides can be naturally occurring or synthetic, but aretypically prepared by synthetic means. Preferred nucliec acids of theinvention include segments of DNA, or their complements including anyone of the polymorphic sites shown in Table 1. The segments are usuallybetween 5 and 100 contiguous bases, and often range from 5, 10, 12, 15,20, or 25 nucleotides to 10, 15, 30, 25, 20, 50 or 100 nucleotides.Nucleic acids between 5-10, 5-20, 10-20, 12-30, 15-30, 10-50, 20-50 or20-100 bases are common. The polymorphic site can occur within anyposition of the segment. The segments can be from any of the allelicforms of DNA shown in Table 1. For brevity in Table 1, the symbol T isused to represent both thymidine in DNA and uracil in RNA. Thus, in RNAoligonucleotides, the symbol T should be construed to indicate a uracilresidue.

Hybridization probes are capable of binding in a base-specific manner toa complementary strand of nucleic acid. Such probes include nucleicacids, peptide nucleic acids, as described in Nielsen et al., Science254, 1497-1500 (1991).

The term primer refers to a single-stranded oligonucleotide capable ofacting as a point of initiation of template-directed DNA synthesis underappropriate conditions (i.e., in the presence of four differentnucleoside triphosphates and an agent for polymerization, such as, DNAor RNA polymerase or reverse transcriptase) in an appropriate buffer andat a suitable temperature. The appropriate length of a primer depends onthe intended use of the primer but typically ranges from 15 to 30nucleotides. Short primer molecules generally require coolertemperatures to form sufficiently stable hybrid complexes with thetemplate. A primer need not reflect the exact sequence of the templatebut must be sufficiently complementary to hybridize with a template. Theterm primer site refers to the area of the target DNA to which a primerhybridizes. The term primer pair means a set of primers including a 5′upstream primer that hybridizes with the 5′ end of the DNA sequence tobe amplified and a 3′, downstream primer that hybridizes with thecomplement of the 3′ end of the sequence to be amplified.

Linkage describes the tendency of genes, alleles, loci or geneticmarkers to be inherited together as a result of their location on thesame chromosome, and can be measured by percent recombination betweenthe two genes, alleles, loci or genetic markers. Loci occurring within50 centimorgan of each other are linked. Some linked markers occurwithin the same gene or gene cluster.

Polymorphism refers to the occurrence of two or more geneticallydetermined alternative sequences or alleles in a population. Apolymorphic marker or site is the locus at which divergence occurs.Preferred markers have at least two alleles, each occurring at frequencyof greater than 1%, and more preferably greater than 10% or 20% of aselected population. A polymorphic locus may be as small as one basepair. Polymorphic markers include restriction fragment lengthpolymorphisms, variable number of tandem repeats (VNTR's), hypervariableregions, minisatellites, dinucleotide repeats, trinucleotide repeats,tetranucleotide repeats, simple sequence repeats, and insertion elementssuch as Alu. The first identified allelic form is arbitrarily designatedas a the reference form and other allelic forms are designated asalternative or variant alleles. The allelic form occurring mostfrequently in a selected population is sometimes referred to as thewildtype form. Diploid organisms may be homozygous or heterozygous forallelic forms. A diallelic polymorphism has two forms. A triallelicpolymorphism has three forms.

A single nucleotide polymorphism occurs at a polymorphic site occupiedby a single nucleotide, which is the site of variation between allelicsequences. The site is usually preceded by and followed by highlyconserved sequences of the allele (e.g., sequences that vary in lessthan 1/100 or 1/1000 members of the populations).

A single nucleotide polymorphism usually arises due to substitution ofone nucleotide for another at the polymorphic site. A transition is thereplacement of one purine by another purine or one pyrimidine by anotherpyrimidine. A transversion is the replacement of a purine by apyrimidine or vice versa. Single nucleotide polymorphisms can also arisefrom a deletion of a nucleotide or an insertion of a nucleotide relativeto a reference allele.

A set of polymorphisms means at least 2, and sometimes 5, 10, 20, 50 ormore of the polymorphisms shown in Table 1.

Hybridizations are usually performed under stringent conditions, forexample, at a salt concentration of no more than 1 M and a temperatureof at least 25° C. For example, conditions of 5×SSPE (750 mM NaCl, 50 mMNa Phosphate, 5 mM EDTA, pH 7.4) and a temperature of 25-300° C. aresuitable for allele-specific probe hybridizations.

An isolated nucleic acid means an object species invention that is thepredominant species present (i.e., on a molar basis it is more abundantthan any other individual species in the composition). Preferably, anisolated nucleic acid comprises at least about 50, 80 or 90 percent (ona molar basis) of all macromolecular species present. Most preferably,the object species is purified to essential homogeneity (contaminantspecies cannot be detected in the composition by conventional detectionmethods).

Linkage disequilibrium or allelic association means the preferentialassociation of a particular allele or genetic marker with a specificallele, or genetic marker at a nearby chromosomal location morefrequently than expected by chance for any particular allele frequencyin the population. For example, if locus X has alleles a and b, whichoccur equally frequently, and linked locus Y has alleles c and d, whichoccur equally frequently, one would expect the haplotype ac to occurwith a frequency of 0.25 in a population of individuals. If ac occursmore frequently, then alleles a and c are in linkage disequilibrium.Linkage disequilibrium may result from natural selection of certaincombination of alleles or because an allele has been introduced into apopulation too recently to have reached equilibrium with linked alleles.

A marker in linkage disequilibrium can be particularly useful indetecting susceptibility to disease (or other phenotype) notwithstandingthat the marker does not cause the disease. For example, a marker (X)that is not itself a causative element of a disease, but which is inlinkage disequilibrium with a gene (including regulatory sequences) (Y)that is a causative element of a phenotype, can be used detected toindicate susceptibility to the disease in circumstances in which thegene Y may not have been identified or may not be readily detectable.Younger alleles (i.e., those arising from mutation relatively late inevolution) are expected to have a larger genomic sequencement in linkagedisequilibrium. The age of an allele can be determined from whether theallele is shared between ethnic human groups and/or between humans andrelated species.

DETAILED DESCRIPTION

The invention provides a substantial collection of novel polymorphismsin several genes encoding products known or suspected to have roles inbiochemical pathways relating to blood pressure. Detection ofpolymorphisms in such genes is useful in designing and performingdiagnostic assays for hypertension. Analysis of polymorphisms is alsouseful in designing prophylactic and therapeutic regimes customized tounderlying abnormalities. As with other human polymorphisms, thepolymorphisms of the invention also have more general applications, suchas forensics, paternity testing, linkage analysis and positionalcloning.

I. Novel Polymorphisms of the Invention

The invention provides polymorphic sites in 75 candidate genes, known orsuspected to have roles in hypertension. A gene was designated acandidate based on known or suggested involvement in blood pressurehomeostasis and/or hypertension in one of the following biochemicalpathways: renin-angiotensin, neural, or hormonal pathways regulatingblood pressure; regulation of vascular constriction, growth, and repair;ion and other small molecule transportation pathways in the kidney; and,regulation of glucose metabolism. Experimental evidence supportingselection of candidate genes included blood pressure physiology, animalmodels with altered blood pressure (including transgenic and knockoutmouse or rat animal models), and human genetic linkage and associationstudies.

To maximize the chances of identifying informative single nucleotidepolymorphisms (SNPs), DNA samples from 40 Africans and 35 US.individuals of Northern European descent were screened to include both arange of human genetic diversity and hypertension phenotype diversity.Human genetic diversity is greater within African, as compared toEuropean, Asian or American, populations (The History and Geography ofHuman Genes (Cavalli-Sforza et al., Eds.,Princeton University Press,Princeton, N.J., 1994)). There are also significant differences in theprevalence and phenotype of hypertension between Africans (or US Blacks)and Northern Europeans (or US Whites). Hypertension has a greaterprevalence, an earlier onset and a higher frequency of salt-sensitivecases in populations of African descent. The individuals sampled wereselected from the top and bottom 2.5th percentile of a normalized bloodpressure distribution. Regression analysis was performed within eachcommunity sample, of systolic, diastolic and mean arterial bloodpressure against age and sex, and calculated the ranked frequencydistribution of residuals. Equal numbers of individuals were selectedfrom both ends of this latter distribution to maximize potential geneticdifferences it the genes screened for SNPs.

874 SNPs in 75 individuals were identified at a frequency of one SNP per217 bases. 387 SNPs were in coding sequences, 150 in introns, and 337 in5′ and 3′ UTRs. Of coding sequence chances, 178 and 209 SNPs led tosynonymous and nonsynonymouse substitutions in the translated protein.On average, 12 SNPs were identified per gene, with the number rangingfrom zero (HSD11) to 54 (PGIS), with ten genes harboring 20 or moreSNPs.

A large collection of polymorphisms of the invention are listed inTable 1. The first column of the Table 1 lists the gene and exon inwhich a given polymorphism occurs. For example, ACEEX13 means that apolymorphism occurs in exon 13 of angiotensin I-converting enzyme.AGTEX2 means that a polymorphism occurs in exon 2 of the angiotensinogengene. The full names of the 75 genes shown in Table 1 are shown in Table3. Sequences of each of the genes are available at http//World WideWeb.ncbi.nlm.nih.gov/Entrez/nucleotide.html. The second column of Table1 shows the position of a polymorphism. Numbering of nucleotides followsthat of previously published reference sequences with nucleotides insequence tags shown in column 8 being assigned the same number as thecorresponding nucleotide in a reference sequence when the two aremaximally aligned. In general, nucleotides in exons are numberedconsecutively from the first base of the exon. Column 3 shows the baseoccupying the polymorphic position in a previously published sequence(arbitrarily designated a reference sequence). Column 4 of Table 1 showsthe population frequency of the reference allele. For example atposition 138 of exon 13 of ACE, a C nucleotide occurs in 63% of thepopulation. Column 5 of the table shows a nucleotide occupying apolymorphic position that differs from previously published sequences.An allele containing such a nucleotide is designated an alternativeallele. Column 6 of the Table shows the population frequency of thealternative allele. Column 7 of the Table shows the population frequencyof heterozygosity at a polymorphic position. For example, for thepolymorphic position at position 138 of exon 13 of the ACE gene, 37% ofthe human population are heterozygous. A high frequency ofheterozygosity is advantageous in many applications of polymorphisms.The eighth column of the table shows a polymorphic position and about 15nucleotides of flanking sequence on either side. The bases occupying thepolymorphic position are indicated using IUPAC ambiguity nomenclature.For polymorphisms occurring in coding regions, columns 9 and 10 of theTable indicate the codons of the reference and alternate allelesincluding the polymorphic site. These columns are left blank forpolymorphisms occurring in noncoding regions. Column 11 indicateswhether the change between reference and alternate alleles is synonymous(i.e., no amino acid substitution due to polymorphic variation),nonsynonymous (i.e, polymorphic variation causes amino acidsubstitution). If the polymoprhic site does not occur in a codingregion, column 11 characterizes the polymorphic site as “other.” Forpolymorphic sites occurring in noncoding regions column 12 indicates thetype of region in which the site occurs (e.g., 5′ UTR, intron). Forpolymorphic sites occurring in coding regions, column 12 indicates theamino acid encoded by the codon of the reference allele in which thepolymorphic site occurs. Column 13 indicates the amino acid encoded bythe codon of the alternative allele in which the polymorphic siteoccurs.

The polymorphisms shown in Tables 1 were identified by resequencing oftarget sequences from unrelated individuals of diverse ethnic andgeographic backgrounds by hybridization to probes immobilized tomicrofabricated arrays. About 190 kb of genomic sequence from 75candidate genes in 75 humans (150 alleles) or about 28 MB total wasanalyze. The sequence included 87 kb coding DNA, 25 kb intron and 77 kbof 5′ and 3′ UTR sequences. Multiple target sequences from an individualwere amplified from human genomic DNA using primers complementary topublished sequences. The amplified target sequences were fluorescentlylabelled during or after PCR.

Polymorphisms were identified by hybridization of amplified DNA toarrays of oligonucleotide probes. Each genomic region was amplified bythe polymerase chain reaction (PCR) in multiple segments, ranging from80 bp to 14 kb, by both conventional and long PCR protocols. 205distinct PCR products, averaging 3 kb, representing all 75 genes werepooled for each individual for each chip design

The strategy and principles for design and use of arrays ofoligonucleotide probes are generally described in WO 95/11995. Thestrategy provides arrays of probes for analysis of target sequencesshowing a high degree of sequence identity to the published sequencesdescribed above. A typical probe array used in this analysis has twogroups of four sets of probes that respectively tile both strands of areference sequence. A first probe set comprises a plurality of probesexhibiting perfect complementarily with one of the reference sequences.Each probe in the first probe set has an interrogation position thatcorresponds to a nucleotide in the reference sequence. That is, theinterrogation position is aligned with the corresponding nucleotide inthe reference sequence, when the probe and reference sequence arealigned to maximize complementarily between the two. For each probe inthe first set, there are three corresponding probes from threeadditional probe sets. Thus, there are four probes corresponding to eachnucleotide in the reference sequence. The probes from the threeadditional probe sets are identical to the corresponding probe from thefirst probe set except at the interrogation position, which occurs inthe same position in each of the four corresponding probes from the fourprobe sets, and is occupied by a different nucleotide in the four probesets. Arrays tiled for multiple different references sequences wereincluded on the same substrate.

The labelled target sequences were hybridized with a substrate bearingimmobilized arrays of probes. The amount of label bound to probes wasmeasured. Analysis of the pattern of label revealed the nature andposition of differences between the target and reference sequence. Forexample, comparison of the intensities of four corresponding probesreveals the identity of a corresponding nucleotide in the targetsequences aligned with the interrogation position of the probes. Thecorresponding nucleotide is the complement of the nucleotide occupyingthe interrogation position of the probe showing the highest intensity(see WO 95/11995). The existence of a polymorphism is also manifested bydifferences in normalized hybridization intensities of probes flankingthe polymorphism when the probes hybridized to corresponding targetsfrom different individuals. For example, relative loss of hybridizationintensity in a “footprint” of probes flanking a polymorphism signals adifference between the target and reference (i.e., a polymorphism) (seeEP 717,113, incorporated by reference in its entirety for all purposes).Additionally, hybridization intensities for corresponding targets fromdifferent individuals can be classified into groups or clusterssuggested by the data, not defined a priori, such that isolates in agive cluster tend to be similar and isolates in different clusters tendto be dissimilar. See WO 97/29212, filed Feb. 7, 1997 (incorporated byreference in its entirety for all purposes). Hybridizations to samplesfrom different individuals were performed separately.

II. Analysis of Polymorphisms

A. Preparation of Samples

Polymorphisms are detected in a target nucleic acid from an individualbeing analyzed. For assay of genomic DNA, virtually any biologicalsample (other than pure red blood cells) is suitable. For example,convenient tissue samples include whole blood, semen, saliva, tears,urine, fecal material, sweat, buccal, skin and hair. For assay of cDNAor mRNA, the tissue sample must be obtained from an organ in which thetarget nucleic acid is expressed.

Many of the methods described below require amplification of DNA fromtarget samples. This can be accomplished by e.g., PCR. See generally PCRTechnology: Principles and Applications for DNA Amplification (ed. H.A.Erlich, Freeman Press, N.Y., N.Y., 1992); PCR Protocols: A Guide toMethods and Applications (eds. Innis, et al., Academic Press, San Diego,Calif., 1990); Mattila et al., Nucleic Acids Res. 19, 4967 (1991);Eckert et al., PCR Methods and Applications 1, 17 (1991); PCR (eds.McPherson et al., IRL Press, Oxford); and U.S. Pat. No. 4,683,202 (eachof which is incorporated by reference for all purposes).

Other suitable amplification methods include the ligase chain reaction(LCR) (see Wu and Wallace, Genomics 4, 560 (1989), Landegren et al.,Science 241, 1077 (1988), transcription amplification (Kwoh et al.,Proc. Natl. Acad. Sci. USA 86, 1173 (1989)), and self-sustained sequencereplication (Guatelli et al., Proc. Nat. Acad. Sci. USA, 87, 1874(1990)) and nucleic acid based sequence amplification (NASBA). Thelatter two amplification methods involve isothermal reactions based onisothermal transcription, which produce both single stranded RNA (ssRNA)and double stranded DNA (dsDNA) as the amplification products in a ratioof about 30 or 100 to 1, respectively.

B. Detection of Polymorphisms in Target DNA

The identity of bases occupying the polymorphic sites shown in Table 1can be determined in an individual (e.g., a patient being analyzed) byseveral methods, which are described in turn.

1. Allele-Specific Probes

The design and use of allele-specific probes for analyzing polymorphismsis described by e.g., Saiki et al., Nature 324, 163-166 (1986);Dattagupta, EP 235,726, Saiki, WO 89/11548. Allele-specific probes canbe designed that hybridize to a segment of target DNA from oneindividual but do not hybridize to the corresponding segment fromanother individual due to the presence of different polymorphic forms inthe respective segments from the two individuals. Hybridizationconditions should be sufficiently stringent that there is a significantdifference in hybridization intensity between alleles, and preferably anessentially binary response, whereby a probe hybridizes to only one ofthe alleles. Some probes are designed to hybridize to a segment oftarget DNA such that the polymorphic site aligns with a central position(e.g., in a 15 mer at the 7 position; in a 16 mer, at either the 8 or 9position) of the probe. This design of probe achieves gooddiscrimination in hybridization between different allelic forms.

Allele-specific probes are often used in pairs, one member of a pairshowing a perfect match to a reference form of a target sequence and theother member showing a perfect match to a variant form. Several pairs ofprobes can then be immobilized on the same support for simultaneousanalysis of multiple polymorphisms within the same target sequence.

2. Tiling Arrays

The polymorphisms can also be identified by hybridization to nucleicacid arrays, some example of which are described by WO 95/11995(incorporated by reference in its entirety for all purposes). One formof such arrays is described in the Examples section in connection withde novo identification of polymorphisms. The same array or a differentarray can be used for analysis of characterized polymorphisms. WO95/11995 also describes subarrays that are optimized for detection of avariant forms of a precharacterized polymorphism. Such a subarraycontains probes designed to be complementary to a second referencesequence, which is an allelic variant of the first reference sequence.The second group of probes is designed by the same principles asdescribed in the Examples except that the probes exhibit complementarilyto the second reference sequence. The inclusion of a second group (orfurther groups) can be particular useful for analyzing shortsubsequences of the primary reference sequence in which multiplemutations are expected to occur within a short distance commensuratewith the length of the probes (i.e., two or more mutations within 9 to21 bases).

3. Allele-Specific Primers

An allele-specific primer hybridizes to a site on target DNA overlappinga polymorphism and only primes amplification of an allelic form to whichthe primer exhibits perfect complementarily. See Gibbs, Nucleic AcidRes. 17, 2427-2448 (1989). This primer is used in conjunction with asecond primer which hybridizes at a distal site. Amplification proceedsfrom the two primers leading to a detectable product signifying theparticular allelic form is present. A control is usually performed witha second pair of primers, one of which shows a single base mismatch atthe polymorphic site and the other of which exhibits perfectcomplementarily to a distal site. The single-base mismatch preventsamplification and no detectable product is formed. The method works bestwhen the mismatch is included in the 3′-most position of theoligonucleotide aligned with the polymorphism because this position ismost destabilizing to elongation from the primer. See, e.g., WO93/22456.

4. Direct-Sequencing

The direct analysis of the sequence of polymorphisms of the presentinvention can be accomplished using either the dideoxy- chaintermination method or the Maxam -Gilbert method (see Sambrook et al.,Molecular Cloning, A Laboratory Manual (2nd Ed., CSHP, New York 1989);Zyskind et al., Recombinant DNA Laboratory Manual, (Acad. Press, 1988)).

5. Denaturing Gradient Gel Electrophoresis

Amplification products generated using the polymerase chain reaction canbe analyzed by the use of denaturing gradient gel electrophoresis.Different alleles can be identified based on the differentsequence-dependent melting properties and electrophoretic migration ofDNA in solution. Erlich, ed., PCR Technology, Principles andApplications for DNA Amplification, (W.H. Freeman and Co, New York,1992), Chapter 7.

6. Single-Strand Conformation Polymorphism Analysis

Alleles of target sequences can be differentiated using single-strandconformation polymorphism analysis, which identifies base differences byalteration in electrophoretic migration of single stranded PCR products,as described in Orita et al., Proc. Nat. Acad. Sci. 86, 2766-2770(1989). Amplified PCR products can be generated as described above, andheated or otherwise denatured, to form single stranded amplificationproducts. Single-stranded nucleic acids may refold or form secondarystructures which are partially dependent on the base sequence. Thedifferent electrophoretic mobilities of single-stranded amplificationproducts can be related to base-sequence difference between alleles oftarget sequences.

III. Methods of Use

After determining polymorphic form(s) present in an individual at one ormore polymorphic sites, this information can be used in a number ofmethods.

A. Association Studies with Hypertension

The polymorphisms of the invention may contribute to the phenotype of anorganism in different ways. Some polymorphisms occur within a proteincoding sequence and contribute to phenotype by affecting proteinstructure. The effect may be neutral, beneficial or detrimental, or bothbeneficial and detrimental, depending on the circumstances. By analogy,a heterozygous sickle cell mutation confers resistance to malaria, but ahomozygous sickle cell mutation is usually lethal. Other polymorphismsoccur in noncoding regions but may exert phenotypic effects indirectlyvia influence on replication, transcription, and translation. A singlepolymorphism may affect more than one phenotypic trait. Likewise, asingle phenotypic trait may be affected by polymorphisms in differentgenes. Further, some polymorphisms predispose an individual to adistinct mutation that is causally related to a certain phenotype.

The polymorphism shown in Table 1 are analyzed for a correlation withhypertension, the metabolic processes that lead to hypertension, andresponse to drugs used to treat hypertension. For purposes of thesestudies, hypertension can be defined as a dichotomous trait (e.g.,diastolic blood pressure greater than 90 mm Hg), as a continuous scaleof increasing severity based on blood pressure values, or as severalintermediate phenotypes. Because it is likely that the causation ofhypertension in the population is heterogenous, use of intermediatephenotypes can increase the strength of correlations identified. Someuseful subtypes for association studies are mendelian forms of humanhypertension, forms characterized by increased erythrocytesodium-lithium countertransport, forms characterized by altered urinarykallikrein levels, and forms characterized by sensitivity of bloodpressure to increases or decreases in sodium intake.

Correlation is performed for a population of individuals who have beentested for the presence or absence of hypertension or an intermediatephenotype and for one or polymorphic markers. To perform such analysis,the presence or absence of a set of polymorphic forms (i.e. apolymorphic set) is determined for a set of the individuals, some ofwhom exhibit a particular trait, and some of which exhibit lack of thetrait. The alleles of each polymorphism of the set are then reviewed todetermine whether the presence or absence of a particular allele isassociated with the trait of interest. Correlation can be performed bystandard statistical methods such as a K-squared test and statisticallysignificant correlations between polymorphic form(s) and phenotypiccharacteristics are noted. For example, it might be found that thepresence of allele A1 at polymorphism A correlates with hypertension asa dichotomous trait. As a further example, it might be found that thecombined presence of allele A1 at polymorphism A and allele B1 atpolymorphism B correlates with increased erythrocyte sodium lithiumcounter transport, an intermediate phenotype in development ofhypertension.

B. Diagnosis of Hypertension

Polymorphic forms that correlate with hypertension or intermediatephenotypes are useful in diagnosing hypertension or susceptibilitythereto. Combined detection of several such polymorphic forms (forexample, 2, 5, 10 or 20 of the polymorphisms listed in Table 1)typically increases the probability of an accurate diagnosis. Forexample, the presence of a single polymorphic form known to correlatewith hypertension might indicate a probability of 20% that an individualhas or is susceptible to hypertension, whereas detection of fivepolymorphic forms, each of which correlates with hypertension, mightindicate a probability of 80% that an individual has or is susceptibleto hypertension. Analysis of the polymorphisms of the invention can becombined with that of other polymorphisms or other risk factors ofhypertension, such as family history or obesity, as well as measurementsof blood pressure.

Patients diagnosed with hypertension can be treated with conventionaltherapies and/or can be counselled to undertake remedial life stylechanges, such as a low fat, low salt diet or more exercise. Conventionaltherapies include diuretics (e.g., thiazides), which lower bloodpressure by depleting the body of sodium and reducing blood volume;sympathoplegic agents (e.g., methyldopa and clonidine), which lowerblood pressure by reducing peripheral vascular resistance, inhibitingcardiac function and increasing venous pooling in capacitance vessels;direct vasodilators (e.g., hydralazine, minoxidil, diazoxide and sodiumnitroprusside), which reduce pressure by relaxing vascular smoothmuscle; agents that block production or action of angiotensin (e.g.,captopril, enalapril and lisinopril), and thereby reduce peripheralvascular resistance; and adrenergic neuron blocking agents (e.g.,guanethidine, reserpine, propranolol) which prevent release ofnorepinephrine. See, e.g., Basic and Clinical Pharmacology (Ed. Katzung,Appleton & Lange, CT, 1989).

C. Drug Screening

The polymorphism(s) showing the strongest correlation with hypertensionwithin a given gene are likely to have a causative role in hypertension.Such a role can be confirmed by producing a transgenic animal expressinga human gene bearing such a polymorphism and determining whether theanimal develops hypertension. Polymorphisms in coding regions thatresult in amino acid changes usually cause hypertension by decreasing,increasing or otherwise altering the activity of the protein encoded bythe gene in which the polymorphism occurs. Polymorphisms in codingregions that introduce stop codons usually cause hypertension byreducing (heterozygote) or eliminating (homozygote) functional proteinproduced by the gene. Occasionally, stop codons result in production ofa truncated peptide with aberrant activities relative to the full-lengthprotein. Polymorphisms in regulatory regions typically causehypertension by causing increased or decreased expression of the proteinencoded by the gene in which the polymorphism occurs. Polymorphisms inintronic sequences can cause hypertension either through the samemechanism as polymorphisms in regulatory sequences or by causing alteredspliced patterns resulting in an altered protein. For example,alternative splice patterns have been reported for the human angiotensinII receptor gene (Cumow et al., Molecular Endocrinology 9, 1250-1262(1995)).

The precise role of polymorphisms in hypertension can be elucidated byseveral means. Alterations in expression levels of a protein (e.g.,sodium-calcium ion channel) can be determined by measuring proteinlevels in samples groups of persons characterized as having or nothaving hypertension (or intermediate phenotypes). Alterations in enzymeactivity (e.g., renin), can similarly be detected by assaying for enzymeactivity in samples from the above groups of persons. Alterations inreceptor transducing activity (e.g., angiotensin II receptor,β-3-adrenergic receptor or bradykinin receptor B2) can be detected bycomparing receptor ligand binding, either in vitro or in a cellularexpression system.

Having identified certain polymorphisms as having causative roles inhypertension, and having elucidated at least in general terms whethersuch polymorphisms increase or decrease the activity or expression levelof associated proteins, customized therapies can be devised for classesof patients with different genetic subtypes of hypertension. Forexample, if a polymorphism in a given protein causes hypertension byincreasing the expression level or activity of the protein, hypertensionassociated with the polymorphism can be treated by administering anantagonist of the protein. If a polymorphism in a given protein causeshypertension by decreasing the expression level or activity of aprotein, the form of hypertension associated with the polymorphism canbe treated by administering the protein itself, a nucleic acid encodingthe protein that can be expressed in a patient, or an analog or agonistof the protein.

Agonists, antagonists can be obtained by producing and screening largecombinatorial libraries. Combinatorial libraries can be produced formany types of compound that can be synthesized in a step by stepfashion. Such compounds include polypeptides, beta-turn mimetics,polysaccharides, phospholipids, hormones, prostaglandins, steroids,aromatic compounds, heterocyclic compounds, benzodiazepines, oligomericN-substituted glycines and oligocarbamates. Large combinatoriallibraries of the compounds can be constructed by the encoded syntheticlibraries (ESL) method described in Affymax, WO 95/12608, Affymax, WO93/06121, Columbia University, WO 94/08051, Pharmacopeia, WO 95/35503and Scripps, WO 95/30642 (each of which is incorporated by reference forall purposes). Peptide libraries can also be generated by phage displaymethods. See, e.g., Devlin, WO 91/18980. The libraries of compounds canbe initially screened for specific binding to the protein for whichagonists or antagonists are to be identified, or to its natural bindingpartner. Preferred agents bind with a Kd<μM. For example, for receptorligand combinations, the assay can be performed using cloned receptorimmobilized to a support such as a microtiter well and binding ofcompounds can be measured in competition with ligand to the receptor.Agonist or antagonist activity can then be assayed using a cellularreporter system or a transgenic animal model.

The polymorphisms of the invention are also useful for conductingclinical trials of drug candidates for hypertension. Such trials areperformed on treated or control populations having similar or identicalpolymorphic profiles at a defined collection of polymorphic sites. Useof genetically matched populations eliminates or reduces variation intreatment outcome due to genetic factors, leading to a more accurateassessment of the efficacy of a potential drug.

D. Other Diseases

The polymorphisms in Table 1 can also be tested for association withother disease that have known but hitherto unmapped genetic components(e.g., agammaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome,muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familialhypercholesterolemia, polycystic kidney disease, hereditaryspherocytosis, von Willebrand's disease, tuberous sclerosis, hereditaryhemorrhagica telangiectasia, familial colonic polyposis, Ehlers-Danlossyndrome, osteogenesis imperfecta, and acute intermittent porphyria).Phenotypic traits also include symptoms of, or susceptibility to,multifactorial diseases of which a component is or may be genetic, suchas autoimmune diseases, inflammation, cancer, diseases of the nervoussystem, and infection by pathogenic microorganisms. Some examples ofautoimmune diseases include rheumatoid arthritis, multiple sclerosis,diabetes (insulin-dependent and non-independent), systemic lupuserythematosus and Graves disease. Some examples of cancers includecancers of the bladder, brain, breast, colon, esophagus, kidney,leukemia, liver, lung, oral cavity, ovary, pancreas, prostate, skin,stomach and uterus. Phenotypic traits also include characteristics suchas longevity, appearance (e.g., baldness, obesity), strength, speed,endurance, fertility, and susceptibility or receptivity to particulardrugs or therapeutic treatments.

Such correlations can be exploited in several ways. In the case of astrong correlation between a set of one or more polymorphic forms and adisease for which treatment is available, detection of the polymorphicform set in a human or animal patient may justify immediateadministration of treatment, or at least the institution of regularmonitoring of the patient. Detection of a polymorphic form correlatedwith serious disease in a couple contemplating a family may also bevaluable to the couple in their reproductive decisions. For example, thefemale partner might elect to undergo in vitro fertilization to avoidthe possibility of transmitting such a polymorphism from her husband toher offspring. In the case of a weaker, but still statisticallysignificant correlation between a polymorphic set and human disease,immediate therapeutic intervention or monitoring may not be justified.Nevertheless, the patient can be motivated to begin simple life-stylechanges (e.g., diet, exercise) that can be accomplished at little costto the patient but confer potential benefits in reducing the risk ofconditions to which the patient may have increased susceptibility byvirtue of variant alleles. Identification of a polymorphic set in apatient correlated with enhanced receptiveness to one of severaltreatment regimes for a disease indicates that this treatment regimeshould be followed.

E. Forensics

Determination of which polymorphic forms occupy a set of polymorphicsites in an individual identifies a set of polymorphic forms thatdistinguishes the individual. See generally National Research Council,The Evaluation of Forensic DNA Evidence (Eds. Pollard et al., NationalAcademy Press, DC, 1996). The more sites that are analyzed the lower theprobability that the set of polymorphic forms in one individual is thesame as that in an unrelated individual. Preferably, if multiple sitesare analyzed, the sites are unlinked. Thus, polymorphisms of theinvention are often used in conjunction with polymorphisms in distalgenes. Preferred polymorphisms for use in forensics are diallelicbecause the population frequencies of two polymorphic forms can usuallybe determined with greater accuracy than those of multiple polymorphicforms at multi-allelic loci.

The capacity to identify a distinguishing or unique set of forensicmarkers in an individual is useful for forensic analysis. For example,one can determine whether a blood sample from a suspect matches a bloodor other tissue sample from a crime scene by determining whether the setof polymorphic forms occupying selected polymorphic sites is the same inthe suspect and the sample. If the set of polymorphic markers does notmatch between a suspect and a sample, it can be concluded (barringexperimental error) that the suspect was not the source of the sample.If the set of markers does match, one can conclude that the DNA from thesuspect is consistent with that found at the crime scene. If frequenciesof the polymorphic forms at the loci tested have been determined (e.g.,by analysis of a suitable population of individuals), one can perform astatistical analysis to determine the probability that a match ofsuspect and crime scene sample would occur by chance.

p(ID) is the probability that two random individuals have the samepolymorphic or allelic form at a given polymorphic site. In diallelicloci, four genotypes are possible: AA, AB, BA, and BB. If alleles A andB occur in a haploid genome of the organism with frequencies x and y,the probability of each genotype in a diploid organism are (see WO95/12607):

Homozygote: p(AA)=x2

Homozygote: p(BB)=y2=(1−x)2

Single Heterozygote: p(AB)=p(BA)=xy=x(1−x)

Both Heterozygotes: p(AB+BA)=2xy=2x(1−x)

The probability of identity at one locus (i.e, the probability that twoindividuals, picked at random from a population will have identicalpolymorphic forms at a given locus) is given by the equation:

p(ID)=(x2)2+(2xy)2+(y2)2.

These calculations can be extended for any number of polymorphic formsat a given locus. For example, the probability of identity p(ID) for a3-allele system where the alleles have the frequencies in the populationof x, y and z, respectively, is equal to the sum of the squares of thegenotype frequencies:

p(ID)=x4+(2xy)2+(2yz)2+(2xz)2+z4+y4

In a locus of n alleles, the appropriate binomial expansion is used tocalculate p(ID) and p(exc).

The cumulative probability of identity (cum p(ID)) for each of multipleunlinked loci is determined by multiplying the probabilities provided byeach locus.

 cum p(ID)=p(ID1)p(ID2)p(ID3) . . . p(IDn)

The cumulative probability of non-identity for n loci (i.e. theprobability at two random individuals will be different at 1 or moreloci) is given by the equation:

cum p(nonID)=1−cum p(ID).

If several polymorphic loci are tested, the cumulative probability ofnon-entity for random individuals becomes very high (e.g., one billionto one). Such probabilities can be taken into account together withother evidence in determining the guilt or innocence of the suspect.

F. Paternity Testing

The object of paternity testing is usually to determine whether a maleis the father of a child. In most cases, the mother of the child isknown and thus, the mother's contribution to the child's genotype can betraced. Paternity testing investigates whether the part of the child'sgenotype not attributable to the mother is consistent with that of theputative father. Paternity testing can be performed by analyzing sets ofpolymorphisms in the putative father and the child.

If the set of polymorphisms in the child attributable to the father doesnot match the putative father, it can be concluded, barring experimentalerror, that the putative father is not the real father. If the set ofpolymorphisms in the child attributable to the father does match the setof polymorphisms of the putative father, a statistical calculation canbe performed to determine the probability of coincidental match.

The probability of parentage exclusion (representing the probabilitythat a random male will have a polymorphic form at a given polymorphicsite that makes him incompatible as the father) is given by the equation(see WO 95/12607):

p(exc)=xy(1−xy)

where x and y are the population frequencies of alleles A and B of adiallelic polymorphic site.

(At a triallelic site p(exc)=xy(1−xy)+yz(1−yz)+xz(1−xz) +3xyz(1−xyz))),where x, y and z and the respective population frequencies of alleles A,B and C).

The probability of non-exclusion is

p(non-exc)=1−p(exc)

The cumulative probability of non-exclusion (representing the valueobtained when n loci are used) is thus:

cum p(non-exc)=p(non-exc1)p(non-exc2)p(non-exc3) . . . p(non-excn)

The cumulative probability of exclusion for n loci (representing theprobability that a random male will be excluded)

cum p(exc)=1−cum p(non-exc).

If several polymorphic loci are included in the analysis, the cumulativeprobability of exclusion of a random male is very high. This probabilitycan be taken into account in assessing the liability of a putativefather whose polymorphic marker set matches the child's polymorphicmarker set attributable to his/her father.

G. Genetic Mapping of Phenotypic Traits

The polymorphisms shown in table I can also be used to establishphysical linkage between a genetic locus associated with a trait ofinterest and polymorphic markers that are not associated with the trait,but are in physical proximity with the genetic locus responsible for thetrait and co-segregate with it. Such analysis is useful for mapping agenetic locus associated with a phenotypic trait to a chromosomalposition, and thereby cloning gene(s) responsible for the trait. SeeLander et al., Proc. Natl. Acad. Sci. (USA) 83, 7353-7357 (1986); Landeret al., Proc. Natl. Acad. Sci. (USA) 84, 2363-2367 (1987); Donis-Kelleret al., Cell 51, 319-337 (1987); Lander et al., Genetics 121, 185-199(1989)). Genes localized by linkage can be cloned by a process known asdirectional cloning. See Wainwright, Med. J. Australia 159, 170-174(1993); Collins, Nature Genetics 1, 3-6 (1992) (each of which isincorporated by reference in its entirety for all purposes).

Linkage studies are typically performed on members of a family.Available members of the family are characterized for the presence orabsence of a phenotypic trait and for a set of polymorphic markers. Thedistribution of polymorphic markers in an informative meiosis is thenanalyzed to determine which polymorphic markers co-segregate with aphenotypic trait. See, e.g., Kerem et al., Science 245, 1073-1080(1989); Monaco et al., Nature 316, 842 (1985); Yamoka et al., Neurology40, 222-226 (1990); Rossiter et al., FASEB Journal 5, 21-27 (1991).

Linkage is analyzed by calculation of LOD (log of the odds) values. Alod value is the relative likelihood of obtaining observed segregationdata for a marker and a genetic locus when the two are located at arecombination fraction θ, versus the situation in which the two are notlinked, and thus segregating independently (Thompson & Thompson,Genetics in Medicine (5th ed, W.B. Saunders Company, Philadelphia,1991); Strachan, “Mapping the human genome” in The Human Genome (BIOSScientific Publishers Ltd, Oxford), Chapter 4). A series of likelihoodratios are calculated at various recombination fractions (θ), rangingfrom θ=0.0 (coincident loci) to θ=0.50 (unlinked). Thus, the likelihoodat a given value of 0 is: probability of data if loci linked at θ toprobability of data if loci unlinked. The computed likelihoodsare-usually expressed as the log10 of this ratio (i.e., a lod score).For example, a lod score of 3 indicates 1000:1 odds against an apparentobserved linkage being a coincidence. The use of logarithms allows datacollected from different families to be combined by simple addition.Computer programs are available for the calculation of lod scores fordiffering values of θ (e.g., LIPED, MLINK (Lathrop, Proc. Nat. Acad.Sci. (USA) 81, 3443-3446 (1984)). For any particular lod score, arecombination fraction may be determined from mathematical tables. SeeSmith et al., Mathematical tables for research workers in human genetics(Churchill, London, 1961); Smith, Ann. Hum. Genet. 32, 127-150 (1968).The value of θ at which the lod score is the highest is considered to bethe best estimate of the recombination fraction. Positive lod scorevalues suggest that the two loci are linked, whereas negative valuessuggest that linkage is less likely (at that value of θ) than thepossibility that the two loci are unlinked. By convention, a combinedlod score of +3 or greater (equivalent to greater than 1000:1 odds infavor of linkage) is considered definitive evidence that two loci arelinked. Similarly, by convention, a negative lod score of −2 or less istaken as definitive evidence against linkage of the two loci beingcompared. Negative linkage data are useful in excluding a chromosome ora segment thereof from consideration. The search focuses on theremaining non-excluded chromosomal locations.

IV. Modified Polypeptides and Gene Sequences

The invention further provides variant forms of nucleic acids andcorresponding proteins. The nucleic acids comprise one of the sequencesdescribed in Table 1, column 8, in which the polymorphic position isoccupied by an alternative base for that position. Some nucleic acidencode full-length variant forms of proteins. Similarly, variantproteins have the prototypical amino acid sequences of encoded bynucleic acid sequence shown in Table 1, column 8, (read so as to bein-frame with the full-length coding sequence of which it is acomponent) except at an amino acid encoded by a codon including one ofthe polymorphic positions shown in the Table. That position is occupiedby the amino acid coded by the corresponding codon in the alternativeforms shown in the Table.

Variant genes can be expressed in an expression vector in which avariant gene is operably linked to a native or other promoter. Usually,the promoter is a eukaryotic promoter for expression in a mammaliancell. The transcription regulation sequences typically include aheterologous promoter and optionally an enhancer which is recognized bythe host. The selection of an appropriate promoter, for example trp,lac, phage promoters, glycolytic enzyme promoters and tRNA promoters,depends on the host selected. Commercially available expression vectorscan be used. Vectors can include host-recognized replication systems,amplifiable genes, selectable markers, host sequences useful forinsertion into the host genome, and the like.

The means of introducing the expression construct into a host cellvaries depending upon the particular construction and the target host.Suitable means include fusion, conjugation, transfection, transduction,electroporation or injection, as described in Sambrook, supra. A widevariety of host cells can be employed for expression of the variantgene, both prokaryotic and eukaryotic. Suitable host cells includebacteria such as E. coli, yeast, filamentous fungi, insect cells,mammalian cells, typically immortalized, e.g., mouse, CHO, human andmonkey cell lines and derivatives thereof. Preferred host cells are ableto process the variant gene product to produce an appropriate maturepolypeptide. Processing includes glycosylation, ubiquitination,disulfide bond formation, general post-translational modification, andthe like.

The protein may be isolated by conventional means of proteinbiochemistry and purification to obtain a substantially pure product,i.e., 80, 95 or 99% free of cell component contaminants, as described inJacoby, Methods in Enzymology Volume 104, Academic Press, New York(1984); Scopes, Protein Purification, Principles and Practice, 2ndEdition, Springer-Verlag, New York (1987); and Deutscher (ed), Guide toProtein Purification, Methods in Enzymology, Vol. 182 (1990). If theprotein is secreted, it can be isolated from the supernatant in whichthe host cell is grown. If not secreted, the protein can be isolatedfrom a lysate of the host cells.

The invention further provides transgenic nonhuman animals capable ofexpressing an exogenous variant gene and/or having one or both allelesof an endogenous variant gene inactivated. Expression of an exogenousvariant gene is usually achieved by operably linking the gene to apromoter and optionally an enhancer, and microinjecting the constructinto a zygote. See Hogan et al., “Manipulating the Mouse Embryo, ALaboratory Manual,” Cold Spring Harbor Laboratory. Inactivation ofendogenous variant genes can be achieved by forming a transgene in whicha cloned variant gene is inactivated by insertion of a positiveselection marker. See Capecchi, Science 244, 1288-1292 (1989). Thetransgene is then introduced into an embryonic stem cell, where itundergoes homologous recombination with an endogenous variant gene. Miceand other rodents are preferred animals. Such animals provide usefuldrug screening systems.

In addition to substantially full-length polypeptides expressed byvariant genes, the present invention includes biologically activefragments of the polypeptides, or analogs thereof, including organicmolecules which simulate the interactions of the peptides. Biologicallyactive fragments include any portion of the full-length polypeptidewhich confers a biological function on the variant gene product,including ligand binding, and antibody binding. Ligand binding includesbinding by nucleic acids, proteins or polypeptides, small biologicallyactive molecules, or large cellular structures.

Polyclonal and/or monoclonal antibodies that specifically bind tovariant gene products but not to corresponding prototypical geneproducts are also provided. Antibodies can be made by injecting mice orother animals with the variant gene product or synthetic peptidefragments thereof. Monoclonal antibodies are screened as are described,for example, in Harlow & Lane, Antibodies, A Laboratory Manual, ColdSpring Harbor Press, New York (1988); Goding, Monoclonal antibodies,Principles and Practice (2d ed.) Academic Press, New York (1986).Monoclonal antibodies are tested for specific immunoreactivity with avariant gene product and lack of immunoreactivity to the correspondingprototypical gene product. These antibodies are useful in diagnosticassays for detection of the variant form, or as an active ingredient ina pharmaceutical composition.

V. Kits

The invention further provides kits comprising at least oneallele-specific oligonucleotide as described above. Often, the kitscontain one or more pairs of allele-specific oligonucleotideshybridizing to different forms of a polymorphism. In some kits, theallele-specific oligonucleotides are provided immobilized to asubstrate. For example, the same substrate can comprise allele-specificoligonucleotide probes for detecting at least 10, 100 or all of thepolymorphisms shown in Table 1. Optional additional components of thekit include, for example, restriction enzymes, reverse-transcriptase orpolymerase, the substrate nucleoside triphosphates, means used to label(for example, an avidin-enzynie conjugate and enzyme substrate andchromogen if the label is biotin), and the appropriate buffers forreverse transcription, PCR, or hybridization reactions. Usually, the kitalso contains instructions for carrying out the methods.

VI. Computer Systems For Storing Polymorphism Data

FIG. 1A depicts a block diagram of a computer system 10 suitable forimplementing the present invention. Computer system 10 includes a bus 12which interconnects major subsystems such as a central processor 14, asystem memory 16 (typically RAM), an input/output (I/O) controller 18,an external device such as a display screen 24 via a display adapter 26,serial ports 28 and 30, a keyboard 32, a fixed disk drive 34 via astorage interface 35 and a floppy disk drive 36 operative to receive afloppy disk 38, and a CD-ROM (or DVD-ROM) device 40 operative to receivea CD-ROM 42. Many other devices can be connected such as a user pointingdevice, e.g., a mouse 44 connected via serial port 28 and a networkinterface 46 connected via serial port 30.

Many other devices or subsystems (not shown) may be connected in asimilar manner. Also, it is not necessary for all of the devices shownin FIG. 1A to be present to practice the present invention, as discussedbelow. The devices and subsystems may be interconnected in differentways from that shown in FIG. 1A. The operation of a computer system suchas that shown in FIG. 1A is well known. Databases storing polymorphisminformation according to the present invention can be stored, e.g., insystem memory 16 or on storage media such as fixed disk 34, floppy disk38, or CD-ROM 42. An application program to access such databases can beoperably disposed in system memory 16 or sorted on storage media such asfixed disk 34, floppy disk 38, or CD-ROM 42.

FIG. 1B depicts the interconnection of computer system 10 to remotecomputers 48, 50, and 52. FIG. 1B depicts a network 54 interconnectingremote servers 48, 50, and 52. Network interface 46 provides theconnection from client computer system 10 to network 54. Network 54 canbe, e.g., the Internet. Protocols for exchanging data via the Internetand other networks are well known. Information identifying thepolymorphisms described herein can be transmitted across network 54embedded in signals capable of traversing the physical media employed bynetwork 54.

Information identifying polymorphisms shown in Table 1 is represented inrecords, which optionally, are subdivided into fields. Each recordstores information relating to a different polymorphisms in Table 1.Collectively, the records can store information relating to all of thepolymorphisms in Table 1, or any subset thereof, such as 5, 10, 50, or100 polymorphisms from Table 1. In some databases, the informationidentifies a base occupying a polymorphic position and the location ofthe polymorphic position. The base can be represented as a single lettercode (i.e., A, C, G or T/U) present in a polymorphic form other thanthat in the reference allele. Alternatively, the base occupying apolymorphic site can be represented in IUPAC ambiguity code as shown inTable 1. The location of a polymorphic site can be identified as itsposition within one of the sequences shown in Table 1. For example, inthe first sequence shown in Table 1, the polymorphic site occupies the15th base. The position can also be identified by reference to, forexample, a chromosome, and distance from known markers within thechromosome. In other databases, information identifying a polymorphismcontains sequences of 10-100 bases shown in Table 1 or the complementsthereof, including a polymorphic site. Preferably, such informationrecords at least 10, 15, 20, or 30 contiguous bases of sequencesincluding a polymorphic site.

From the foregoing, it is apparent that the invention includes a numberof general uses that can be expressed concisely as follows. Theinvention provides for the use of any of the nucleic acid segmentsdescribed above in the diagnosis or monitoring of diseases, particularlyhypertension. The invention further provides for the use of any of thenucleic acid segments in the manufacture of a medicament for thetreatment or prophylaxis of such diseases. The invention furtherprovides for the use of any of the DNA segments as a pharmaceutical.

All publications and patent applications cited above are incorporated byreference in their entirety for all purposes to the same extent as ifeach individual publication or patent application were specifically andindividually indicated to be so incorporated by reference. Although thepresent invention has been described in some detail by way ofillustration and example for purposes of clarity and understanding, itwill be apparent that certain changes and modifications may be practicedwithin the scope of the appended claims.

TABLE 1 Heteroz Alt Base Ref ygosity Ref Alt Type of amino acid Refamino amino SEQ Gene/Exon Position Allele Freq (P) Alt Allele Freq (Q)(H) Sequence Tag Codon Codon change acid acid ID NO: AADDEX1 305 G 0.98A 0.03 0.05 ACGGGGGCGGAGCCTGAGCCGGAGCCGAC . . Other 5′ UTR . 1 AADDEX10246 G 0.86 T 0.14 0.23 AAGCTTCCGAGGAAKGGCAGAATGGAAGC GGG TGGNonsynonymous Gly Trp 2 AADDEX12 43 A 0.94 T 0.06 0.01GATCCGAGAGCAGAWTTTACAGGACATTA AAT AAT Nonsynonymous Asn Ile 3 AADDEX13173 C 0.70 G 0.30 0.42 GAAGCAGAAGGGCTSTGAAGGTGAGTGCT TCT TGTNonsynonymous Ser Cys 4 AADDEX15 74 C 0.73 T 0.27 0.40CCTAGTAAGTACCGYGCTGCCTCCGCTCT . . Other Intron . 5 AADDEX16 1071 G 0.99A 0.01 0.02 ATTCCTGTCATAGGRAAGGTATATCAGGA . . Other 3′ UTR . 6 AADDEX161321 C 0.98 T 0.02 0.04 GCCCTGGGGCCCCTYGACATCACCGTCAT . . Other 3′ UTR .7 AADDEX16 1328 A 0.91 G 0.09 0.17 GGCCCCTCGACATCRCCGTCATTGATGGA . .Other 3′ UTR . 8 AADDEX16 1478 A 0.89 G 0.11 0.19CAGCCTGACTAGGTRCAGGCAAGCTTGTG . . Other 3′ UTR . 9 AADDEX16 691 C 0.99 G0.01 0.02 CAGCTTTGGCTGCASGTCACCCTCCTGAG . . Other 3′ UTR . 10 AADDEX16995 C 0.94 T 0.06 0.11 TATGCATGTCTGACYGACGATCCCTCGAC . . Other 3′ UTR .11 AADDEX2 31 A 0.98 G 0.03 0.05 TTTGATTCTGTAGGRACCTAGAAAGATTG . . Other5′ UTR . 12 AADDEX7 96 T 0.98 A 0.02 0.04 TTGGAGAAGTGGCTWATCATGACTACCATTAT AAT Nonsynonymous Tyr Asn 13 AADDEX9 173 A 0.93 T 0.07 0.13ATTGGTGAGCAGGAWTTTGAAGCCCTCAT GAA GAT Nonsynonymous Glu Asp 14 ACEEX13151 T 0.75 C 0.25 0.38 CCAGCCAGGAGGCAYCCCAACAGGTGACA TCT CCTNonsynonymous Ser Pro 15 ACEEX13 202 A 0.75 G 0.25 0.38AGGCAACAACCAGCRGCCAGACAACCACC AGC GGC Nonsynonymous Ser Gly 16 ACEEX15144 G 0.80 A 0.20 0.32 CTAGAACGGGCAGCRCRGCCTGCCCAGGA GCG GCA SynonymousAla Ala 17 ACEEX17 19 C 0.59 A 0.31 0.43 CTCAAGCCATTCAAMCCCCTACCAGATCT .. Other Intron . 18 ACEEX18 130 C 0.95 G 0.05 0.09CAGCCACTCTACCTSAACCTGCATGCCTA CTC CTG Synonymous Leu Leu 19 ACEEX21 150T 0.98 C 0.03 0.05 CTTCCATGAGGCCAYTGGGGACGTGCTAG ATT ACT NonsynonymousIle Thr 20 ACEEX22 19 T 0.99 G 0.01 0.03 AGCATGACATCAACKTTCTGATGAAGATGTTT GTT Nonsynonymous Phe Val 21 ACEEX24 118 C 0.95 T 0.05 0.10CAGTCCAAGGAGGCYGGGCAGCGCCTGGG GCC GCT Synonymous Ala Ala 22 ACEEX24 16 T0.57 C 0.43 0.49 TGCTCCAGGTACTTYGTCAGCTTCATCAT TTT TTC Synonymous PhePhe 23 ACEEX26 154 G 0.98 A 0.03 0.05 GGGCCTCAGCCAGCRGCTCTTCAGCATCC CGGCAG Nonsynonymous Arg Gln 24 ACEEX26 174 C 0.90 A 0.10 0.18TCAGCATCCGCCACMGCAGCCTCCACCGG CGC AGC Nonsynonymous Arg Ser 25 ACEEX26205 A 0.98 C 0.02 0.03 CTCCCACGGGCCCCMGTTCGGCTCCGAGG CAG CCGNonsynonymous Gln Pro 26 ACEEX26 224 G 0.94 A 0.06 0.11GGCTCCGAGGTGGARCTGAGACACTCCTG GAG GAA Synonymous Glu Glu 27 ADDBEX10 81G 0.98 T 0.03 0.05 CTCCTGGAGCAGGAKAAGCACCGGCCCCA GAG GAT NonsynonymousGlu Asp 28 ADDBEX15 68 G 0.99 A 0.01 0.03 GCTCTGGTCCGGCCRTGTGCGAGTTCTTCCCG CCA Synonymous Pro Pro 29 ADDBEX15 85 C 0.90 T 0.10 0.18TGCGAGTTCTTCAGYGTTGCCCTCCACAT GCG GTG Nonsynonyrnous Ala Val 30 ADDBEX17147 C 0.98 A 0.02 0.04 GAGGAAATCCTCAGMAAAGGCCTGAGCCA AGC AGANonsynonymous Ser Arg 31 ADDBEX3 138 G 0.89 A 0.11 0.19GCTTTCTCAGAGGACRACCCCGAGTACATG GAC AAC Nonsynonymous Asp Asn 32 ADDBEX4134 C 0.99 G 0.01 0.02 CATGGCCAGCACCTSCCACGCAGTCTTCC TCC TGCNonsynonymous Ser Cys 33 ADDBEX8 173 A 0.96 G 0.04 0.07CCACCTGCAAGGTTRGCTTAGCTCTTCTG . . Other Intron . 34 ADDBEX9 69 T 0.99 C0.01 0.02 GTAGAGGAGGCATTYTACAAGATCTTCCA TTT TTC Synonymous Phe Phe 35ADDG 2087 T 0.98 C 0.02 0.03 TGACATTGCACATCYAAATACCACATTTA . . Other3′ UTR . 36 ADORA2AEX1 429 C 0.97 T 0.03 0.07GGTGTCACTGGCGGYGGCCGACATCGCAG GCG GTG Nonsynonymous Ala Val 37ADORA2AEX2 1230 G 0.97 T 0.03 0.06 TGCAGAAGCATCTGKAAGCACCACCTTGT . .Other 3′ UTR . 38 ADORA2AEX2 596 G 0.97 A 0.03 0.06CCGCCAGACCTTCCRCAAGATCATTCGCA CGC CAC Nonsynonymous Arg His 39ADORA2AEX2 741 C 0.92 T 0.08 0.15 GGAGTGTGGGCCAAYGGCAGTGCTCCCCA AAC AATSynonymous Asn Asn 40 ADRB3EX1 1020 C 0.96 T 0.04 0.07GGCCCCGGTGGGGAYGTGCGCTCCGCCCG ACG ATG Nonsynonymous Thr Met 41 ADRB3EX11354 C 0.89 T 0.11 0.20 TGCGCCGCCGCCCGYCCGGCCCTCTTCCC CGC CGT SynonymousArg Arg 42 ADRB3EX1 1445 G 0.90 T 0.10 0.18GGTAGGTAACCGGGKCAGAGGGACCGGCG . . Other Intron . 43 ADRB3EX1 44 A GGCTACTCCTCCCCCRAGAGCGGTGGCACC . . Other 5′ UTR . 44 ADRB3EX2 301 G 0.96C 0.04 0.08 GTGGTAGTGTCCAGSTGCCGTGGAGCAGC . . Other 3′ UTR . 45 ADRB3EX2408 C 0.80 T 0.20 0.32 TGGTTCCATTCCTTYTGCCACCCAAACCC . . Other 3′ UTR .46 ADROMEX1 1197 C 0.98 T 0.02 0.04 TGGGACGTCTGAGAYTTTCTCCTTCAAGT . .Other 5′  UTR . 47 ADROMEX1 154 G 0.98 T 0.02 0.05ATGTTACCTTCCTTKCCTGACTCAAGGGT . . Other Promoter . 48 ADROMEX1 723 C0.97 T 0.03 0.06 GGGCTCTTGCTGTTYTTCGCCAGGAGGCT . . Other Promoter . 49ADROMEX1 981 G 0.99 A 0.01 0.03 GAGCAGGAGCGCGCRTGGCTGAGGAAAGA . . OtherPromoter . 50 ADROMEX2 101 A 0.96 C 0.04 0.07TCGCTCGCCTTCCTMGGCGCTGACACCGC CTA CTC Synonymous Leu Leu 51 ADROMEX3 81C 0.95 G 0.05 0.09 CTGCGGATGTCCAGSAGCTACCCCACCGG AGC AGG NonsynonymousSer Arg 52 ADROMEX4 1033 T 0.95 C 0.05 0.09ACCGAGTCTCTGTAYAATCTATTTACATA . . Other 3′ UTR . 53 ADROMEX4 1292 A 0.98G 0.02 0.05 TGTCCTGGGTGCGARTCAGGGCTTCGCGG . . Other 3′ UTR . 54 ADROMEX41389 T 0.97 C 0.03 0.06 GCGAGCCTGGACTCYCGGGTTGCGCAACG . . Other 3′ UTR .55 ADROMEX4 388 G 0.98 C 0.02 0.05 CAAGCATCCCGCTGSTGCCTCCCGGGACG . .Other 3′ UTR . 56 ADROMEX4 536 T 0.98 G 0.02 0.04CGCTTCTTAGCCTKGCTCAGGTGCAAGT . . Other 3′ UTR . 57 ADROMEX4 918 A 0.91 G0.09 0.16 ATTTTAAGACGTGARTGTCTCAGCGAGGT . . Other 3′ UTR . 58 AE1EX1 298G 0.95 A 0.05 0.10 GGGGCATGAGTCAGRGGTTTGCGAGCTGC . . Other Promoter . 59AE1EX1 80 A 0.98 C 0.02 0.04 TCAAACCTTCATCCMCAAAGGAAGAGTCA . . OtherPromoter . 60 AE1EX10 77 G 0.99 A 0.01 0.02CGAGGGGAGCTGCTRCACTCCCTAGAGGG CTG CTA Synonymous Leu Leu 61 AE1EX11 181C 0.95 T 0.05 0.10 GTCATCTTCATCTAYTTTGCTGCACTGTC TAC TAT Synonymous TyrTyr 62 AE1EX11 191 C 0.99 T 0.01 0.03 TCTACTTTGCTGCAYTGTCACCCGCCATC CTGTTG Synonymous Leu Leu 63 AE1EX11 228 A 0.98 T 0.02 0.04CGGCCTCCTGGGTCWGTGCCAATACCGT . . Other Intron . 64 AE1EX12 70 G 0.93 A0.07 0.13 GTGTCGGAGCTGCTRATCTCCACTGCAGT CTG CTA Synonymous Leu Leu 65AE1EX12 71 A 0.96 T 0.04 0.07 TGTCGGAGCTGCTGWTCTCCACTGCAGTG ATC TTCNonsynonymous Ile Phe 66 AE1EX14 159 A 0.93 T 0.07 0.13CCTTCTTCTTTGCCWTGATGCTGCTGCAAG ATG TTG Nonsynonymous Met Leu 67 AE1EX15107 T 0.79 C 0.21 0.33 TTCTTCATTCAGGAYACCTACACCCAGGT GAT GAC SynonymousAsp Asp 68 AE1EX16 92 C 0.97 T 0.03 0.06 GGCTGGGTCATCCAYCCACTGGGCTTGCGCAC CAT Synonymous His His 69 AE1EX17 34 A 0.97 G 0.03 0.06CCTACAGTAGGCTGRTTGTCAGCAAACCT ATT GTT Nonsynonymous Ile Val 70 AE1EX1740 A 0.99 G 0.01 0.02 GTAGGCTGATTGTCRGCAAACCTGAGCGC AGC GGCNonsynonymous Ser Gly 71 AE1EX17 72 C 0.94 T 0.06 0.11ATGGTCAAGGGCTCYGGCTTCCACCTGGA TCC TCT Synonymous Ser Ser 72 AE1EX19 132G 0.96 A 0.04 0.07 TGGCCCTGCCCTTCRTCCTCATCCTCACT CGT CAT NonsynonymousArg His 73 AE1EX19 43 G 0.99 A 0.01 0.02 GGTGAAGACCTGGCRCATGCACTTATTCACGC CAC Nonsynonymous Arg His 74 AE1EX20 1007 G 0.99 A 0.01 0.03AATCAGTGGACTCCRAGGGGACTGAGACA . . Other 3′  UTR . 75 AE1EX20 1213 A 0.64T 0.36 0.46 ATTTGAGAGCCATTWTCCTCAACTCCATC . . Other 3′ UTR . 76 AE1EX201542 T 0.94 C 0.06 0.12 AAAAATACAAAAATYAGCTGGGTGTCTCG . . Other 3′ UTR .77 AE1EX20 1628 G 0.95 C 0.05 0.10 CCCAGGAGGTGGAGSTTGCAGTGAGCCAA . .Other 3′ UTR . 78 AE1EX20 1679 A 0.68 G 0.32 0.44CTGGGCAACAGAGCRAGACCCTGTCTCAA . . Other 3′ UTR . 79 AE1EX20 379 G 0.97 A0.03 0.06 TCACTGGGGATCCCRTGCTGGAAGACTTA . . Other 3′ UTR . 80 AE1EX20418 C 0.99 A 0.01 0.03 CTCCCTCTTCCCAGMACAGGCAGGGGTAG . . Other 3′ UTR .81 AE1EX20 991 G 0.99 A 0.01 0.02 TTACTGAGGGCCCCRGAATCAGTGGACTC . .Other 3′ UTR . 82 AE1EX4 17 C 0.98 T 0.03 0.05CAATACTAACCGACYTCTGGTTTTCAGCT . . Other Intron . 83 AE1EX4 36 A 0.91 C0.09 0.16 GTTTTCAGCTCACGMCACCGAGGCAACAG GAC GCC Nonsynonymous Asp Ala 84AE1EX4 89 A 0.78 G 0.23 0.35 ACCCGGGTACCCACRAGGTGAGGACCCCA AAG GAGNonsynonymous Lys Glu 85 AE1EX5 197 A 0.97 T 0.03 0.06CTAGAGCTGCGTAGWGTCTTCACCAAGGG AGA AGT Nonsynonymous Arg Ser 86 AE1EX8 35T 0.99 C 0.01 0.03 TTCCCACAGGGAGAYGGGGGCACAGAAGG GAT GAC Synonymous AspAsp 87 AGTEX2 181 C 0.99 T 0.01 0.03 AGAGTACCTGTGAGYAGCTGGCAAAGGCC CAGTAG Nonsynonymous Gln STOP 88 AGTEX2 354 C 0.99 T 0.01 0.03GTCGGGATGCTGGCYAACTTCTTGGGCTT GCC GCT Synonymous Ala Ala 89 AGTEX2 755 TG GGACTTCACAGAACKGGATGTTGCTGCTG CTG CGG Nonsynonymous Leu Arg 90 AGTEX5258 C 0.96 T 0.04 0.08 TGGCAAGGCCTCTGYCCCTGGCCTTTGAG . . Other 3′ UTR .91 AGTEX5 376 C 0.97 G 0.03 0.06 AGCTGGAAAGCAGCSGTTTCTCCTTGGTC . . Other3′ UTR . 92 AGTEX5 385 T 0.97 C 0.03 0.06 GCAGCCGTTTCTCCYTGGTCTAAGTGTGC. . Other 3′ UTR . 93 AGTEX5 641 T 0.93 G 0.07 0.13GCCTTCGGTTTGTAKTTAGTGTCTTGAAT . . Other 3′ UTR . 94 AGTEXP1 101 G 0.99 C0.01 0.03 CTGGCTGTGCTATTSTTGGTGTTTAACAG . . Other Promoter . 95 AGTEXP2160 G 0.99 A 0.01 0.03 GGAACCTTGGCCCCRACTCCTGCAAACTT . . Other Promoter. 96 AGTEXP2 35 G 0.97 A 0.03 0.06 CCCTCTGCACCTCCRGCCTGCATGTCCCT . .Other Promoter . 97 AGTEXP3 158 A 0.72 G 0.29 0.41CTCGTGACCCGGCCRGGGGAAGAAGCTGC . . Other Promoter . 98 AGTEXP3 173 C 0.96T 0.04 0.08 GGGGAAGAAGCTGCYGTTGTTCTGGGTAC . . Other Promoter . 99ALDREDEX1 162 A 0.86 T 0.14 0.23 GCGCCAAGATGCCCWTCCTGGGGTTGGGT ATC TTCNonsynonymous Ile Phe 100 ALDREDEX1 71 C 0.41 G 0.59 0.48AAAGGTACGCGCCCSGGCCAAGGCCGCAC . . Other Promoter . 101 ALDREDEX10 150 T0.91 G 0.09 0.16 TTGCAAATGTAGTAKGGCCTGTGTCACTC . . Other 3′ UTR . 102ALDREDEX2 180 C 0.94 G 0.06 0.11 TGAAGCGTGAGGAGSTCTTCATCGTCAGC CTC GTCNonsynonymous Leu Val 103 ALDREDEX2 204 T 0.95 G 0.05 0.10TCAGCAAGGTATCGKTCCGCGGTGGGGCT . . Ither Intron . 104 ALDREDEX2 88 A 0.98T 0.03 0.05 CGTCGGGTACCGCCWCATCGACTGTGCCC CAC CTC Nonsynonymous His Leu105 ALDREDEX3 28 A 0.95 T 0.05 0.10 CCTCTCGCTGGCTTWGCTGTGGTGCACGT . .Other Intron . 106 ALDREDEX4 101 G 0.98 A 0.03 0.05AACATTCTGGACACRTGGGCGGTAAGACA ACG ACA Synonymous Thr Thr 107 ALDREDEX687 G 0.94 A 0.06 0.11 ACTGCCAGTCCAAARGCATCGTGGTGACC GGC AGCNonsynonymous Gly Ser 108 ALDREDEX9 67 C 0.99 T 0.01 0.02CCAGGATATGACCAYCTTACTCAGCTACA ACC ATC Nonsynonymous Thr Ile 109 ANPEX1252 G 0.99 A 0.01 0.03 CCATGTACAATGCCRTGTCCAACGCAGAC GTG ATGNonsynonymous Val Met 110 ANPEX1 297 C 0.97 T 0.03 0.06TAGGGCCAGGAAAGYGGGTGCAGTCTGGG . . Other Intron . 111 ANPEX3 106 G 0.97 T0.03 0.06 TCCTGTCCCCTGGGKTCTCTGCTGCATTT . . Other 3′ UTR . 112 ANPEX3127 T 0.91 C 0.09 0.16 CTGCATTTGTGTCAYCTTGTTGCCATGGA . . Other 3′ UTR .113 APOA1 101 C 0.76 T 0.24 0.36 GCCTTGCCCCAGGCYGGGCCTCTGGGTAC . . OtherPromoter . 114 APOA1 1016 A 0.76 C 0.24 0.36CGTAACTGGGCACCMGTCCCAGCTCTGTC . . Other Intron . 115 APOA1 1162 G 0.94 C0.06 0.12 AGGTGTCACCCAGGSCTCACCCCTGATAG . . Other Intron . 116 APOA11163 C 0.93 T 0.08 0.14 GGTGTCACCCAGGGYTCACCCCTGATAGG . . Other Intron .117 APOA1 1401 G 0.99 C 0.01 0.02 TGCAGCCCTACCTOSACGACTTCCAGAAG GAC CACNonsynonymous Asp His 118 APOA1 1576 G 0.98 C 0.02 0.04TGTGGACGCGCTGCSCACGCATCTGGCCC CGC CCC Nonsynonymous Arg Pro 119 APOA11643 G 0.98 A 0.02 0.04 CTTGAGGCTCTCAARGAGAACGGCGGCGC AAG AAA SynonymousLys Lys 120 APOA1 1757 C 0.94 G 0.06 0.11 CAAGGCCTGCTGCCSGTGCTGGAGAGCTTCCC CCG Synonymous Pro Pro 121 APOA1 2007 T 0.64 A 0.36 0.46CTCCGTGCCCAGACWGGACGTCTTAGGGC . . Other 3′ UTR . 122 APOA1 334 T 0.69 C0.31 0.43 AACCATCGGGGGGCYTTCTCCCTAAATCC . . Other Intron . 123 APOA1 620C 0.92 T 0.08 0.14 TTTGAAGGCTCCGCYTTGGGAAAACAGCT GCC GCT Synonymous AlaAla 124 APOA1 771 C 0.96 T 0.04 0.07 CTGGATGGAGAAACYGGAATGGATCTCCA . .Other Intron . 125 APOA1 840 G 0.99 A 0.01 0.02GGGCTGCCCGATGCRTGATCACAGAGCCA . . Other Intron . 126 APOA2 1334 T 0.99 A0.01 0.03 AGATTAGGCTTAAAWTGCAGAGAAAAAGT . . Other Intron . 127 APOA21412 G 0.82 C 0.18 0.29 AAGAACTGGGCCTTSAATTTCAGTCTCTA . . Other Intron .128 APOA2 1414 A 0.95 T 0.05 0.10 GAACTGGGCCTTGAWTTTCAGTCTCTAGA . .Other Intron . 129 APOA2 1459 C 0.99 T 0.01 0.03AGCAAAGGTCTTGAYTCTATTCCTACCTA . . Other Intron . 130 APOA2 1672 C 0.94 T0.06 0.11 AGGCTGGAACGGAAYTGGTTAACTTCTTG CTG TTG Synonymous Leu Leu 131APOA2 249 T 0.55 C 0.45 0.50 TGCTTCCTGTTGCAYTCAAGTCCAAGGAC . . OtherPromoter . 132 APOA2 547 A 0.99 C 0.01 0.01GACGCTGGCTAGGTMAGATAAGGAGGCAA . . Other Intron . 133 APOA4 1228 A 0.75 G0.25 0.38 GACCAGGTGGCCACRGTGATGTGGGACTA ACA ACG Synonymous Thr Thr 134APOA4 1338 T 0.03 C 0.97 0.06 GGGACTACAGTGTGYGGTGGTGACGGGGA . . OtherIntron . 135 APOA4 1479 C 0.98 T 0.03 0.05 CCACATATGTAAACYGGAAGTTTGGACCG. . Other Intron . 136 APOA4 1529 T 0.86 C 0.14 0.24TTGCTTTGACGTTCYAGAGTTTGACAAAT . . Other Intron . 137 APOA4 1597 T 0.50 C0.41 0.48 GGAGGAAAATGTCAYGTGAGCTGATTTCT . . Other Intron . 138 APOA41617 G 0.99 A 0.01 0.02 CTGATTTCTAATACRTTTCAGAAAGACAG . . Other Intron .139 APOA4 1879 C 0.94 G 0.06 0.11 GATTCTGAGACAAASTATGTGGGAGATCC . .Other Intron . 140 APOA4 1961 G 0.96 A 0.04 0.07CTGCACCACCATAGRGAGGGTGAACTCGG . . Other Intron . 141 APOA4 1998 T 0.63 C0.37 0.47 AGCACTCACCTGTCYTAGCACGTGTGCAT . . Other Intron . 142 APOA42134 C 0.73 T 0.28 0.40 GAAGTGAACACTTAYGCAGGTGACCTGCA TAC TAT SynonymousTyr Tyr 143 APOA4 2138 G 0.99 A 0.01 0.02 TGAACACTTACGCARGTGACCTGCAGAAGGGT AGT Nonsynonymous Gly Ser 144 APOA4 2140 T 0.94 C 0.06 0.12AACACTTACGCAGGYGACCTGCAGAAGAA GGT GGC Synonymous Gly Gly 145 APOA4 2358A 0.89 G 0.11 0.20 GCGCACCCAGGTCARCACGCAGGCCGAGC AAC AGC NonsynonymousAsn Ser 146 APOA4 2698 C 0.95 T 0.05 0.10 ATCTCGGCCAGTGCYGAGGAGCTGCGGCAGCC GCT Synonymous Ala Ala 147 APOA4 2764 C 0.92 T 0.08 0.15CTGAGGGGCAACACYGAGGGGCTGCAGAA ACC ACT Synonymous Thr Thr 148 APOA4 2806G 0.99 A 0.01 0.02 CTGGGTGGGCACCTRGACCAGCAGGTGGA CTG CTA Synonymous LeuLeu 149 APOA4 2837 G 0.98 C 0.02 0.04 AGTTCCGACGCCGGSTGGAGCCCTACGGG GTGCTG Nonsynonymous Val Leu 150 APOA4 2926 G 0.81 T 0.19 0.30CATGCGGGGGACGTKGAAGGCCACTTGAG GTG GTT Synonymous Val Val 151 APOA4 3058T 0.16 G 0.84 0.26 CAGCAGGAACAGCAKCAGGAGCAGCAGCA CAT CAG NonsynonymousHis Gln 152 APOA4 350 G 0.88 A 0.12 0.21 GCCAGCAGGGCCTCRAGGCATCAGTCCCG .. Other Promoter . 153 APOA4 637 G 0.96 C 0.04 0.08TGGCGATAGGGAGASAGTTTAAATGTCTG . . Other Promoter . 154 APOA4 687 G 0.96A 0.04 0.07 GTTCCCACTGCAGCRCAGGTGAGCTCTCC . . Other Promoter . 155APOC1EX1 1020 G 0.93 T 0.07 0.13 TTGTATTTTCAGTAKAGACAGGGTTTCAC . . OtherIntron . 156 APOC1EX1 1044 G 0.95 A 0.05 0.10TTCACCGTGGTCTCRATCTCCTGACTTTG . . Other Intron . 157 APOC1EX1 1057 T0.64 C 0.36 0.46 CGATCTCCTGACTTYGTGATCCGCCTGCC . . Other Intron . 158APOC1EX1 1111 C 0.89 T 0.11 0.20 CAGGCGTGAGCCACYGCGTCCGGCCATTC . . OtherIntron . 159 APOC1EX1 1376 G 0.57 T 0.43 0.49GCACGCGCCTGTAGKCCCAGCTACTCGGG . . Other Intron . 160 APOC1EX1 1411 C0.99 G 0.01 0.02 AGGCAGGAGAATCASTTGAACCCGGGAGG . . Other Intron . 161APOC1EX1 432 G 0.97 A 0.03 0.06 AGGCTCTTCCTGTCRCTCCCGGTCCTGGT TCG TCASynonynmous Ser Ser 162 APOC1EX1 462 C 0.61 G 0.39 0.47GTGGTTCTGTCGATSGTCTTGGAAGGTAA ATC ATG Nonsynonymous Ile Met 163 APOC1EX1496 G 0.01 C 0.99 0.02 GGATGGGAGAATTGSGGAGTTTGGAGATT . . Other Intron .164 APOC1EX1 713 C 0.99 T 0.01 0.02 ACCTCTGGGATTGGYTGTCCTGCTTCGAC . .Other Intron . 165 APOC2 1084 T 0.91 G 0.09 0.17TCTGAGGACTCAAGKGCCAAGATGGAGGG . . Other 3′ UTR . 166 APOC2 126 C 0.99 T0.01 0.02 CAGGTCTCTGGACAYTATGGGCACACGAC . . Other 5′ UTR . 167 APOC2 13T 0.34 A 0.66 0.45 CTGGGACACCGAGCWCACACAGAGCAGGA . . Other Promoter .168 APOC2 472 G 0.99 A 0.01 0.02 CCCAGAACCTGTACRAGAAGACATACCTG GAG AAGNonsynonymous Glu Lys 169 APOC2 553 G 0.99 A 0.01 0.02TGGCCCATACCACCRACTGCATCCAGGAC . . Other Intron . 170 APOC2 725 T 0.19 C0.81 0.31 CCCAGGAGTCCAGGYCCCCAGACCCTCCT . . Other Intron . 171 APOC2 804A 0.97 T 0.03 0.06 TGTGCTTTCTCCCCWGGGACTTGTACAGC . . Other Intron . 172APOC2 819 A 0.82 C 0.18 0.30 GGGACTTGTACAGCMAAAGCACAGCAGCC AAA CAANonsynonymous Lys Gln 173 APOC3 1148 T 0.95 A 0.05 0.10CTGGGGACTAAGAAWGTTTATGAACACCT . . Other Intron . 174 APOC3 1322 G 0.71 A0.29 0.41 CACGGGCTTGAATTRGGTCAGGTGGGGCC . . Other Intron . 175 APOC31468 A 0.97 C 0.03 0.06 ATACGCCTGAGCTCMGCCTCCTGTCAGAT . . Other Intron .176 APOC3 1519 A 0.95 G 0.05 0.10 GGAGTGTGAACCCTRTTGTGAACTGCACA . .Other Intron . 177 APOC3 1637 T 0.96 A 0.04 0.07GGCCCATGGAAAAAWTGTCCACCACAAAA . . Other Intron . 178 APOC3 1722 A 0.84 G0.16 0.27 AGGAAAATGGGCCRGGCGCAGTGGCTCG . . Other Intron . 179 APOC3 1728A 0.73 G 0.27 0.40 ATGGGGCCAGGCGCRGTGGCTCATGCCTG . . Other Intron . 180APOC3 1736 A 0.85 G 0.15 0.26 AGGCGCAGTGGCTCRTGCCTGTAATCCCA . . OtherIntron . 181 APOC3 1774 A 0.76 C 0.24 0.36 GAGGCCGAGGCAGGMGGATCCCCTGAGGT. . Other Intron . 182 APOC3 1817 T 0.69 C 0.31 0.43CAACCTGGCCAACAYGGTGAAACCCCATC . . Other Intron . 183 APOC3 1931 C 0.98 T0.02 0.04 TTGAACCCGGGAGAYGGAGGTTGCAGTGA . . Other Intron . 184 APOC31975 G 0.99 A 0.01 0.03 CTGCACTCCAGCCTRGGTGACAGAGGGAG . . Other Intron .185 APOC3 2221 G 0.96 A 0.04 0.08 AGGGCTAAAACGGCRCGGCCCTAGGACTG . .Other Intron . 186 APOC3 2535 G 0.81 A 0.19 0.30GCGTGCTTCATGTARCCCTGCATGAAGCT GGC GGT Synonymous Gly Gly 187 APOC3 2854C 0.70 T 0.30 0.42 CCCTGGGGAGGTGGYGTGGCCCCTAAGGT . . Other Promoter .188 APOC3 429 A 0.69 C 0.31 0.43 GCAACCTACAGGGGMAGCCCTGGAGATTG . . Other3′ UTR . 189 APOC3 460 G 0.99 C 0.01 0.03 GGACCCAAGGAGCTSGCAGGATGGATAGG. . Other 3′ UTR . 190 APOC3 636 G 0.96 A 0.04 0.07TAAATCAGTCAGGGRAAGCAACAGAGCAG . . Other Intron . 191 APOC3 954 A 0.89 G0.11 0.19 GTGCAAACAGCACCRCCTGGAGTTGCACA . . Other Intron . 192 APOC41150 T 0.39 C 0.61 0.47 AAGTGCTAGGATTAYAGGCGTGAGCCACT . . Other Intron .193 APOC4 1246 A 0.33 C 0.67 0.44 AGGCTGGTCTTGAAMTCCTGACCTCAGGT . .Other Intron . 194 APOC4 1281 C 0.91 T 0.09 0.16CCCGCCTTGGCCTCYCAAAGTGCTGGGAT . . Other Intron . 195 APOC4 1287 T 0.95 C0.05 0.10 TTGGCCTCCCAAAGYGCTGGGATTACAGG . . Other Intron . 196 APOC41313 A 0.42 G 0.58 0.49 AGGCATGAGCCACCRCGCCCGGCCATGTA . . Other Intron .197 APOC4 1406 G 0.87 A 0.13 0.22 ACAGGGCCAGGCACRGTGGCTCATGCCTG . .Other Intron . 198 APOC4 1446 G 0.91 A 0.09 0.16CTTTCGGAGGCCGARGCGGGTGGATCGCA . . Other Intron . 199 APOC4 1587 C 0.29 A0.71 0.41 CGGGAGGCTGAGGCMGGAGAATCACTTGA . . Other Intron . 200 APOC41782 G 0.96 C 0.04 0.07 ATAACCCTGAGGTASATATTATTACCCCG . . Other Intron .201 APOC4 1794 C 0.94 T 0.06 0.11 TAGATATTATTACCYCGTTCTACAAAAGG . .Other Intron . 202 APOC4 1842 G 0.98 A 0.03 0.05CAGGATAAGTCACCRGCCAAGGCACACAG . . Other Intron . 203 APOC4 1858 T 0.36 C0.64 0.46 CCAAGGCACACAGCYAGCTACATGTGGCC . . Other Intron . 204 APOC41875 C 0.96 T 0.04 0.07 CTACATGTGGCCCCYGCGTGACGGCTGGT . . Other Intron .205 APOC4 2206 A 0.92 G 0.08 0.15 TGAAGAGATGGCCCRGCCGGACGGGGTGG . .Other Intron . 206 APOC4 2237 C 0.94 T 0.06 0.12CACATCTGTAATCCYAGCATTTTGGGAGC . . Other Intron . 207 APOC4 2276 T 0.65 C0.35 0.46 TGGATCACTTGAGGYCAGGAGTTCGAGGC . . Other Intron . 208 APOC42345 A 0.74 G 0.26 0.38 ATTAGCCGGGCATGRTGGCAGATGCCTGT . . Other Intron .209 APOC4 2366 T 0.51 A 0.49 0.50 ATGCCTGTAATCCCWGCTACTCGGGAGGC . .Other Intron . 210 APOC4 2767 G 0.99 A 0.01 0.02AAGATGAGTCGCTGRAGCCTGGTGAGGGG TGG TGA Nonsynonymous Trp Stop 211 APOC43027 G 0.98 A 0.03 0.05 TCACAGAGAGGAGCRGATAAATGGGGCAG . . Other Intron .212 APOC4 3078 G 0.96 C 0.04 0.08 GCCTCCACTGTGATSTCCTCTCTCCTGTA . .Other Intron . 213 APOC4 3162 T 0.51 G 0.49 0.50GGACCTGGGTCCGCKCACCAAGGCCTGGT CTC CGC Nonsynonymous Leu Arg 214 APOC43252 A 0.91 T 0.09 0.17 TGGGGACAAGGACCWGGGTTAAAATGTTC CAG CTGNonsynonymous Gln Leu 215 APOC4 483 T 0.95 G 0.05 0.10CTGAGAGTGAAGTGKGAATGTCACATTGG . . Other Intron . 216 APOC4 931 A 0.97 G0.03 0.06 CCAGGCTGGAGTGCRGTGGCGTGATCTTG . . Other Intron . 217 APOC4 968C 0.76 T 0.24 0.36 CAAGCTCCGCCTCCYGGGTTCACGCCATT . . Other Intron . 218APOER2EX1 454 G 0.98 C 0.02 0.04 CGCGGCAAGGACTCSGAGGGCTGAGACGC . . Other5′ UTR . 219 APOER2EX12 68 A 0.96 C 0.04 0.07ACCAACTGTCCAGCMTTGACTTCAGTGGA ATT CTT Nonsynonymous Ile Leu 220APOER2EX13 55 G 0.99 C 0.01 0.02 CGAGGCCATTTTCASTGCAAATCGGCTCA AGT ACTNonsynonymous Ser Thr 221 APOER2EX14 162 G 0.98 A 0.03 0.05GAAGAGGTGCTACCRAGGTAAGCAGACCT CGA CAA Nonsynonymous Arg Gln 222APOER2EX17 55 A 0.98 G 0.03 0.05 TACCTGATCTGGAGRAACTGGAAGCGGAA AGA AGGSynonymous Arg Arg 223 APOER2EX19 1005 G 0.52 C 0.48 0.50AGAGTGCTCAGAAASTCAAGATAGGATAT . . Other 3′ UTR . 224 APOER2EX19 1060 T0.96 C 0.04 0.07 TAAAGTTCAGCTCTYTGAGTAACTTCTTC . . Other 3′ UTR . 225APOER2EX19 1149 A 0.98 T 0.03 0.05 TGCCATCCTTACAGWGCTAAGTGGAGACG . .Other 3′ UTR . 226 APOER2EX19 13 G 0.51 A 0.49 0.50GTTGTCTCCCCAGCRAGTGGCATTAAGCC CGA CAA Nonsynonymous Arg Gln 227APOER2EX19 602 A 0.93 G 0.07 0.13 TTTAGAGAAGTGAGRGTATTTATTTTTGG . .Other 3′ UTR . 228 APOER2EX19 931 A 0.99 C 0.01 0.02CCATGGCTGCTGTGMCTCCTACCAGGGCT . . Other 3′ UTR . 229 APOER2EX9 116 G0.99 A 0.01 0.03 TGCTCAAGAATGTCRTGGCACTAGATGTG GTG ATG Nonsynonymous ValMet 230 APOER2EX9 157 G 0.99 C 0.01 0.02 AATCGCATCTACTGSTGTGACCTCTCCTATGG TGC Nonsynonymous Trp Cys 231 AT1EX5 1158 A 0.95 G 0.05 0.10TGAGGTTGAGTGACRTGTTCGAAACCTGT . . Other 3′ UTR . 232 AT1EX5 1226 T 0.92G 0.08 0.15 TCCTCTGCAGCACTKCACTACCAAATGAG . . Other 3′ UTR . 233 AT1EX51242 A 0.53 C 0.47 0.50 ACTACCAAATGAGCMTTAGCTACTTTTCA . . Other 3′ UTR .234 AT1EX5 1249 A 0.99 G 0.01 0.03 AATGAGCATTAGCTRCTTTTCAGAATTGA . .Other 3′ UTR . 235 AT1EX5 1473 G 0.91 A 0.09 0.17CCTGCTTTTGTCCTRTTATTTTTTATTTC . . Other 3′ UTR . 236 AT2EX3 1355 T 0.39G 0.61 0.47 GTTTGTACAAGATTKTCATTGGTGAGACA . . Other 3′ UTR . 237 AT2EX31361 G 0.69 A 0.31 0.43 ACAAGATTTTCATTRGTGAGACATATTTA . . Other 3′ UTR .238 AT2EX3 562 T 0.99 C 0.01 0.03 TATATAGTTCCCCTYGTTTGGTGTATGGC CTT CTCSynonymous Leu Leu 239 AT2EX3 807 G 0.94 A 0.06 0.12CTATGGGAAGAACARGATAACCCGTGACC AGG AAG Nonsynonymous Arg Lys 240 AT2EX3844 T 0.93 C 0.07 0.13 AAGATGGCAGCTGCYGTTGTTCTGGCCTT GCT GCC SynonymousAla Ala 241 AVPEX2 154 C 0.96 T 0.04 0.08 GGAGAACTACCTGCYGTCGCCCTGCCAGTCCG CTG Nonsynonymous Pro Leu 242 AVPR2EX1 114 A 0.97 T 0.03 0.06TCATGGCGTCCACCWCTTCCGGTAAGGCT ACT TCT Nonsynonymous Thr Ser 243 AVPR2EX2109 G 0.98 A 0.02 0.04 ACCCGGGACCCGCTRCTAGCCCGGGCGGA CTG CTA SynonymousLeu Leu 244 AVPR2EX2 129 C 0.85 T 0.15 0.25CCGGGCGGAGCTGGYGCTGCTCTCCATAG GCG GTG Nonsynonymous Ala Val 245 AVPR2EX2184 G 0.94 T 0.06 0.11 GGCCTGGTGCTGGCKGCCCTAGCTCGGCG GCG GCT SynonymousAla Ala 246 AVPR2EX2 444 C 0.87 T 0.13 0.23CCGTCCCATGCTGGYGTACCGCCATGGAA GCG GTG Nonsynonymous Ala Val 247 AVPR2EX3112 C 0.05 T 0.05 0.10 TCTTTCAGCAGCAGYGTGTCCTCAGAGCT AGC AGT SynonymousSer Ser 248 AVPR2EX3 232 G 0.95 A 0.05 0.10AAGGACACTTCATCRTGAGGAGCTGTTGG TCG TCA Synonymous Ser Ser 249 AVPR2EX3252 T 0.97 C 0.03 0.06 AGCTGTTGGGTGTCYTGCCTCTAGAGGCT . . Other 3′ UTR .250 AVPR2EX3 46 A 0.50 G 0.50 0.50 GCGCCCTTTGTGCTRCTCATGTTGCTGGC CTA CTGSynonymous Leu Leu 251 BIR 1069 C 0.98 T 0.03 0.05CAGGaCTGGCTGGAYGCACAGCTCTAGGG . . Other 3′ UTR . 252 BIR 1142 G 0.67 A0.33 0.44 GGTGAGCCAGTCCTRAATTGGGTTGGGAG . . Other 3′ UTR . 253 BIR 1185G 0.98 T 0.03 0.05 ATAACCCAGTACAGKTTCCTGCTGAGGCC . . Other 3′ UTR . 254BIR 1265 G 0.95 A 0.05 0.10 GGAGGCTGACCTGARGCTGGCCCAGCCTC . . Other3′ UTR . 255 BIR 1295 C 0.24 T 0.76 0.37 CACCAGGCCCTGGCYGGGCTACATACCAC .. Other 3′ UTR . 256 BIR 1441 T 0.99 C 0.01 0.02AGGGGCCCGCGGGCYGAGGCGAGGGTCAG TCA TCG Synonymous Ser Ser 257 BIR 1521 C0.26 T 0.74 0.38 TGTGGGCACTTTGAYGGTGTTGCCAAACT GTC ATC Nonsynonymous ValIle 258 BIR 1729 G 0.99 C 0.01 0.03 GGTGCCAGGTCGTASAGTGGGCTGTTGGC CTCCTG Synonymous Leu Leu 259 BIR 1946 C 0.99 T 0.01 0.02GCATGAAGCAGAGGYGGCCGTGGCGCAGG CGC CAC Nonsynonymous Arg His 260 BIR 1960G 0.75 A 0.25 0.38 CGGCCGTGGCGCAGRGCGATCACCGCATG GCC GCT Synonymous AlaAla 261 BIR 2463 T 0.22 C 0.78 0.34 ACGGTACCTGGGCTYGGCAGGGTCCTCTG AAGGAG Nonsynonymous Lys Glu 262 BIR 2664 T 0.97 C 0.03 0.06TGTGCTGGCCTCACYTCTGAGATAACTCC . . Other 5′ UTR . 263 BIR 2894 T 0.99 G0.01 0.03 TGGTGGTGCGCACCKGTAATCCCACCTAC . . Other Promoter . 264 BIR2954 G 0.97 C 0.03 0.06 CCCGAGAGGCGGAGSTTGCAGTGAGCCAA . . Other Promoter. 265 BIR 3174 C 0.70 T 0.30 0.42 TCCCGCTAAGAGCCYTTCTCCCCGCCCAG . .Other Promoter . 266 BIR 369 G 0.97 A 0.03 0.06CAACACTGCTCCAARGGTCCAGGCACGGG . . Other 3′ UTR . 267 BIR 510 T 0.99 C0.01 0.02 CCTTCTGGACAAAGYGAGTGGCAGCCACT . . Other 3′ UTR . 268 BIR 657 T0.92 A 0.08 0.14 CACAGAGCCCTCACWGCACGAGGCCGATG . . Other 3′ UTR . 269BIR 981 G 0.98 A 0.03 0.05 TTGGAGCCACAGACTCAAAGCAGCAGCCC . . Other3′ UTR . 270 BKRB2EX1 55 T 0.77 G 0.23 0.35GGTGGGGACGGTGGKGACGGTGGGGACAT . . Other 5′ UTR . 271 BKRB2EX3 1513 T0.93 C 0.07 0.13 ATCTCCAGGAGAACYGCCATCCAGCTTTG . . Other 3′ UTR . 272BKRB2EX3 1833 G 0.95 A 0.05 0.10 ACTCAAGTGGGAACRACTGGGCACTGCCA . . Other3′ UTR . 273 BKRB2EX3 747 G 0.93 A 0.07 0.13AAGGAGATCCAGACRGAGAGGAGGGCCAC ACG ACA Synonymous Thr Thr 274 BNPEX1 343G 0.99 T 0.01 0.02 TTTCCTGGGAGGTCKTTCCCACCCGCTGG CGT CTT NonsynonymousArg Leu 275 BNPEX2 15 C 0.97 G 0.03 0.07 TGAGGCTTGGACGCSCCCATTCATTGCAG .. Other Intron . 276 BNPEX2 174 A 0.99 T 0.01 0.02GTGGGCACCGCAAAWTGGTCCTCTACACC ATG TTG Nonsynonymous Met Leu 277 BNPEX237 G 0.97 A 0.03 0.06 ATTGCAGGAGCAGCRCAACCATTTGCAGG CGC CACNonsynonymous Arg His 278 BRS3EX1 424 G 0.95 A 0.05 0.10AGAACTGAAGCAAARGAGTATCTGGATGT . . Other Promoter . 279 BRS3EX1 730 A0.97 C 0.03 0.06 GTGCCATCTATATTMCTTATGCTGTGATC ACT CCT Nonsynonymous ThrPro 280 BRS3EX1 879 A 0.95 T 0.05 0.10 CTAACTTGTGTGCCWGTGGATGCAACTCA CCACCT Synonymous Pro Pro 281 BRS3EX2 144 T 0.94 A 0.06 0.11GCTCTACCTGAGGCWATATTTTCAAATGT GCT GCA Synonymous Ala Ala 282 BRS3EX2 80T 0.98 A 0.02 0.04 CTCCAATGCCATCCWGAAGACTTGTGTAA CTG CAG NonsynonymousLeu Gln 283 BRS3EX3 173 T 0.94 C 0.06 0.12 GCCATGCATTTCATYTTCACCATTTTCTCATT ATC Synonymous Ile Ile 284 CAL/ 1063 T 0.98 G 0.02 0.05CCCCAGTCACAGGCKCTGGGAGCAAAGAG . . Other 5′ UTR . 285 CGRPEX1+2 CAL/ 940G 0.86 A 0.14 0.24 GTGCGATCAGGGACRGCGTCTGGAGCCCA . . Other 5′ UTR . 286CGRPEX1+2 CAL/CGRPEX3 112 G 0.92 A 0.08 0.15CTGCACTGGTGCAGRACTATGTGCAGATG GAC AAC Nonsynonymous Asp Asn 287CAL/CGRPEX3 120 G 0.99 T 0.01 0.02 GTGCAGGACTATGTKCAGATGAAGGCCAG GTG GTTSynonymous Val Val 288 CAL/CGRPEX4 30 C 0.91 A 0.09 0.16TGTTTTCCCTGCAGMCTGGACAGCCCCAG AGC AGA Nonsynonymous Ser Arg 289CAL/CGRPEX5 309 A 0.59 T 0.41 0.48 ATGTGGTTTTAAAAWATCCATAAGGGAAG . .Other 3′ UTR . 290 CAL/CGRPEX5 433 C 0.78 T 0.22 0.34CAGACCAAGAAATAYAGATCCTGTTTATT . . Other 3′ UTR . 291 CAL/CGRPEX5 719 G0.91 A 0.09 0.16 AAAGAGCAAGTGAGRTAATAGATGTTAAG . . Other 3′ UTR . 292CHYEX1 158 T 0.86 A 0.14 0.24 TTGCCTTCTGGGAGWTATAAAACCCAAGA . . Other5′ UTR . 293 CHYEX1 65 T 0.70 C 0.30 0.42 TCTAGGGGAACTFCYGATCAGAAACAGCC. . Other 5′ UTR . 294 CHYEX2 107 G 0.95 C 0.05 0.09TTGTAACTTCCAACSGTCCCTCAAAATTT GGT CGT Nonsynonymous Gly Arg 295 CHYEX2168 A 0.92 G 0.08 0.14 GCTGACGGCTGCTCRTTGTGCAGGAAGGT CAT CGTNonsynonymous His Arg 296 CHYEX3 26 A 0.91 G 0.09 0.17CCTTCTTCCTCACARCAGGTCTATAACAG . . Other Intron . 297 CHYEX4 83 A 0.92 C0.08 0.15 CTCCCCTTCCCATCMCAATTCAACTTTGT TCA TCC Synonymous Ser Ser 298CHYEX5 274 C 0.89 T 0.11 0.19 TCCCTCAGCCACAAYCCTAAGCCTCCAGA . . Other3′ UTR . 299 CLCNKBEX10 33 G 0.56 C 0.44 0.49CTCTGGCCACCTTGSTTCTCGCCTCCATC GTT CTT Nonsynonymous Val Leu 300CLCNKBEX13 12 C 0.94 T 0.06 0.12 GGAGGAGCTGCTATYGGGCGCCTCTTTGG ATC ATTSynonymous Ile Ile 301 CLCNKBEX15 64 C 0.94 T 0.06 0.11ACTGGCCAAGGACAYGCCACTGGAGGAGG ACG ATG Nonsynonymous Thr Met 302CLCNKBEX15 68 A 0.34 G 0.66 0.45 GCCAAGGACACGCCRCTGGAGGAGGTGGT CCA CCGSynonymous Pro Pro 303 CLCNKBEX18 51 C 0.96 T 0.04 0.08CCTCTTTGTGACGTYGCGGGGCAGAGCTG TCG TGG Nonsynonymous Ser Trp 304CLCNKBEX3 34 A 0.94 C 0.06 0.11 GGGAGATTGGGGACMGCCACCTGCTCCGG AGC CGCNonsynonymous Ser Arg 305 CLCNKBEX3 96 G 0.93 A 0.07 0.13GTCTCTTTCTCTTCRGGCTTCTCTCAGAG TCG TCA Synonymous Ser Ser 306 CLCNKBEX419 G 0.35 C 0.65 0.46 CTGGAATCCCGGAGSTGAAGACCATGTTG GTG CTGNonsynonymuus Val Leu 307 CLCNKBEX4 70 A 0.92 C 0.08 0.15ACCTGGATATCAAGMACTTTGGGGCCAAA AAC CAC Nonsynonymous Asn His 308CLCNKBEX7 108 G 0.89 A 0.11 0.20 TTCCGGCTCCTGGCRGTCTTCAACAGCGA GCG GCASynonymous Ala Ala 309 CNPEX1 1018 C 0.91 A 0.09 0.16GCAGCGCCAACTTTMTGCCTGTATGACTT . . Other 5′ UTR . 310 CNPEX1 144 G 0.98 T0.02 0.04 GCCTTCACGCCTGGKGACAGCCACTGCAC . . Other 5′ UTR . 311 CNPEX11457 C 0.98 G 0.02 0.05 GCAGCACTGGGACCSTGCTCGCCCTGCAG . . Other 5′ UTR .312 CNPEX1 578 G 0.91 A 0.09 0.16 ATTGTTCCCACAGARGGAGTTCACCAGCG . .Other 5′  UTR . 313 CNPEX1 592 G 0.94 A 0.06 0.11GGGAGTTCACCAGCRGAGTCAGACCCCGG . . Other 5′ UTR . 314 CNPEX2 1171 T 0.92A 0.08 0.14 AACATCCCAGCCTCWGACATTGACAGTCA . . Other 3′ UTR . 315 CNPEX2139 G 0.96 A 0.04 0.08 GGACACCAAGTCGCRGGCAGCGTGGGCTC CGG CAGNonsynonymous Arg Gln 316 CNPEX2 357 A 0.95 G 0.05 0.10CCCGCCGCCCAGCCRGCCTTCGGAGGCGC . . Other 3′ UTR . 317 CNPEX2 41 T 0.98 C0.02 0.03 GCTGCGGGCGGCGGYCAGAAGAAGGGCGA GGT GGC Synonymous Gly Gly 318COX1 1063 A 0.99 G 0.01 0.02 TTTCCTGCAGCTGARATTTGACCCAGAGC AAA AGANonsynonymous Lys Arg 319 COX1 1314 A 0.99 G 0.01 0.02ACATGGACCACCACRTCCTGCATGTGGCT ATC GTC Nonsynonymous Ile Val 320 COX11386 A 0.99 G 0.01 0.02 TCAATGAGTACCGCRAGAGGTTTGGCATG AAG GAGNonsynonymous Lys Glu 321 COX1 1428 G 0.98 A 0.02 0.03CCTTCCAGGAGCTCRTAGGAGAGAAGGAG GTA ATA Nonsynonymous Val Ile 322 COX11906 T 0.96 C 0.04 0.08 GGTGAGTGTTGGGGYTGACATTTAGAACT . . Other 3′ UTR .323 COX1 1948 T 0.99 C 0.01 0.02 ATTATCTGGAATATYGTGATTCTGTTTAT . . Other3′ UTR . 324 COX1 2037 T 0.99 G 0.01 0.02 GTCTGCCAGAATACKGGGTTCTTAGTTGA. . Other 3′ UTR . 325 COX1 310 G 0.99 A 0.01 0.02TGCCACCTTCATCCRAGAGATGCTCATGC CGA CAA Nonsynonymous Arg Gln 326 COX1 626C 0.91 A 0.09 0.16 TTCAAAACTTCTGGMAAGATGGGTCCTGG GGC GGA Synonymous GlyGly 327 COX1 696 C 0.98 A 0.02 0.03 TTTATGGAGACAATMTGGAGCGTCAGTAT CTGATG Nonsynonymous Leu Met 328 COX1 938 T 0.98 C 0.02 0.04GACCTGCTGAAGGCYGAGCACCCCACCTG GCT GCC Synonymous Ala Ala 329 COX2EX1 186C 0.84 G 0.16 0.27 CGATTTTCTCATTSCGTGGGTAAAAAAC . . Other Promoter . 330COX2EX1 358 T 0.84 G 0.16 0.27 GCGACCAATTGTCAKACGACTTGCAGTGA . . OtherPromoter . 331 COX2EX10 156 T 0.94 C 0.06 0.12AACCATGGTAGAAGYTGGAGCACCATTCT GTT GCT Nonsynonymous Val Ala 332 COX2EX10379 C 0.98 A 0.03 0.05 GCAAGTTCTTCCCGMTCCGGACTAGATGA CGC CGA SynonymousArg Arg 333 COX2EX10 866 T 0.51 C 0.49 0.50AAAGTACTTTTGGTYATTTTTCTGTCATC . . Other 3′ UTR . 334 COX2EX10 87 A 0.99G 0.01 0.02 CATCGATGCTGTGGRGCTGTATCCTGCCC GAG GGG Nonsynonymous Glu Gly335 COX2EX10 937 G 0.83 A 0.17 0.28 ATTAGACATTACCARTAATTTCATGTCTA . .Other 3′ UTR . 336 COX2EX3 166 G 0.93 C 0.07 0.13ATTATGAGTTATGTSTTGACATGTAAGTA GTG GTC Synonymous Val Val 337 COX2EX7 206T 0.96 C 0.04 0.07 AACAGAGTATGCGAYGTGCTTAAACAGGA GAT GAC Synonymous AspAsp 338 COX2EX8 268 T 0.95 C 0.05 0.10 ATATTGCTGGAACAYGGAATTACCCAGTT CATCAC Synonymous His His 339 CYP11B1EX1 351 T 0.97 C 0.03 0.06TGACGTGATCCCTCYCGAAGGCAAGGCAC . . Other Promoter . 340 CYP11B1EX1 525 C0.99 G 0.01 0.03 AGGACAGTGCTGCCSTTTGAAGCCATGCC CCC CCG Synonymous ProPro 341 CYP11B1EX1 542 G 0.97 A 0.03 0.06 TGAAGCCATGCCCCRGCGTCCAGGCAACACGG CAG Nonsynonymous Arg Gln 342 CYP11B1EX1 601 G 0.97 C 0.03 0.06AGCAGGGTTATGAGSACCTGCACCTGGAA GAC CAC Nonsynonymous Asp His 343CYP11B1EX2 184 C 0.99 T 0.01 0.03 GTGGCGTGTTCTTGYTGTAAGCGGCGAGC CTG TTGSynonymous Leu Leu 343 CYP11B1EX2 188 A 0.96 G 0.04 0.07CGTGTTCTTGCTGTRAGCGGCGAGCTGAG . . Other Intron . 345 CYP11B1EX2 36 T0.46 C 0.54 0.50 CCCCACAGGTACGAYTTGGGAGGAGCAGG GAT GAC Synonymous AspAsp 346 CYP11B1EX2 78 C 0.96 T 0.04 0.08 ATGCTGCCGGAGGAYGTGGAGAAGCTGCAGAC GAT Synonymous Asp Asp 347 CYP11B1EX3 114 G 0.99 C 0.01 0.02AGGTTCCTCCCGATSGTGGATGCAGTGGC ATG ATC Nonsynonymous Met Ile 348CYP11B1EX4 177 C 0.98 T 0.02 0.04 CCTGTCTCGCTGGAYCAGCCCCAAGGTGT ACC ATCNonsynonymous Thr Ile 349 CYP11B1EX4 205 T 0.92 G 0.08 0.15TGGAAGGAGCACTTKGAGGCCTGGGACTG TTT TTG Nonsynonymous Phe Leu 350CYP11B1EX4 247 C 0.91 G 0.09 0.16 GGTGAGGCCAGGGASCCGGGCAGTGCTAT . .Other Intron . 351 CYP11B1EX5 103 G 0.97 A 0.03 0.06ACCAGCATCGTGGCRGAGCTCCTGTTGAA GCG GCA Synonymous Ala Ala 352 CYP11B1EX5107 C 0.84 G 0.16 0.26 GCATCGTGGCGGAGSTCCTGTTGAATGCG CTC GTCNonsynonymous Leu Val 353 CYP11B1EX5 16 C 0.58 T 0.42 0.49TGAGGGCTGCCTCCYGCTCCCGGGATAGG . . Other Intron . 354 CYP11B1EX5 55 T0.97 C 0.03 0.06 ATCCAGAAAATCTAYCAGGAACTGGCCTT TAT TAC Synonymous TyrTyr 355 CYP11B1EX5 72 G 0.99 A 0.01 0.03 GGAACTGGCCTTCARCCGCCCTCAACAGTAGC AAC Nonsynonymous Ser Asn 356 CYP11B1EX7 52 C 0.99 T 0.01 0.03CTGTGGGTCTGTTTYTGGAGCGAGTGGCG CTG TTG Synonymous Leu Leu 357 CYP11B1EX8144 T 0.96 C 0.04 0.08 CCGGCAGGAACTTCYACCACGTGCCCTTT TAC CACNonsynonymous Tyr His 358 CYP11B1EX9 16 G 0.96 C 0.04 0.07CCAGATGGAAACCCSGCTTCTGTCCTAGG . . Other Intron . 359 CYP11B1EX9 274 T0.91 C 0.09 0.16 AGCCCCAGCACAAAYGGAACTCCCGAGGG . . Other 3′ UTR . 360CYP11B1EX9 350 T 0.88 G 0.12 0.21 GCTGGGGAAGATCTKGCTGACCTTGTCCC . .Other 3′ UTR . 361 CYP11B1EX9 459 G 0.72 A 0.28 0.40CCTCGTGTGGCCATRCAAGGGTGCTGTGG . . Other 3′ UTR . 362 CYP11B1EX9 592 A0.93 C 0.07 0.13 TCTAGAGTCCAGTCMAGTTCCCTCCTGCA . . Other 3′ UTR . 363CYP11B1EX9 62 C 0.99 T 0.01 0.03 GTGGAGACACTAACYCAAGAGGACATAAA ACC ACTSynonymous Thr Thr 364 CYP11B1EX9 657 G 0.66 A 0.34 0.45CTCTGAAAGTTGTCRCCCTGGAATAGGGT . . Other 3′ UTR . 365 CYP11B1EX9 786 A0.87 G 0.13 0.22 ATCGTGTCAGCCTCRTGCCCCTGGCCTCA . . Other 3′ UTR . 366CYP11B1EX9 835 C 0.77 T 0.23 0.35 GTTCCAGGAGTGGGYGTTGGGTCCTCTGC . .Other 3′ UTR . 367 CYP11B1EX9 879 A 0.68 G 0.32 0.44CTGGGGAAGGTCCCRAGGATGCTGTCAGG . . Other 3′ UTR . 368 CYP11B2EX1 163 A0.97 G 0.03 0.06 TCCTGGGTGAGATARAAGGATTTGGGCTG . . Other Promoter . 369CYP11B2EX3 138 C 0.66 T 0.34 0.45 GTGGCCAGGGACTTYTCCCAGGCCCTGAA TTC TTTSynonymous Phe Phe 370 CYP11B2EX3 152 A 0.71 G 0.29 0.41XTXXXAGGCCCTGARGAAGAAGGTGCTGC AAG AGG Nonsynonymous Lys Arg 371CYP11B2EX3 20 G 0.98 C 0.03 0.05 CAAGCTCTGCCCTGSCCTCTGTAGGAATG . . OtherIntron . 372 CYP11B2EX3 243 G 0.97 A 0.03 0.06GGTGTGGGCCATGCRGGAAGGTCCAGCCC . . Other Intron . 373 CYP11B2EX4 177 T0.96 C 0.04 0.07 CCTGTCTCGCTGGAYCAGCCCCAAGGTGT ATC ACC Nonsynonymous IleThr 374 CYP11B2EX4 250 G 0.98 A 0.02 0.04 GAGGCCAGGGACCCRGGCAGTGCTATGGG. . Other Intron . 375 CYP11B2EX4 99 A 0.94 C 0.06 0.12TTCTGCCAGCCTGAMCTTCCTCCATGCCC AAC ACC Nonsynonymous Asn Thr 376CYP11B2EX5 103 G 0.05 A 0.95 0.10 ACAGGCATCGTGGCRGAGCTCCTGTTGAA GCG GCASynonymous Ala Ala 377 CYP11B2EX5 121 G 0.78 A 0.23 0.35CTCCTGTTGAAGGCRGAACTGTCACTAGA GCG GCA Synonymous Ala Ala 378 CYP11B2EX555 C 0.99 T 0.01 0.02 ATCCAGAAAATCTAYCAGGAACTGGCCTT TAC TAT SynonymousTyr Tyr 379 CYP11B2EX5 72 A 0.99 G 0.01 0.02GGAACTGGCCTTCARCCGCCCTCAACACT AAC AGC Nonsynonymous Asn Ser 380CYP11B2EX6 195 A 0.84 C 0.16 0.27 TCAAGGAGACCTTGMGGTGGGTGCTGGCT AGG CGGSynonymous Arg Arg 381 CYP11B2EX6 91 T 0.38 C 0.63 0.47CGACGTGCAGCAGAYCCTGCGCCAGGAGA ATC ACC Nonsynonymous Ile Thr 382CYP11B2EX7 52 T 0.99 C 0.01 0.03 CTGTGGGTCTGTTTYTGGAGCGAGTGGTG TTG CTGSynonymous Leu Leu 383 CYP11B2EX7 56 T 0.97 T 0.03 0.06GGGTCTGTTTTTGGWGCGAGTGGTGAGCT GAG GTG Nonsynonymous Glu Val 384CYP11B2EX7 65 T 0.91 C 0.09 0.17 TTTGGAGCGAGTGGYGAGCTCAGACTTGG GTG GCGNonsynonymous Val Ala 385 CYP11B2EX7 78 G 0.82 A 0.18 0.30GTGAGCTCAGACTTRGTGCTTCAGAACTA TTG TTA Synonymous Leu Leu 386 CYP11B2EX8132 G 0.97 A 0.03 0.06 ACATCAGGGGCTCCRGCAGGAACTTCCAC GGC AGCNonsynonymous Gly Ser 387 CYP11B2EX8 18 C 0.99 T 0.01 0.02TGATCCCTGCTCTGYACCGTCCGCAGACA . . Other Intron . 388 CYP11B2EX8 182 C0.98 T 0.02 0.04 ATGCGCCAGTGCCTYGGGCGGCGCCTGGC CTC CTT Synonymous LeuLeu 389 CYP11B2EX8 37 T 0.99 A 0.01 0.02 TCCGCAGACATTGGWACAGGTTTTCCTCTGTA GAA Nonsynonymous Val Glu 390 CYP11B2EX9 224 G 0.89 A 0.11 0.20GTCTTCTCTCCCACRTGCACAGCTTCCTG . . Other 3′ UTR . 391 CYP11B2EX9 90 T0.99 G 0.01 0.03 AGATGGTCTACAGCKTCATATTGAGGCCT TTC GTC Nonsynonymous PheVal 392 DBHEX1 152 G 0.99 A 0.01 0.02 GGGCCAGCCTGCCCRGCCCCAGCATGCGG . .Other 5′ UTR . 393 DBHEX3 153 G 0.92 A 0.08 0.14AGTTGCCCTCAGACTCGTGCACCATGGAG GCG ACG Nonsynonymous Ala Thr 394 DBHEX3239 G 0.97 C 0.03 0.06 AAGGAGCTTCCAAASGGCTTCTCTCGGCA AAG AACNonsynonymous Lys Asn 395 DBHEX3 257 C 0.98 T 0.03 0.05TTCTCTCGGCACCAYATTATCAAGGTACG CAC CAT Synonymous His His 396 DBHEX3 63 G0.96 C 0.04 0.08 CGTTCCGGTCACTGSAGGCCATCAACGGC GAG CAG Nonsynonymous GluGln 397 DBHEX4 12 G 0.96 C 0.04 0.08 CCTCCTCACAGTACSAGCCCATCGTCACC GAGCAG Nonsynonymous Glu Gln 398 DBHEX4 132 G 0.94 A 0.06 0.11CCAAGATGAAACCCRACCGCCTCAACTAC GAC AAC Nonsynonymous Asp Asn 399 DBHEX537 T 0.94 C 0.06 0.11 AGAGGAAGCCGGCCYTGCCTTCGGGGGTC CTT CCTNonsynonymous Leu Pro 400 DBHEX5 39 G 0.94 T 0.06 0.11AGGAAGCCGGCCTTKCCTTCGGGGGTCCA GCC TCC Nonsynonymous Ala Ser 401 DD1R 122A 0.84 G 0.16 0.27 CCTATTCCCTGCTTRGGAACTTGAGGGGT . . Other Promoter .402 DD1R 1521 G 0.96 A 0.04 0.08 CTGAACTCGCAGATRAATCCTGCCACACA . . Other3′ UTR . 403 DD1R 278 A 0.96 C 0.04 0.08 TGCTCATCCTGTCCMCGCTCCTGGGGAACACG CCG Nonsynonymous Thr Pro 404 DD1R 279 C 0.99 G 0.01 0.02GCTCATCCTGTCCASGCTCCTGGGGAACA ACG AGG Nonsynonymous Thr Arg 405 DD1R 310C 0.98 G 0.02 0.04 CTGGTCTGTGCTGCSGTTATCAGGTTCCG GCC GCG Synonymous AlaAla 406 DD1R 319 G 0.99 T 0.01 0.02 GCTGCCGTTATCAGKTTCCGACACCTGCG AGGAGT Nonsynonymous Arg Ser 407 DD1R 76 G 0.98 A 0.03 0.05GCAAAGTGCTGCCTRGTGGGGAGGACTCC . . Other Promoter . 408 DD1R 764 T 0.98 G0.03 0.05 ATGCCATCTCATCCKCTGTAATAAGCTTT TCT GCT Nonsynonymous Ser Ala409 EDNRAEX6 124 A 0.28 G 0.72 0.40 ACTGTGTATAACGARATGGACAAGAACCG GAAGAG Synonymous Glu Glu 410 EDNRAEX6 88 C 0.31 T 0.69 0.43TGGTTCCCTCTTCAYTTAAGCCGTATATT CAC CAT Synonymous His His 411 EDNRAEX81157 G 0.66 A 0.34 0.45 TTTTCAGATGATTCRGAAATTTTCATTCA . . Other 3′ UTR .412 EDNRAEX8 1380 C 0.52 T 0.48 0.50 ACGATTCTTCACTTYTTGGGGTTTTCAGT . .Other 3′ UTR . 413 EDNRAEX8 1687 A 0.83 G 0.17 0.28TTGTGCCAAAGTGCRTAGTCTGAGCTAAA . . Other 3′ UTR . 414 EDNRAEX8 228 C 0.47G 0.53 0.50 CAAGGCAACTGTGASTCCGGGAATCTCTT . . Other 3′ UTR . 415EDNRAEX8 295 A 0.99 G 0.01 0.02 AAGAAATGCTTTCCRAAACCGCAAGGTAG . . Other3′ UTR . 416 EDNRAHX8 622 G 0.38 A 0.62 0.47ACAATATGGGCTCARGTCACTTTTATTTG . . Other 3′ UTR . 417 EDNRAEX8 655 G 0.99A 0.01 0.03 GTCATTTGGTGCCARTATTTTTTAACTGC . . Other 3′ UTR . 418EDNRAEX8 788 A 0.88 G 0.12 0.21 CTATTTATTTTTTTRAAACACAAATTCTA . . Other3′ UTR . 419 EDNRAEX8 950 T 0.96 C 0.04 0.08GAACATGTTTTGTAYGTTAAATTCAAAAG . . Other 3′ UTR . 420 EDNRAEX8 985 T 0.97C 0.03 0.06 TTCAATCAGATAGTYCTTTTTCACAAGTT . . Other 3′ UTR . 421EDNRBEX1 33 T 0.98 A 0.03 0.05 GCCGCCTCCAAGTCWGTGCGGACGCGCCC CTG CAGNonsynonymous Leu Gln 422 EDNRBEX1 347 T 0.99 G 0.01 0.02TGTCCTGCCTTGTGKTCGTGCTGGGGATC TTC GTC Nonsynonymous Phe Val 423 EDNRBEX162 C 0.99 T 0.01 0.02 TGGTTGCGCTGGTTYTTGCCTGCGGCCTG CTT TTTNonsynonymous Leu Phe 424 EDNRBEX2 78 C 0.95 T 0.05 0.10ATACAGAAAGCCTCYGTGGGAATCACTGT TCC TCT Synonymous Ser Ser 425 EDNRBEX2 87C 0.99 T 0.01 0.03 GCCTCCGTGGGAATYACTGTGCTGAGTCT ATC ATT Synonymous IleIle 426 EDNRBEX3 144 C 0.94 T 0.06 0.11 TTTTGATATAATTAYGATGGACTACAAAGACG ATG Nonsynonymous Thr Met 427 EDNRBEX4 122 G 0.99 A 0.01 0.03GTTGAGAAAGAAAARTGGCATGCAGATTG AGT AAT Nonsynonymous Ser Asn 428 EDNRBEX439 G 0.82 A 0.18 0.29 AAAGATTGGTGGCTRTTCAGTTTCTATTT CTG CTA SynonymousLeu Leu 429 ELAM1EX1 143 A 0.93 G 0.07 0.13TCTTTGACCTAAATRATGAAAGTCTTAAA . . Other Promoter . 430 ELAM1EX1 209 T0.97 G 0.03 0.06 TTATTGCACTAGTGKCCTTTGCCCAAAAT . . Other Promoter . 431ELAM1EX10 107 C 0.91 T 0.09 0.16 CATTAGCACCATTTYTCCTCTGGCTTCGG CTC TTCNonsynonymous Leu Phe 432 ELAM1EX12 54 T 0.96 C 0.04 0.08AGCCTTGAATCAGAYGGAAGCTACCAAAA GAT GAC Synonymous Asp Asp 433 ELAM1EX131004 T 0.98 G 0.02 0.04 CAGAAATATGTGGTKTCCACGATGAAAAA . . Other 3′ UTR .434 ELAM1EX13 1158 G 0.18 A 0.82 0.29 GATGTTTGTCAGATRTGATATGTAAACAT . .Other 3′ UTR . 435 ELAM1EX13 1549 G 0.39 A 0.61 0.47TGAACACTGGCAACRACAAAGCCAACAGT . . Other 3′ UTR . 436 ELAM1EX13 967 T0.97 C 0.03 0.06 ACTGAATGGAAGGTYTGTATATTGTCAGA . . Other 3′ UTR . 437ELAM1EX2 382 C 0.98 G 0.02 0.04 AATGATGAGAGGTGSAGCAAGAAGAAGCT TGC TGGNonsynonymous Cys Trp 438 ELAM1EX3 152 T 0.95 C 0.05 0.10GTAAGTCTGGTTCTYGCCTCTTTCTTCAC . . Other Intron . 439 ELAM1EX3 53 A 0.97C 0.03 0.06 CCAATACATCCTGCMGTGGCCACGGTGAA AGT CGT Nonsynonymous Ser Arg440 ELAM1EX5 197 G 0.95 A 0.05 0.10 GGAATTGGGACAACRAGAAGCCAACGTGT GAGAAG Nonsynonymous Glu Lys 441 ELAM1EX5 55 T 0.97 C 0.03 0.06GATGCTGTGACAAAYCCAGCCAATGGGTT AAT AAC Synonymous Asn Asn 442 ELAM1EX7199 C 0.94 T 0.06 0.12 GGGGAGTGGGACAAYGAGAAGCCCACATG AAC AAT SynonymousAsn Asn 443 ELAM1EX7 200 G 0.94 C 0.06 0.11GGGAGTGGGACAACSAGAAGCCCACATGT GAG CAG Nonsynonymous Glu Gln 444 ELAM1EX8152 C 0.96 T 0.04 0.08 AGGGATTTGAATTAYATGGATCAACTCAA CAT TATNonsynonymous His Tyr 445 ELAM1EX8 22 T 0.91 C 0.09 0.16AGTGCTCTCTCGTGYGTTCCAGCTGTGAG . . Other Intron . 446 ENDOTHELIN2 440 T0.97 C 0.03 0.07 CCCCTGCAGACGTGYTCCAGACTGGCAAG TTC CTC Nonsynonymous PheLeu 447 ENDOTHELIN2 556 G 0.99 A 0.01 0.02 ATGCGGGAGCCTCGRTCCACACATTCCAGCGG CGA Synonymous Arg Arg 448 ENDOTHELIN2 976 A 0.84 G 0.16 0.27AGCCAGCCCTGGAGRCTGGATGGCTCCCC . . Other 3′ UTR . 449 ET1EX3 114 G 0.88 A0.12 0.21 GCAACAGACCGTGARAATAGATGCCAATG GAG GAA Synonymous Glu Glu 450ET1EX5 90 G 0.69 T 0.31 0.43 AAGCTGAAAGGCAAKCCCTCCAGAGAGCG AAG AATNonsynonymous Lys Asn 457 GALNREX1 1052 G 0.94 T 0.06 0.11CTGCCCACCTGGGTKCTGGGCGCCTTCAT GTG GTT Synonymous Val Val 452 GALNREX1325 C 0.98 G 0.02 0.04 GGTGCAGCACGCAGSCGCTCCGGGAGCCA . . Other Promoter. 453 GALNREX1 327 G 0.81 C 0.19 0.30 TGCAGCACGCAGCCSCTCCGGGAGCCAGG . .Other Promoter . 454 GALNREX1 553 G 0.49 C 0.51 0.50TCTCTCAGAAGGTCSCGGCGCAAAGACGG . . Other Promoter . 455 GALNREX1 887 C0.49 T 0.51 0.50 ATCTTCGCGCTGGGYGTGCTGGGCAACAG GGC GGT Synonymous GlyGly 456 GALNREX3 298 A 0.68 G 0.32 0.43 TGATACTAAAGAAARTAAAAGTCGAATAGAAT AGT Nonsynonymous Asn Ser 457 GALNREX3 322 C 0.98 T 0.02 0.04AATAGACACCCCACYATCAACCAATTGTA CCA CTA Nonsynonymous Pro Leu 458 GALNREX3388 T 0.98 C 0.02 0.04 AGTTTCCATATAAGYGGACCAGACACAGA . . Other 3′ UTR .459 GALNREX3 418 C 0.97 G 0.03 0.06 ACAAACAGAATGAGSTAGTAAGCGATGCT . .Other 3′ UTR . 460 GALNREX3 523 G 0.98 T 0.02 0.04TAGGAAATTCCTAGKTCTAGTGAGAATTA . . Other 3′ UTR . 461 GALNREX3 650 C 0.94T 0.06 0.11 TCCATATATATGTTYAACTCTTCATAGAT . . Other 3′ UTR . 462GALNREX3 799 A 0.84 G 0.16 0.26 ATGTATTTTAAAATRTGATCATGGACACA . . Other3′ UTR . 463 GGREX1 125 G 0.98 A 0.02 0.04 CTGCTGTTGCTGCTRCTGCTGGCCTGCCACTG CTA Synonymous Leu Leu 464 GGREX1 57 C 0.91 T 0.09 0.16CACGAAGTGGTCTTYGCCTTCGTGACGGA TTC TTT Synonymous Phe Phe 465 GGREX4 68 C0.98 G 0.02 0.05 GACCCCGGGGGCAGSCTTGGCGTGATGCC CCT GCT Nonsynonymous ProAla 466 GGREX5 71 C 0.83 G 0.17 0.28 CTGTCCCTGGGGGCSCTGCTCCTCGCCTT GCCGCG Synonymous Ala Ala 467 GGREX9 29 T 0.93 G 0.07 0.12TGACAACATGGGCTKCTGGTGGATCCTGC TTC TGC Nonsynonymous Phe Cys 468 GH1EX4144 G 0.98 A 0.02 0.03 CCTCTGACAGCAACRTCTATGACCTCCTA GTC ATCNonsynonymous Val Ile 469 GH2EX3 126 A 0.94 T 0.06 0.12CAACACCTTCCAACWGGGTGAAAACGCAG AGG TGG Nonsynonymous Arg Trp 470 GIPREX272 C 0.93 G 0.08 0.14 CTTCGCCGCCCTCASGATGACTACCTCTC . . Other 5′ UTR .471 GIPREX7 51 C 0.79 T 0.21 0.33 CATTGCACTAGAAAYTATATCCACATCAA AAC AATSynonymous Asn Asn 472 GIPREX8 180 C 0.98 G 0.03 0.05GCTACTACCTGCTCSTCGGCTGGGGTGAG CTC GTC Nonsynonymous Leu Val 473 GLUT2EX1137 C 0.32 A 0.68 0.44 CCACAGCACTAATTMTCTGTGGAGCAGAG . . Other Promoter. 474 GLUT2EX1 164 T 0.31 C 0.69 0.43 AGTGCAGTGTGCCTYCCATGCTCCACAGC . .Other Promoter . 475 GLUT2EX1 237 T 0.96 C 0.04 0.07AAAGATTTCTCTTTYCACCGGCTCCCAAT . . Other Promoter . 476 GLUT2EX1 242 G0.34 A 0.66 0.45 TTTCTCTTTTCACCRGCTCCCAATTACTG . . Other Promoter . 477GLUT2EX10 161 G 0.99 A 0.01 0.02 GAATTCCAAAAGAARAGTGGCTCAGCCCA AAG AAASynonymous Lys Lys 478 GLUT2EX10 87 C 0.99 G 0.01 0.03TCCTGGCCTTTACCSTGTTTACATTTTTT CTG GTG Nonsynonymous Leu Val 479GLUT2EX10 92 T 0.35 C 0.65 0.46 GCCTTTACCCTGTTYACATTTTTTAAAGT TTT TTCSynonymous Phe Phe 480 GLUT2EX3 250 C 0.87 T 0.13 0.23AGTTGGTGGAATGAYTGCATCATTCTTTG ACT ATT Nonsynonymous Thr Ile 481GLUT2EX4A 153 T 0.96 C 0.04 0.08 TCAGGACTATATTGYGGTAAGTCTCACAC TGT TGCSynonymous Cys Cys 482 GLUT2EX4A 162 T 0.83 A 0.17 0.28TATTGTGGTAAGTCWCACACACACACACA . . Other Intron . 483 GLUT2EX4A 164 A0.94 T 0.06 0.11 TTGTGGTAAGTCTCWCACACACACACACA . . Other Intron . 484GLUT2EX4B 127 A 0.28 G 0.72 0.40 CTGGCCATCGTCACRGGCATTCTTATTAG ACA ACGSynonymous Thr Thr 485 GLUT2EX5 78 C 0.93 T 0.08 0.14ATCTGTGGCACATCYTGCTTGGCCTGTCT CTG TTG Synonymous Leu Leu 486 GLUT2EX6 15T 0.10 C 0.90 0.18 TGTTTCAACCTGATYATTTTCTTGGACAG . . Other Intron . 487GLUT2EX8 21 T 0.88 C 0.12 0.21 TAATTTCTTTAAAAYTGTCCTAGGTATTC . . OtherIntron . 488 GLUT2EX8 38 T 0.95 C 0.05 0.10TCCTAGGTATTCCTYGTGGAGAAGGCAGG CTT CTC Synonymous Leu Leu 489 GLUT4EX11002 A 0.99 C 0.01 0.02 CGTTGTGGGAACGGMATTTCCTGGCCCCC . . Other Promoter. 490 GLUT4EX1 1051 C 0.74 T 0.26 0.38 AGCATGTCGCGGACYCTTTAAGGCGTCAT . .Other Promoter . 491 GLUT4EX1 1228 A 0.86 T 0.14 0.24TCTCAGGCCGCTGGWGTTTCCCCGGGGCA . . Other Promoter . 492 GLUT4EX1 1632 A0.71 C 0.29 0.42 CAGCCCCGCTCCACMAGATCCGCGGGAGC . . Other 5′ UTR . 493GLUT4EX1 1662 A 0.64 G 0.36 0.46 CCACTGCTCTCCGGRTCCTTGGCTTGTGG . . Other5′ UTR . 494 GLUT4EX1 1683 G 0.98 C 0.02 0.05GCTTGTGGCTGTGGSTCCCATCGGGCCCG . . Other 5′ UTR . 495 GLUT4EX1 1691 G0.94 A 0.06 0.11 CTGTGG6TCCCATGRGGCCCGCCCTCGCA . . Other 5′ UTR . 496GLUTAEX1 368 6 0.96 A 0.04 0.07 ACAGGA66AATCGARCCTGACTTCTACCA . . OtherPromoter . 497 GLUT4EX1 560 A 0.90 G 0.10 0.19GCGGAAAGGCGAGARATAGTGGGTTGAGA . . Other Promoter . 498 GLUT4EX1 615 G0.93 A 0.07 0.14 TCGCTCGCCCTCCARGTGGCAGCACAACC . . Other Promoter . 499GLUT4EX1 91 C 0.95 T 0.05 0.10 CAGGAGGTTTTGTTYACTCTGAAAAGGGA . . OtherPromoter . 500 GLUT4EX1 966 C 0.95 A 0.05 0.10CTGAAAGACAGGACMAAGCAGCCCGGCCA . . Other Promoter . 501 GLUT4EX10 19 C0.94 G 0.06 0.11 TCCACCCTCCCTGTSTGGCCCCTAGGAGC . . Other Intron . 502GLUT4EX11 1005 G 0.83 A 0.17 0.28 GTGCTGGGATTACARGCGTGAGCCACCGC . .Other 3′ UTR . 503 GLUT4EX11 1099 A 0.95 C 0.05 0.10GAAAGTATGTGCCCMTGTGTGGCAAGATG . . Other 3′ UTR . 504 GLUT4EX11 791 T0.03 C 0.07 0.14 CGAGTGCAGTGGCGYGATCTTGCTTCACT . . Other 3′ UTR . 505GLUT4EX11 827 C 0.90 T 0.10 0.18 GTCTCCCAGGTTCAYGCCATTCTCCTGCC . . Other3′ UTR . 506 GLUT4EX11 872 G 0.79 A 0.21 0.33CTGGGACTACAGGCRCATGCCACCACACC . . Other 3′ UTR . 507 GLUT4EX11 874 A0.92 C 0.08 0.15 GGGACTACAGGCGCMTGCCACCACACCTG . . Other 3′ UTR . 508GLUT4EX11 884 A 0.73 G 0.27 0.40 GCGCATGCCACCACRCCT6GCTAATTTAT . . Other3′ UTR . 509 GLUT4EX11 897 A 0.89 T 0.11 0.20CACCTGGCTAATTTWTTTTGTATTTTTAG . . Other 3′ UTR . 510 GLUT4EX11 930 A0.88 G 0.13 0.22 TACGCGGTTTCACCRTGTTAGCCAGAATG . . Other 3′ UTR . 511GLUT4EX11 935 A 0.86 G 0.14 0.24 GGTTTCACCATGTTRGCCAGAATGGTCTC . . Other3′ UTR . 512 GLUT4EX11 941 A 0.49 G 0.51 0.50ACCATGTTAGCCAGRATGGTCTCGATCTC . . Other 3′ UTR . 513 GLUT4EX11 963 C0.96 T 0.04 0.07 CGATCTCCTGACCTYGTGATCTGCCTGCC . . Other 3′ UTR . 514GLUT4EX3 112 C 0.90 G 0.10 0.17 TCCAGGCACCCTCASCACCCTCTGGGCCC ACC AGCNonsynonymous Thr Ser 515 GLUT4EX4 96 C 0.71 T 0.29 0.42ATGGGCCTGGCCAAYGCTGCTGCCTCCTA AAC AAT Synonymous Asn Asn 516 GLUT4EX7 19C 0.95 T 0.05 0.09 TCAGGCCTGACCTTYCCTTCTCCAGGTCT . . Other Intron . 517GLUT4EX7 227 6 0.99 C 0.01 0.02 ATGCTGTATGTGTGSAGCAGCCTCCAGGC . . OtherIntron . 518 GLUT5EX1 184 6 0.95 A 0.05 0.10AAAAGGAGGTGAGCRGCACTCTGCCCTTC . . Other 5′ UTR . 519 GNB3EX1 184 A 0.89C 0.11 0.20 GACAGATGGGGAACMCTGTGCCTCCCTGA . . Other Promoter . 520GNB3EX1 201 A 0.63 G 0.37 0.47 GTGCCTCCCTGAACRGAAATGGCAGGGGA . . OtherPromoter . 521 GNB3EX1 328 A 0.63 G 0.37 0.47GCCAGGGGCCAGTCRAGTGTATCACAGAT . . Other Promoter . 522 GNB3EX10 144 G0.93 A 0.07 0.13 AGAGCATCATCTGCRGCATCACGTCCGTG GGC AGC Nonsynonymous GlySer 523 GNB3EX10 155 C 0.61 T 0.39 0.48 TGCGGCATCACGTCYGTGGCCTTCTCCCTTCC TCT Synonymous Ser Ser 524 GNB3EX11 129 G 0.97 T 0.03 0.06CTTCCTCAAAATCTKGAACTGAGGAGGCT TGG TTG Nonsynonymous Trp Leu 525 GNB3EX11254 C 0.75 T 0.25 0.38 CCACTAAGCTTTCTYCTTTGAGGGCAGTG . . Other 3′ UTR .526 GNB3EX11 536 C 0.60 T 0.40 0.48 TATGGCTCTGGCACYACTAGGGTCCTGGC . .Other 3′ UTR . 527 GSY1EX10 46 A 0.99 G 0.01 0.02GGAGCCTTCCCGACRTGAACAAGATGCTG ATG GTG Nonsynonymous Met Val 528 GSY1EX12152 A 0.95 G 0.05 0.10 CCTTGGGGCTACACRCCGGGTGAGTGTAG ACA ACG SynonymousThr Thr 529 GSY1EX12 163 G 0.95 A 0.05 0.09CACACCGGGTGAGTRTAGTGGGCAGGGGA . . Other Intron . 530 GSY1EX15 75 G 0.96C 0.04 0.07 CCAAGGCCTTTCCASAGCACTTCACCTAC GAG CAG Nonsynonymos Glu Gln531 GSY1EX16 152 C 0.99 T 0.01 0.02 CCGCTGGAGGAAGAYGGCGAGCGCTACGA GACGAT Synonymous Asp Asp 532 GSY1EX16 210 C 0.94 G 0.06 0.11GCAACATCCGTGCASCAGAGTGGCCGCGC CCA GCA Nonsynonymous Pro Ala 533 GSY1EX1665 G 0.94 A 0.06 0.11 CGGCCAGCCTCGGTRCCACCGTCGCCCTC GTG GTA SynonymousVal Val 534 GSY1EX2 219 G 0.99 A 0.01 0.03 CTGCAAGGTGGGACRTGGCCCAGCCCAGG. . Other Intron . 535 GSY1EX3 117 A 0.95 G 0.05 0.10CCCTGGAGCGCTGGRAGGGAGAGCTCTGG AAG GAG Nonsynonymous Lys Glu 536 GSY1EX3134 T 0.96 C 0.04 0.08 GGAGAGCTCTGGGAYACCTGCAACATCGG GAT GAC SynonymousAsp Asp 537 GSY1EX3 149 A 0.95 G 0.05 0.10 ACCTGCAACATCGGRGTGCCGTGGTACGAGGA GGG Synonymous Gly Gly 538 GSY1EX3 53 C 0.99 G 0.01 0.03GGGCGCTGGCTGATSGAGGGAGGCCCTCT ATC ATG Nonsynonymous Ile Met 539 GSY1EX416 C 0.93 T 0.07 0.12 ACAGTGGCCCTGTCYCTGTTGCCCACAGT . . Other Intron .540 GSY1EX5 44 G 0.96 A 0.04 0.08 TTCAACGTGGACAARGAAGCAGGGGAGAG AAG AAASynonymous Lys Lys 541 GSY1EX6 54 A 0.99 G 0.01 0.03CCCCAATGGGCTGARTGTGAAGAAGTTTT AAT AGT Nonsynonymous Asn Ser 542 GSY1EX7114 C 0.71 T 0.29 0.42 GGTGCTGACGTCTTYCTGGAGGCATTGGC TTC TTT SynonymousPhe Phe 543 GSY1EX7 16 T 0.98 G 0.02 0.04 GCTTTACCGTGCCTKGTGGGTTCTTTAGG. . Other Intron . 544 GSY1EX7 17 G 0.99 C 0.01 0.02CTTTACCGTGCCTTSTGGGTTCTTTAGGC . . Other Intron . 545 GSY1EX8 43 A 0.94 G0.06 0.11 GGTGAACGGCAGCGRGCAGACAGTGGTTG GAG GGG Nonsynonymous Glu Gly546 HAPTEX1 135 T 0.97 C 0.03 0.06 GATAAAGAGACAGAYTGATGGTTCCTGCC . .Other 5′ UTR . 547 HAPTEX1 188 C 0.90 T 0.10 0.18GATTTCAGGAAATAYTTTGGCAGGTTTGT . . Other 5′ UTR . 548 HAPTEX1 239 T 0.95G 0.05 0.09 CTTGGGATTTGTAAKAGAACATCACAAGA . . Other 5′ UTR . 549 HAPTEX1326 T 0.45 A 0.55 0.50 ACTGGAAAAGATAGWGACCTTACCAGGGC . . Other 5′ UTR .550 HAPTEX1 329 C 0.76 G 0.24 0.37 GGAAAAGATAGTGASCTTACCAGGGCCAA . .Other 5′ UTR . 551 HAPTEX1 369 A 0.88 C 0.12 0.21ACAGGAATTACGAAMTGGAGAAGGGGGAG . . Other 5′ UTR . 552 HAPTEX1 375 A 0.89G 0.11 0.19 ATTACGAAATGGAGRAGGGGGAGAAGTGA . . Other 5′ UTR . 553 HAPTEX434 A 0.53 G 0.47 0.50 TTTGTTTCAGGAGTRTACACCTTAAATGA GTA GTG SynonymousVal Val 554 HAPTEX6 34 G 0.66 A 0.34 0.45 TTTGTTTCAGGAGTRTACACCTTAAACAAGTA GTG Synonymous Val Val 555 HAPTEX7 1331 C 0.98 T 0.02 0.03CATGCTGTTGCCTCYTCAAAGTGAATTAG . . Other 3′ UTR . 556 HAPTEX7 367 G 0.98A 0.02 0.03 GTGTCTGTTAATGARAGAGTGATGCCCAT GAG GAA Synonymous Glu Glu 557HAPTEX7 610 T 0.98 C 0.02 0.04 CACACCTTCTGTGCYGGCATGTCTAAGTA GCT GCCSynonymous Ala Ala 558 HAPTEX7 673 C 0.98 T 0.02 0.03GCCTTTGCCGTTCAYGACCTGGAGGAGGA CAC CAT Synonymous His His 559 HSD11KEX2232 C 0.95 A 0.05 0.10 ACCAAGGCCCACACMACCAGCACCGGTCA ACC ACA SynonymousThr Thr 560 HSD11KEX3 139 G 0.83 A 0.18 0.29AATTTCTTTGGCGCRCTCGAGCTGACCAA GCG GCA Synonymous Ala Ala 561 HSD11KEX5951 T 0.96 A 0.04 0.08 ACTGTACTTCCCAAWTGCCACATTTTAAA . . Other 3′ UTR .562 HSTSCGENE 1392 C 0.97 T 0.03 0.06 ATCTTCGGGGCCACYCTCTCCTCTGCCCT ACCACT Synonymnus Thr Thr 563 HSTSCGENE 1881 G 0.98 A 0.02 0.03GCCCTCAGCTACTCRGTGGGCCTCAATGA TCG TCA Synonymous Ser Ser 564 HSTSCGENE2139 C 0.88 T 0.13 0.22 TCGGATGTCATTGCYGAGGACCTCCGCAG GCC GCT SynonymousAla Ala 565 HSTSCGENE 2595 C 0.90 T 0.10 0.18CGTGTGTTCGTAGGYGGCCAGATTAACAG GGC GGT Synonymous Gly Gly 566 HSTSCGENE3269 G 0.81 A 0.19 0.30 GGTCTTGTGTTTATRGGCTAGAGAAATAG . . Other 3′ UTR .567 HSTSCGENE 3660 C 0.94 T 0.06 0.11 CTGCAACCTCCTCCYGGGTTCAAGCATTT . .Other 3′ UTR . 568 HSTSCGENE 3710 G 0.98 C 0.02 0.03TAGCTGGGATTACASGCACCTGCCATCAC . . Other 3′ UTR . 569 HSTSCGENE 3727 C0.69 G 0.31 0.43 ACCTGCCATCACACSAGCTAATTTTTGTA . . Other 3′ UTR . 570HSTSCGENE 3838 G 0.90 A 0.10 0.18 CCCAAAGTGCTGGGRTTACAGGCCTGAGC . .Other 3′ UTR . 571 HUMAPNH1A 3057 T 0.92 C 0.08 0.15AGGGCATCTCTGAGYGTCTCTGCCTGGAG . . Other 3′ UTR . 572 HUMGFAT 2930 T 0.65G 0.35 0.45 ATCTCCTAAAAGTGKTTTTTATTTCCTTG . . Other 3′ UTR . 573HUMGLUTRN 2110 G 0.94 C 0.06 0.12 GGCTATGGCCACCCSTTCTGCTGGCCTGG . .Other 3′ UTR . 574 HUMGLUTRN 933 A 0.99 C 0.01 0.02GATGATGCGGGAGAMGAAGGTCACCATCC AAG ACG Nonsynonymous Lys Thr 575HUMGUANCYC 2388 C 0.93 T 0.07 0.14 ATTGTCACTGAATAYTGTCCTCGTGGGAG TAC TATSynonymous Tyr Tyr 576 HUMGUANCYC 2571 A 0.86 G 0.14 0.24CGTTTTGTGCTCAARATCACAGACTATGG AAA AGA Nonsynonymous Lys Arg 577HUMGUANCYC 2643 G 0.93 A 0.07 0.14 GCCCTCTATGCCAARAAGCTGTGGACTGC AAG AAASynonymous Lys Lys 578 HUMGUANCYC 2787 C 0.93 G 0.07 0.13GAGGGCCTGGACCTSAGCCCCAAAGAGAT CTC CTG Synonymous Leu Leu 579 HUMGUANCYC2905 C 0.97 G 0.03 0.07 AGCGATGTTGGGCTSAGGACCCAGCTGAG CAG GAGNonsynonymous Gln Glu 580 HUMGUANCYC 3300 C 0.81 G 0.19 0.31GACAACTTTGATGTSTACAAGGTGGAGAC GTC GTG Synonymous Val Val 581 HUMGUANCYC3663 G 0.96 A 0.04 0.08 CTTCGGGGGGATGTRGAAATGAAGGGAAA GTG GTA SynonymousVal Val 582 IAPPEX1-2 199 T 0.97 C 0.03 0.06TTTATTTAGAGAAAYGCACACTTGGTGTT . . Other Intron . 583 IAPPEX1-2 358 A0.99 C 0.01 0.02 GACTGTATCAATAAMAATTTTGATCCTTG . . Other Intron . 584IAPPEX3 1050 T 0.83 C 0.18 0.29 TAAAGTCTATTGTTYGTTGTGCTTGCTGG . . Other3′ UTR . 585 IAPPEX3 1076 T 0.75 A 0.25 0.38TGGTACTAAGAGGCWATTTAAAAGTATAA . . Other 3′ UTR . 586 IAPPEX3 1184 A 0.66C 0.34 0.45 TTTAAGTGGCTTTCMGCAAACCTCAGTCA . . Other 3′ UTR . 587 IAPPEX3296 C 0.85 T 0.15 0.26 TGCCCTTTTCATCTYCAGTGTGAATATAT . . Other 3′ UTR .588 IAPPEX3 848 G 0.11 A 0.89 0.19 CTCCAGCCTGGGTGRCAGAGTGAGACTCG . .Other 3′ UTR . 589 IAPPEX3 959 A 0.93 G 0.07 0.13TTCCTTTTTGCAGTRTATTTCTGAAATGA . . Other 3′ UTR . 590 ICAM1EX1 683 A 0.66C 0.34 0.45 AGAGTTGCAACCTCMGCCTCGCTATGGCT . . Other Promoter . 591ICAM1EX2 115 A 0.70 T 0.30 0.42 CTGTGACCAGCCCAWGTTGTTGGGCATAG AAG ATGNonsynonymous Lys Met 592 ICAM1EX3 151 G 0.99 C 0.01 0.02CTCCGTGGGGAGAASGAGCTGAAACGGGA AAG AAC Nonsynonymous Lys Asn 593 ICAM1EX4115 G 0.92 T 0.08 0.15 TGTTCCCTGGACGGKCTGTTCCCAGTCTC GGG GGT SynonymousGly Gly 594 ICAM1EX4 238 C 0.95 T 0.05 0.10GTGACCGCAGAGGAYGAGGGCACCCAGCG GAC GAT Synonymous Asp Asp 595 ICAM1EX5 47G 0.99 A 0.01 0.02 TTCCGGCGCCCAACRTGATTCTGACGAAG GTG ATG NonsynonymousVal Met 596 ICAM1EX6 18 G 0.94 A 0.06 0.12 CATGTCATCTCATCRTGTTTTTCCAGATG. . Other Intron . 597 ICAM1EX6 254 G 0.45 A 0.55 0.50GGGAGGTCACCCGCRAGGTGACCGTGAAT GAG AAG Nonsynonymous Glu Lys 598 ICAM1EX639 G 0.95 A 0.05 0.10 TCCAGATGGCCCCCRACTGGACGAGAGGG CGA CAANonsynonymous Arg Gln 599 ICAM1EX7 304 C 0.99 T 0.01 0.03GCAGCTACACCTACYGGCCCTGGGACGCC . . Other 3′ UTR . 600 ICAM1EX7 869 A 0.99G 0.01 0.03 TGGCAAAAAGATCARATGGGGCTGGGACT . . Other 3′ UTR . 601ICAM1EX7 929 T 0.96 C 0.04 0.07 GAGTGATTTTTCTAYCGGCACAAAAGCAC . . Other3′ UTR . 602 ICAM2EX1 300 C 0.99 T 0.01 0.02GAGATGTCCTCTTTYGGTTACAGGACCCT TTC TTT Synonymous Phe Phe 603 ICAM2EX2 63G 0.93 A 0.07 0.13 GGCCAAAGAAGCTGRCGGTTGAGCCCAAA GCG ACG NonsynonymousAla Thr 604 ICAM2EX3 281 G 0.98 A 0.03 0.05GGACTTGATGTCTCRCGGTGGCAACATCT CGC CAC Nonsynonymous Arg His 605 INSEX1233 T 0.39 A 0.61 0.48 CAGCCCTGCCTGTCWCCCAGATCACTGTC . . Other 5′ UTR .606 INSEX1 247 C 0.97 T 0.03 0.06 TCCCAGATCACTGTYCTTCTGCCATGGCC . .Other 5′ UTR . 607 INSEX1 453 C 0.78 T 0.22 0.34CAGGGTGAGCCAACYGCCCATTGCTGCCC . . Other Intron . 608 INSEX2 14 C 0.99 T0.01 0.02 GAACCTGCTCTGCGYGGCACGTCCTGGCA . . Other Intron . 609 KALSTEX1133 G 0.88 T 0.12 0.21 CTGCTCCTCCTGCTKGTTGGACTACTGGC CTG CTT SynonymousLeu Leu 610 KALSTEX1 511 A 0.89 G 0.11 0.19CATGGGCTGGAAACRCGCGTGGGCAGTGC ACA ACG Synonymous Thr Thr 611 KALSTEX2318 A 0.67 T 0.33 0.44 GTAATCAGTGTGCTWTGGGGGCTGAATCT . . Other Intron .612 KALSTEX2 79 C 0.72 T 0.28 0.40 ACTCCCAAAGACTTYTATGTTGATGAGAA TTC TTTSynonymous Phe Phe 613 KALSTEX3 17 A 0.98 G 0.02 0.05AATGTTCTAACTCARTGCCCCTTTCAGGA . . Other Intron . 614 KALSTEX3 91 T 0.97C 0.03 0.07 CTGGCTCCTATGTAYTAGATCAGATTTTG TTA CTA Synonymous Leu Leu 615KLKEX1 105 G 0.98 T 0.02 0.03 AGGGCATTCTGAAGKCCAAGGCTTATATT . . Other5′ UTR . 616 KLKEX3 253 C 0.68 G 0.32 0.44 TGGAGTTGCCCACCSAGGAACCCGAAGTGCAG GAG Nonsynonymous Gln Glu 617 KLKEX3 50 G 0.98 A 0.02 0.03GCTCTGGCTGGGTCRCCACAACTTGTTTG CGC CAC Nonsynonymous Arg His 618 KLKEX4110 T 0.97 A 0.03 0.07 CCACGTCCAGAAGGWGACAGACTTCATGC GTG GAGNonsynonymous Val Glu 619 KLKEX4 88 A 0.66 G 0.34 0.45CTAATGATGAGTGCRAAAAAGCCCACGTC AAA GAA Nonsynonymous Lys Glu 620 KLKEX5318 A 0.75 G 0.25 0.38 CCCCAGCTGTGTCARTCTCATGGCCTGGA . . Other 5′ UTR .621 MRLEX1B 156 T 0.46 C 0.54 0.50 CCGATCAGCCAATAYTGGACTTGCTGGTG . .Other 5′ UTR . 622 MRLEX1B 16 G 0.90 C 0.10 0.18GGGCGGGTGCCCGCSTCCCCCTCTGCGCG . . Other 5′ UTR . 623 MRLEX2 1338 A 0.97C 0.03 0.05 CTCTTTTAAAGGGAMTCCAACAGTAAACC AAT ACT Nonsynonymous Asn Thr624 MRLEX2 1405 T 0.99 C 0.01 0.03 GATGATAAAGACTAYTATTCCCTATCAGG TAT TACSynonymous Tyr Tyr 625 MRLEX2 1617 G 0.99 A 0.01 0.03AATATCTTTATCACRATGGGCTAGAGACC CGA CAA Nonsynonymous Arg Gln 626 MRLEX21668 A 0.97 G 0.03 0.05 CTTTCCTCCTGTCARTACTTTAGTGGAGT AAT AGTNonsynonymous Asn Ser 627 MRLEX2 1696 C 0.97 T 0.03 0.06TCATGGAAATCACAyGGCGACCTGTCGTC CAC CAT Synonymous His His 628 MRLEX2 1720T 0.50 C 0.50 0.50 TCGTCTAGAAGAAGYGATGGGTATCCGGT AGT AGC Synonymous SerSer 629 MRLEX9 1326 C 0.99 T 0.01 0.03 GGAATGACACACTGYGGTGTCTGCAGCTC . .Other 3′ UTR . 630 MRLEX9 1572 A 0.43 G 0.57 0.49GTTAAAGATCAGCTRTTCCCTTCTGATCT . . Other 3′ UTR . 631 MRLEX9 1670 A 0.88G 0.13 0.22 GGCCCATCTTGGCARGGTTCAGTCTGAAT . . Other 3′ UTR . 632 MRLEX91964 G 0.86 A 0.14 0.24 AATCTTTTAAAAATRATGATAATCATCAG . . Other 3′ UTR .633 MRLEX9 247 T 0.97 C 0.03 0.06 ACCTGTTTTTAACAYGTGATGGTTGATTC . .Other 3′ UTR . 634 MRLEX9 2551 T 0.88 C 0.13 0.22CCAAATTGTCTGTCYGCTCTTATTTTTGT . . Other 3′ UTR . 635 MRLEX9 2635 G 0.36A 0.64 0.46 TCATATAATTTAAARAAACACTAAATTAG . . Other 3′ UTR . 636 MRLEX9869 C 0.99 G 0.01 0.02 TTTGCTGTGCTGTASATTACTGTATGTAT . . Other 3′ UTR .637 MRLEX9 916 A 0.83 C 0.18 0.29 AATAAGGTATAAGGMTCTTTTGTAAATGA . .Other 3′ UTR . 638 NCX1EX12 1135 A 0.57 G 0.43 0.49AGATTCCCAGGAACRTGCAAAATCCTTTC . . Other 3′ UTR . 639 NCX1EX12 1190 C0.80 T 0.20 0.32 TGATTGGCAAGGTCYTTCTTCCAGCATTC . . Other 3′ UTR . 640NCX1EX12 1298 A 0.99 G 0.01 0.03 ATAACCCCATTCAARAAGCACATCATCGT . . Other3′ UTR . 641 NCX1EX12 1366 G 0.99 C 0.01 0.03CGTTGCTTGGGATTSTGTGTCAGTTTTAT . . Other 3′ UTR . 642 NCX1EX12 1407 A0.84 G 0.16 0.26 CCATGGCTTGCACARTCCTGTTCCAGTCA . . Other 3′ UTR . 643NCX1EX12 1841 G 0.97 C 0.03 0.06 ACCCATTAATTCAGSAAGGCCAAGGAGAA . . Other3′ UTR . 644 NCX1EX12 2099 T 0.94 C 0.06 0.11GAAAGAAGCCAGGGYGACCAACGGGCCTT . . Other 3′ UTR . 645 NCX1EX12 2123 T0.70 Del 0.30 0.42 GCCTTTAAAAGTGTTGTCTCCTCTACTTA . . Other 3′ UTR . 646NCX1EX12 2614 T 0.96 C 0.04 0.08 TGTGATTACTATTTYCATGAGTAAAAGTG . . Other3′ UTR . 647 NCX1EX12 2810 G 0.67 A 0.33 0.44TTTATCTTTGACCGRCTTGCAGATAAATA . . Other 3′ UTR . 648 NCX1EX12 2832 C0.99 G 0.01 0.03 ATAAATATATCTCTSCATTTTAAACCAAG . . Other 3′ UTR . 649NCX1EX12 3079 A 0.66 C 0.34 0.45 TAAACATTAGAAAAMTTTTTGCACTCATT . . Other3′ UTR . 650 NCX1EX12 3193 G 0.99 C 0.01 0.03TTGAAAGCTTTTTGSTTTGTTTGCTTTTT . . Other 3′ UTR . 651 NCX1EX12 664 T 0.99C 0.01 0.03 TCTCTCCAGGTTGAYAAATCCTTAAGGCT . . Other 3′ UTR . 652NCX1EX12 709 A 0.94 G 0.06 0.10 TTGGTTTTGTTTTCRGTGGAGCTGGGGAG . . Other3′ UTR . 653 NCX1EX12 948 G 0.89 A 0.11 0.20AGCATGTCTTCATCRTATTACCAAAGTTC . . Other 3′ UTR . 654 NCX1EX4 59 G 0.99 A0.01 0.03 TAGAATATTTGACCRTGAGGAATATGAGA CGT CAT Nonsynonymous Arg His655 NCX1EX9 66 A 0.97 T 0.03 0.06 ACTGACCAGCAAAGWGGAAGAGGAGAGGC . .Other Intron . 656 NETEX11 123 T 0.86 G 0.14 0.24CGTCAGTCCTGCCTKCCTCCTGGTGTGTA TTC TGC Nonsynonymous Phe Cys 657 NETEX1281 T 0.93 C 0.07 0.13 TCACCTACGACGACYACATCTTCCCGCCC TAC CACNonsynonymous Tyr His 658 NETEX13 50 G 0.93 A 0.07 0.12GCCTATGGCATCACRCCAGAGAACGAGCA ACG ACA Synonymous Thr Thr 659 NETEX14 29G 0.93 C 0.07 0.14 TGTCTTTCTCTGCASTTGCAACACTGGCT . . Other Intron . 660NETEX5 121 A 0.93 C 0.07 0.12 CTCCAATGGCATCAMTGCCTACCTGCACA AAT ACTNonsynonymous Asn Thr 661 NETEX5 175 A 0.96 G 0.04 0.07CACGGTCAGTGCTCRGTGACCACCAAGCC . . Other lntron . 662 NETEX5 83 C 0.95 G0.05 0.10 TTCGTGCTCCTGGTSCATGGCGTCACGCT GTC GTG Synonymous Val Val 663NETEX7 112 G 0.92 C 0.08 0.15 TCCTTGGTTACATGSCCCATGAACACAAG GCC CCCNonsynonymous Ala Pro 664 NETEX7 131 A 0.93 G 0.07 0.14TGAACACAAGGTCARCATTGAGGATGTGG AAC AGC Nonsynonymous Asn Ser 665 NETEX773 G 0.94 C 0.06 0.11 GTATCACCAGCTTCSTCTCTGGGTTCGCC GTC CTCNonsynonymous Val Leu 666 NETEX8 17 C 0.55 A 0.45 0.49TGATGAGGTCCTTGMTGTTTCTTACAGGA . . Other Intron . 667 NETEX9 157 A 0.91 G0.09 0.16 GTTCTGCATAACCARGGTGAGTAGGGGCT AAG AGG Nonsynonymous Lys Arg668 NETEX9 56 G 0.96 A 0.04 0.07 GAGGCTGTCATCACRGGCCTGGCAGATGA ACG ACASynonymous Thr Thr 669 NPYEX1 112 G 0.97 A 0.03 0.06GCGCTGGCCGAGGCRTACCCCTCCAAGCC GCG GCA Synonymous Ala Ala 670 NPYEX1 178A 0.90 G 0.10 0.18 GCCAGATACTACTCRGCGCTGGGACACTA TCA TCG Synonymous SerSer 671 NPYEX1 92 C 0.95 A 0.05 0.10 CCCTGCTCGTGTGCMTGGGTGCGCTGGCC CTGATG Nonsynonymous Leu Met 672 NPYEX2 45 T 0.40 C 0.60 0.48TATGGAAAACGATCYAGCCCAGAGACACT TCT TCC Synonymous Ser Ser 673 NPYEX3 100A 0.96 G 0.04 0.08 CCTATTTTCAGCCCRTATTTCATCGTGTA . . Other 3′ UTR . 674NPYFX3 78 G 0.91 T 0.09 0.16 GAGACTTGCTCTCTKGCCTTTTCCTATTT . . Other3′ UTR . 675 NPYR1EX2 144 T 0.94 G 0.06 0.12AACATACTGTCCATKTGTCTAAAATAATC Other 5′ UTR 676 NPYR1EX3 451 A 0.94 C0.06 0.12 AGTCGCATTTAAAAMAATCAACAACAATG AAA ACA Nonsynonymous Lys Thr677 PGISEX1 196 C 0.99 A 0.01 0.03 GCATATAATCTCTTMCTTCCTGTAAATCC . .Other Promoter . 678 PGISFX1 396 T 0.82 G 0.18 0.30TGCGGGGAGCAGGGKTTCTCCCAGAGCGC . . Other Promoter . 679 PGISFX1 419 G0.95 A 0.05 0.09 GAGCGCCCCGGTCCRACCCCTGCGGACCT . . Other Promoter . 680PGISEX1 568 C 0.93 T 0.07 0.12 CCCCGCCAGCCCCGYCAGCCCCGCCAGCC . . Other5′ UTR . 681 PGISEX1 636 C 0.98 T 0.02 0.04CACTGTTGCTGCTGYTGCTACTGAGCCGC CTG TTG Synonymous Leu Leu 682 PGISEX101255 C 0.95 T 0.05 0.09 TTCTGCATTCACAGYGSCTCCTGGRCCTG . . Other 3′ UTR .683 PGISEX10 149 C 0.99 T 0.01 0.03 GCTACCGCATCCGCYCATGACACAGGGAG CCATCA Nonsynonymous Pro Ser 684 PGISEX10 1500 C 0.84 T 0.16 0.28CCTGGCCAACATGGYGAAACCCCGTCTCT . . Other 3′ UTR . 685 PGISEX10 1505 C0.97 T 0.03 0.06 CCAACATGGCGAAAYCCCGTCTCTACTAA . . Other 3′ UTR . 686PGISEX10 1521 C 0.94 A 0.06 0.11 CCGTCTCTACTAAAMATAAAAAAATTAGT . . Other3′ UTR . 687 PGISEX10 1525 A 0.66 C 0.34 0.45CTCTACTAAACATAMAAAAATTAGTCAGG . . Other 3′ UTR . 688 PGISEX10 1544 G0.65 C 0.35 0.45 ATTAGTCAGGTGTGSCGGTGCCGTGCCTG . . Other 3′ UTR . 689PGISEX10 1760 T 0.99 G 0.01 0.02 TTATGATGCTATTTKTATTAATATAAAGT . . Other3′ UTR . 690 PGISEX10 1776 C 0.99 T 0.01 0.02ATTAATATAAAGTCYTGTTTATTGAGACC . . Other 3′ UTR . 691 PGISEX10 1852 A0.91 G 0.09 0.16 CAGCATCTCTATGARGAGAAGGAGGGTTG . . Other 3′ UTR . 692PGISEX10 2474 C 0.90 T 0.10 0.19 CGCAGGCTGCAACCYTGGTGTGCTGGGCG . . Other3′  UTR . 693 PGISEX10 2636 T 0.48 C 0.52 0.50ACTCAAGGAAAAGAYGTGCTCCCACCAGG . . Other 3′ UTR . 694 PGISEX10 270 T 0.99C 0.01 0.03 GCTAGCATTACCACYTCCCTGCTTTTCTC . . Other 3′ UTR . 695PGISEX10 2967 C 0.98 T 0.02 0.04 TTGAGATGGAGTCTYGCTCTGCTGCCCAG . . Other3′ UTR . 696 PGISEX10 2974 C 0.52 T 0.48 0.50GGAGTCTCGCTCTGYTGCCCAGGCTAGAG . . Other 3′ UTR . 697 PGISEX10 3009 T0.91 C 0.09 0.17 GGCGTGATCTCGGCYCACTGCAAGCTCTG . . Other 3′ UTR . 698PGISEX10 3022 T 0.77 C 0.23 0.35 CTCACTGCAAGCTCYGCCTCCCGTGTTCA . . Other3′ UTR . 699 PGISEX10 3061 T 0.69 C 0.31 0.43CTGCCTCAGCCTCCYGAGTAGCTGGGACT . . Other 3′ UTR . 700 PGISEX10 308 G 0.95T 0.05 0.10 TGGGTCCAGGGGAGKGAAAAGCTAAGAGG . . Other 3′ UTR . 701PGISEX10 3082 A 0.88 G 0.12 0.21 CTGGGACTACAGGCRCCCGCCACCACACC . . Other3′ UTR . 702 PGISEX10 3139 A 0.88 G 0.13 0.22TGGGATTTCACCGTRTTAGCCAGGATGGT . . Other 3′ UTR . 703 PGISEX10 3140 T0.82 C 0.18 0.30 GGGATTTCACCGTAYTAGCCAGGATGGTC . . Other 3′ UTR . 704PGISEX10 3186 C 0.90 T 0.10 0.17 TGATCTGCCCGCCTYGGCCTCCCAAAGTG . . Other3′ UTR . 705 PGISEX10 3214 T 0.88 C 0.12 0.21GCTGGGATTACAGGYGTGAGCCACCGCGC . . Other 3′ UTR . 706 PGISEX10 3217 G0.88 A 0.12 0.20 GGGATTACAGGTGTRAGCCACCGCGCCCA . . Other 3′ UTR . 707PGISEX10 3244 A 0.98 C 0.02 0.04 CAGCCAAGAATAAAMTACTCTTAAGTTGA . . Other3′ UTR . 708 PGISEX10 3339 C 0.99 T 0.01 0.03GTTTACCAAATATTYTCCTTTAAACAGAC . . Other 3′ UTR . 709 PGISEX10 3419 G0.95 A 0.05 0.10 GCCCAGGCTGGAGTRCAATGGCACGATCT . . Other 3′ UTR . 710PGISEX10 3540 A 0.98 T 0.02 0.04 CAACTGGTTTTTGTWTTTTTAGTAGAGAC . . Other3′ UTR . 711 PGISEX10 3651 G 0.91 A 0.09 0.16GATTACAGGCATGARCCACCATGCCCGGC . . Other 3′ UTR . 712 PGISEX10 3663 G0.94 A 0.06 0.11 GAGCCACCATGCCCRGCCTAAACTTTGTT . . Other 3′ UTR . 713PGISEX10 3774 C 0.85 T 0.15 0.26 ATGAAAAATAAATTYGCTGGGGAAGGG6G . . Other3′ UTR . 714 PGISEX10 3840 C 0.73 T 0.27 0.40TCTCTGTTACAAAAYGAGATAAGCAAGTR . . Other 3′ UTR . 715 PGISEX10 400 C 0.98T 0.02 0.05 TCAGGCTTTGTCTGYTCCCAATTCACCTC . . Other 3′ UTR . 716PGISEX10 4074 A 0.96 G 0.04 0.07 GATTTTAATGATTARAAAGAATAAACACA . . Other3′ UTR . 717 PGISEX10 454 T 0.98 C 0.02 0.04AAATGCTATTCAGAYAAGGCAGAACTAGG . . Other 3′ UTR . 718 PGISEX10 573 G 0.99T 0.01 0.02 GGATGCTGGCCACAKAAAGGCCACTCAGG . . Other 3′ UTR . 719PGISEX10 578 G 0.99 A 0.01 0.02 CTGGCCACAGAAAGRCCACTCAGGATGTC . . Other3  UTR . 720 PGISEX10 948 C 0.99 A 0.01 0.02CTCCTTAGACTGATMAAGCCAAAAAAGAA . . Other 3′ UTR . 721 PGISEX3 165 T 0.98A 0.02 0.05 CATTACAGCCCCAGWGATGAAAAGGCCAG AGT AGA Nonsynonymous Ser Arg722 PGISEX3 69 G 0.98 T 0.02 0.05 TCCTACGACGCGGTKGTGTGGGAGCCTCG GTG GTTSynonymous Val Val 723 PGISEX4 143 T 0.96 C 0.04 0.07ACTTCTCCTACAGCYTCCTGCTCAGGTGA TTC CTC Nonsynonymous Phe Leu 724 PGISEX493 A 0.99 C 0.01 0.02 GGGCGATGCTACAGMAGCAGGCAGTGGCT GAA GCANonsynonymous Glu Ala 725 PGISEX5 79 C 0.99 T 0.01 0.02CAGGCCCAGGACCGYGTCCACTCAGCTGA CGC CGT Synonymous Arg Arg 726 PGISEX6 35C 0.98 T 0.02 0.05 GCAGTGTCAAAAGTYGCCTGTGGAAGCTG CGC TGC NonsynonymousArg Cys 727 PGISEX6 52 A 0.98 G 0.02 0.05 CTGTGGAAGCTGCTRTCCCCAGCCAGGCTCTA CTG Synonymous Leu Leu 728 PGISEX6 97 G 0.90 A 0.10 0.18CGGAGCAAATGGCTRGAGAGTTACCTGCT CTG CTA Synonymous Leu Leu 729 PGISEX8 102A 0.26 C 0.74 0.38 CCATGGCAGACGGGMGAGAATTCAACCTG AGA CGA Synonymous ArgArg 730 PGISEX9 42 C 0.99 T 0.01 0.02 TTCCTGAACCCTGAYGGATCAGAGAAGAA GACGAT Synonymous Asp Asp 731 PLA2AEX1 302 T 0.96 A 0.04 0.07CCCCGCAGTCTCAAWTCGAGGTTCCCAGT . . Other Intron . 732 PLA2AEX2 118 C 0.95T 0.05 0.10 GGGAGTGACCCCTTYTTGGAATACAACAA TTC TTT Synonymous Phe Phe 733PLA2AEX2 42 A 0.95 C 0.05 0.10 AGTGGCCGCCGCCGMCAGCGGCATCAGCC GAC GCCNonsynonymous Asp Ala 734 PLA2AEX3 103 A 0.95 C 0.05 0.10ATTTCTGCTGGACAMCCCGTACACCCACA AAC ACC Nonsynonymous Asn Thr 735 PLA2AEX3104 C 0.89 A 0.11 0.20 TTTCTGCTGGACAAMCCGTACACCCACAC AAC AAANonsynonymous Asn Lys 736 PLA2AEX3 131 G 0.91 A 0.09 0.17ACCTATTCATACTCRTGCTCTGGCTCGGC TCG TCA Synonymous Ser Ser 737 PLA2AEX3 59C 0.60 T 0.40 0.48 CATGACAACTGCTAYGACCAGGCCAAGAA TAC TAT Synonymous TyrTyr 738 PNMTEX3 181 A 0.89 T 0.11 0.19 GCTTGGAGGCTGTGWGCCCAGATCTTGCC AGCTGC Nonsynonymous Ser Cys 739 PNMTEX3 251 T 0.89 A 0.11 0.19GCCTGGGGGGCACCWCCTCCTCATCGGGG CTC CAC Nonsynonymous Leu His 740 PNMTEX3269 T 0.93 A 0.08 0.14 CCTCATCGGGGCCCWGGAGGAGTCGTGGT CTG CAGNonsynonymous Leu Gln 741 PNMTEX3 380 G 0.96 A 0.04 0.08GGTCCGGGACCTCCRCACCTATATCATGC CGC CAC Nonsynonymous Arg His 742 PNMTEX3445 T 0.96 A 0.04 0.08 GCGTCTTCTTCGCCWGGGCTCAGAAGGTT TGG AGGNonsynonymous Trp Arg 743 PNMTEX3 554 C 0.88 T 0.13 0.22AAATAATACCCTGCYGCTGCGGTCAGTGC . . Other 3′ UTR . 744 PNMTEX3 75 A 0.96 G0.04 0.08 CGAGCCAGGGTGAARCGGGTCCTGCCCAT AAA AAG Synonymous Lys Lys 745PPGLUCEX1 133 G 0.98 A 0.02 0.05 CAGGTATTAAATCCRTAGTCTCGAACTAA . . OtherIntron . 746 PPGLUCEX1 44 C 0.99 T 0.01 0.03ATGAAAAGCATTTAYTTTGTGGCTGGATT TAC TAT Synonymous Tyr Tyr 747 PPGLUCEX1560 C 0.99 T 0.01 0.03 AAGTACTCAAAATTYCTCTGTCCAAAGAA . . Other Intron .748 PPGLUCEX1 635 T 0.92 A 0.08 0.15 ACGTAAACTGTACAWAAATATCTCTTGGC . .Other Intron . 749 PPGLUCEX2 196 G 0.93 A 0.07 0.14AGAGGAACAGGTAARAGTCTAAGCCTGGC . . Other Intron . 750 PPGLUCEX3 119 C0.99 T 0.01 0.02 TTTGGAAGGCCAAGYTGCCAAGGAATTCA GAT GTT Nonsynonymous AlaVal 751 PPGLUCEX4 447 A 0.99 T 0.01 0.02 AAATGAAACATGGGWAATGTTACATCATT .. Other 3′ UTR . 752 PPGLUCEX4 571 C 0.96 T 0.04 0.07TAGTGAGAACTGGAYACCGAAAAATACTT . . Other 3′ UTR . 753 PPGLUCEX4 615 T0.70 C 0.30 0.42 GATTTTTTAATAATYATTCATAATTGTTT . . Other 3′ UTR . 754PPGLUCEX4 672 T 0.98 C 0.02 0.04 AAATAATCTTTAAAYGAAAATATTTTAAG . . Other3′ UTR . 755 PPTHREX1 106 C 0.96 G 0.04 0.08CCCCGGATCCCGGASCCATCCTGTGGAGC . . Other 5′ UTR . 756 PPTHREX1 36 G 0.99C 0.01 0.02 AGAGGGCTCGGCAGSCGCCCGGGGTCCTC . . Other 5′ UTR . 757PPTHREX2 19 G 0.95 A 0.05 0.09 AACCCAGACGCCGCRATGCCCGGCCCTTG . . Other5′  UTR . 758 PPTHREX2 41 C 0.96 G 0.04 0.08GCCCTTGGTTGCTGSTCGCTCTGGCTTTG CTC GTC Nonsynonymous Leu Val 759 PPTHREX279 C 0.99 G 0.01 0.02 CTGACCGGTGTCCCSGGCGGCCGTGCTCA CCC CCG SynonymousPro Pro 760 PPTHREX3 1234 C 0.97 G 0.03 0.06TAATGATAATAAAASCTGCATCCAGATAA . . Other 3′ UTR . 761 PPTHREX3 185 T 0.91C 0.00 0.16 TCATGGTCAGTCGAYGTAACCCAGCACAA GAT GAC Synonymous Asp Asp 762PPTHREX3 401 G 0.95 A 0.05 0.09 CCCTGTGGGCCCCARGGAGCCTATGGTCA CAG CAASynonymous Gln Gln 763 PPTHREX3 425 C 0.90 T 0.10 0.18GGTCAAGCGGGCCTYCTGCTGGGGCTCCT CTC CTT Synonymous Leu Leu 764 PPTHREX3512 G 0.90 A 0.10 0.19 GCAGCCTGGGTCAGRGAGCCCCTGGAGGA AGG AGA SynonymousArg Arg 765 PPTHREX3 576 A 0.91 G 0.09 0.16CTAAGGATGTCTTGRGCCCTGTGTGCCCC . . Other 3′ UTR . 766 PPTHREX3 895 C 0.99A 0.01 0.03 AGCCCCTGGGAGGGMAGCCAGTGAGGGTG . . Other 3′ UTR . 767PPTHREX3 963 G 0.98 C 0.02 0.05 CCCCTCCCCAACCTSGCAGGATTCTCCAT . . Other3′ UTR . 768 PTGER3EX1 232 C 0.96 T 0.04 0.08TGCGGCTCTCTGGAYGCCATCCCCTCCTC . . Other 5′ UTR . 769 PTGFR3EX1 371 C0.96 G 0.04 0.07 GCGCGGGGCAACCTSACGCGCCCTCCAGG CTC CTG Synonymous LeuLeu 770 PTGER3EX1 765 A 0.98 T 0.02 0.04 GGTATGCGAGCCACWTGAAGACGCGTGCCATG TTG Nonsynonymous Met Leu 771 PTGER3EX1 878 G 0.90 T 0.10 0.18CAGTGGCCCGGGACKTGGTGCTTCATCAG ACG ACT Synonymous Thr Thr 772 PTGER3EX10206 T 0.98 C 0.03 0.05 ACATGTTTTTGTACYTTTACTATATCTAC . . Other 3′ UTR .773 PTGER3EX10 281 A 0.85 G 0.15 0.26 GCGTATACATTATCRTATGTAAAATTTGC . .Other 3′ UTR . 774 PTGER3EX2 1293 T 0.38 C 0.62 0.47ACTAAAATGTTTTTYCTACAGTCTACATG . . Other Intron . 775 PTGER3EX2 1295 T0.86 C 0.14 0.23 TAAAATGTTTTTTCYACAGTCTACATGAA . . Other Intron . 776PTGFR3EX2 1393 T 0.84 C 0.16 0.27 GCACTTCTTAAAAAYGTCTCCCCACCAAA . .Other Intron . 777 PTGER3EX2 1403 C 0.98 A 0.03 0.05AAAATGTCTCCCCAMCAAACATAGTAATC . . Other Intron . 778 PTGER3EX2 1614 T0.94 C 0.06 0.11 TAAAGAATTAATTTYGATAGGTACAATAT . . Other Intron . 779PTGER3EX2 1719 G 0.98 C 0.03 0.05 TGGAGACAAAATCTSTTGAGAGTGCTTAT . .Other Intron . 780 PTGER3EX2 2153 A 0.99 G 0.01 0.03AGTCCATCAGGCTGRTAAAGTGAATTATT . . Other Intron . 781 PTGER3EX2 2517 T0.92 C 0.08 0.15 TAGGCATTCGTTAGYATGGGGAAACCTGA . . Other Intron . 782PTGER3EX2 3069 T 0.93 C 0.08 0.14 TAGTGCTGTATATAYCCCAAGATATTTTA . .Other Intron . 783 PTGER3EX2 3101 A 0.91 G 0.09 0.17AAATGTAAGTGTTTRATCATGCCAGATTT . . Other Intron . 784 PTGER3EX2 326 T0.91 A 0.09 0.17 ATATCGCTAAACCTWACTGTGAATTTAGG . . Other Intron . 785PTGER3EX2 3282 A 0.98 G 0.03 0.05 ACTAAAAACTGGCARACAGTATTTTAATA . .Other Intron . 786 PTGER3EX2 3382 T 0.63 C 0.37 0.47TTTTTATAATTTTGYTCTTTTTGACTCCA . . Other Intron . 787 PTGER3EX2 557 G0.99 T 0.01 0.03 TATAAATGATCTTGKTCTATTGGGGAGCG . . Other Intron . 788PTGER3EX2 628 T 0.83 C 0.17 0.28 AACCACATACATCAYTGAAGACAAGGGAT . . OtherIntron . 789 PTGER3EX2 769 T 0.91 A 0.09 0.17GTATAATGTATTTAWAATATTCATCGATA . . Other Intron . 790 PTGER3EX2 787 T0.94 G 0.06 0.12 ATTCATCGATACCAKTATTCAAATATTGC . . Other Intron . 791PTGER3EX2 805 A 0.91 C 0.09 0.16 TCAAATATTGCTCAMTACAGCAAATTAGC . . OtherIntron . 792 PTGER3EX2 850 G 0.98 A 0.02 0.04TTTAAGTTTACTTGRATTGATAATTAGGT . . Other Intron . 793 PTGER3EX2 852 T0.62 A 0.38 0.47 TAAGTTTACTTGGAWTGATAATTAGGTTT . . Other Intron . 794PTGER3EX2 855 A 0.98 T 0.02 0.04 GTTTACTTGGATTGWTAATTAGGTTTACT . . OtherIntron . 795 PTGER3EX3 76 C 0.94 T 0.06 0.12CTCCACCTCCTTACYCTGCCAGTGTTCCT CCC CTC Nonsynonymous Pro Leu 796PTGER3EX3 80 C 0.93 T 0.07 0.13 ACCTCCTTACCCTGYCAGTGTTCCTCAAC TGC TGTSynonymous Cys Cys 797 PTGER3EX4 719 G 0.84 T 0.16 0.27TCTAAGCTTTTGATKACAAAGGAGTGATG . . Other 3′ UTR . 798 PTGER3EX4 94 C 0.98T 0.03 0.05 TTTGCATATTTCTTYCCACCTGAGAAGGA . . Other 3′ UTR . 799PTGER3EX6 197 A 0.98 G 0.03 0.05 GAGTGCTGTGTTTTRAAAAAGCAAGCTCC . . Other3′ UTR . 800 PTGER3EX6 300 G 0.91 A 0.09 0.16GAGATTACCAGCAARCCAGGTCATTTCCG . . Other 3′ UTR . 801 PTGER3EX6 387 T0.98 A 0.03 0.05 CCAATTTAGACTTAWAGTAAGAATAGCAC . . Other 3′ UTR . 802PTGER3EX7 85 A 0.98 G 0.02 0.04 TTGGTGCAGTTCTCRTGATAGTGAGTGAG CAT CGTNonsynonymous His Arg 803 PTGER3EX8 116 C 0.83 T 0.17 0.28GATTTGTCCTTTCCYGCCATGTCTTCATC CCC CCT Synonymous Pro Pro 804 PTGER3EX916 T 0.94 C 0.06 0.12 TGCCTATCACATAAYAGGAGAACCCTGCA . . Other Intron .805 RENEX1 80 A T GGAAGCATGGATGGWTGGAGAAGGATGCC GGA GGT Synonymous GlyGly 806 RENEX2 135 A 0.76 C 0.24 0.37 ATGAAGAGGCTGACMCTTGGCAACACCAC ACAACC Synonymous Thr Thr 807 RENEX4 151 A 0.97 G 0.03 0.05GACATCATCACCGTRAGTTGGGCCGCCCT . . Other Intron . 808 RENEX4 165 T 0.66 G0.34 0.45 AAGTTGGGCCGCCCKAGGTCATCTGCCCC . . Other Intron . 809 RENEX9138 G 0.99 A 0.01 0.03 TTCAGGTGAGGTTCRAGTCGGCCCCCTCG . . Other Intron .810 SAEX1 167 T 0.91 C 0.09 0.17 GTTTTGGGCCAGTCYTGCTCCTCCGGATT . . OtherPromoter . 811 SAEX1 76 G 0.98 T 0.03 0.05 ATTACCTGTAAGAGKAACCGCTGGGAGTC. . Other Promoter . 812 SAEX11 143 C 0.99 T 0.01 0.02AGAGCAGATGATGTYATATTATCCTCTGG GTC GTT Synonymous Val Val 813 SAEX2 54 T0.94 C 0.06 0.12 CTCTGTGCAAATCCYGAGTGCTAAAGCTT . . Other 5′  UTR . 814SAEX3 109 T 0.99 C 0.01 0.03 GAGTTTTGAGGAACYGGGATCTCTGTCCA CTG CCGNonsynonymous Leu Pro 815 SAEX4 187 T 0.82 C 0.18 0.30CACTCCAAGCTGATYGTATCAGAGAACTC ATT ATC Synonymous Ile Ile 816 SAEX5 182 T0.14 C 0.86 0.24 TGGAAGGTATACTTYCACAAAAGTGCAGC . . Other Intron . 817SAEX8 111 G 0.97 C 0.03 0.06 AAATGGAGAAACAASACGGGCCTGGATAT AAG AACNonsynonymous Lys Asn 818 SAEX9 101 C 0.98 T 0.03 0.05CCTTCTCCTGCTTTYGATGTTAAGGTTTG TTC TTT Synonymous Phe Phe 819 SCNN1GEX1167 G 0.48 A 0.52 0.50 GGTGGCCCAGGAAGRCGCAGCGCGGCCGG . . Other Promoter. 820 SCNN1GEX1 236 G 0.81 T 0.19 0.30 TGAAGTCGTGGCCCKCTCCGGGCGGTCTC . .Other Promoter . 821 SCNN1GEX1 498 G 0.99 A 0.01 0.02TGGAGCGGATGCCGRGCGCCAGGGCGTCG . . Other Intron . 822 SCNN1GEX1 552 C0.70 G 0.30 0.42 GAGCCAGCATCAGCSGGTGGCGGCTTCCC . . Other Intron . 823SCNN1GEX1 553 G 0.99 A 0.01 0.02 AGCCAGCATCAGCCRGTGGCGGCTTCCCG . . OtherIntron . 824 SCNN1GEX12 1016 T 0.80 A 0.20 0.32AGATCAGAGTGCCGWGGTGGAGGTCTGGG . . Other 3′ UTR . 825 SCNN1GEX12 1085 A0.75 G 0.25 0.38 CAGGAGATGGATTTRGTTATTCAATTTTG . . Other 3′ UTR . 826SCNN1GEX12 407 C 0.78 G 0.22 0.34 ATGCTGGATGAGCTSTGAGGCAGGGTTGA CTC CTGSynonymous Leu Leu 827 SCNN1GEX12 454 G 0.99 T 0.01 0.02GACCACCAGCCATGKTCTAAGGACATGGA . . Other 3′ UTR . 828 SCNN1GEX12 485 G0.99 A 0.01 0.02 GGGTGCCCCCAGACRTGTGCACAGGGGAC . . Other 3′ UTR . 829SCNN1GEX12 569 T 0.86 G 0.14 0.24 CGCAAGATGGGGCCKGGGCATGCGCAGGA . .Other 3′ UTR . 830 SCNN1GEX12 646 C 0.80 T 0.20 0.32ATAAATCCCGGGACYTGAACTATTAGCAC . . Other 3′ UTR . 831 SCNN1GEX12 678 G0.80 A 0.20 0.32 ACTAGAGACTGGGARCCGAGGCAGTGGTG . . Other 3′ UTR . 832SCNN1GEX12 982 A 0.76 G 0.24 0.37 GAGAACTGGCCCAGRGCCCTTGGAGTGTT . .Other 3′ UTR . 833 SCNN1GEX2 219 G 0.92 T 0.08 0.14TCGTGGTGTCCCGCKGCCGTCTGCGCCGC GGC TGC Nonsynonymous Gly Cys 834SCNN1GEX2 26 G 0.16 C 0.84 0.27 TCTTCTTTGCCCCTSCAGCACGCCCGTCC . . OtherIntron . 835 SCNN1GEX2 43 G 0.36 A 0.64 0.46GCACGCCCGTCCTCRGAGTCCCGTCCTCA . . Other 5′ UTR . 836 SCNN1GEX3 186 T0.79 C 0.21 0.34 TTCTCCCACCGGATYCCGCTGCTGATCTT ATT ATC Synonymous IleIle 837 SCNN1GEX3 259 G 0.94 A 0.06 0.12 GGAAGCGGAAAGTCRGCGGTAGCATCATTGGC AGC Nonsynonymous Gly Ser 838 SCNN1GEX3 261 C 0.91 T 0.09 0.16AAGCGGAAAGTCGGYGGTAGCATCATTCA GGC GGT Synonymous Gly Gly 839 SCNN1GEX3301 G 0.97 A 0.03 0.06 ATGTCATGCACATCRAGTCCAAGCAAGTG GAG AAGNonsynonymous Glu Lys 840 SCNN1GEX3 99 T 0.73 C 0.27 0.40CTGAAGTCCCTGTAYGGCTTTCCAGAGTC TAT TAC Synonymous Tyr Tyr 841 SCNN1GEX447 C 0.96 T 0.04 0.07 TCAAATGACACCTCYGACTGTGCCACCTA TCC TCT SynonymousSer Ser 842 SCNN1GEX7 142 G 0.70 A 0.30 0.42GGTAACAGATTGGCRGGGGCACCCAGCCC . . Other Intron . 843 TBXA2REX1 518 T0.89 A 0.11 0.20 GCTGGGCCCGCCCCWGGTCACAGCCAGAC . . Other 5′  UTR . 844TBXA2REX1B 130 T 0.80 C 0.20 0.32 CTCAGCCTCCCGAGYAGCTGGGATTACAG . .Other 5′ UTR . 845 TBXA2REX2 292 T 0.98 A 0.02 0.04TCCTCACCTTCCTCWGCGGCCTCGTCCTC TGC AGC Nonsynonymous Cys Ser 846TBXA2REX2 329 T 0.98 A 0.03 0.05 CCTGGGGCTGCTGGWGACCGGTACCATCG GTG GAGNonsynonymous Val Glu 847 TBXA2REX2 333 C 0.96 T 0.04 0.08GGGCTGCTGGTGACYGGTACCATCGTGGT ACC ACT Synonymous Thr Thr 848 TBXA2REX2371 A 0.99 T 0.01 0.03 CGCCGCGCTCTTCGWGTGGCACGCCGTGG GAG GTGNonsynonymous Glu Val 849 TBXA2REX2 390 T 0.94 A 0.06 0.12CACGCCGTGGACCCWGGCTGCCGTCTCTG CCT CCA Synonymous Pro Pro 850 TBXA2REX2525 G 0.95 A 0.05 0.10 CCGGCGGTCGCCTCRCAGCGCCGCGCCTG TCG TCA SynonymousSer Ser 851 TBXA2REX2 568 G 0.99 A 0.01 0.02TGGTGTGGGCGGCCRCGCTGGCGCTGGGC GCG ACG Nonsynonymous Ala Thr 852TBXA2REX2 617 T 0.98 A 0.03 0.05 GGGTCGCTACACCGWGCAATACCCGGGGT GTG GAGNonsynonymous Val Glu 853 TBXA2REX2 739 G 0.96 A 0.04 0.07TCCTGCTGAACACGRTCAGCGTGGCCACC GTC ATC Nonsynonymous Val Ile 854TBXA2REX2 852 C 0.98 A 0.02 0.04 ATCATGGTGGTGGCMAGCGTGTGTTGGCT GCC GCASynonymous Ala Ala 855 TBXA2REX3 145 T 0.36 C 0.64 0.46GACCCCTGGGTGTAYATCCTGTTCCGCCG TAT TAC Synonymous Tyr Tyr 856 TBXA2REX3358 A 0.93 G 0.07 0.13 GGGGTGCTGGATGGRCAGTGGGCATCAGC . . Other 3′ UTR .857 TBXA2REX3 528 A 0.89 G 0.11 0.19 AAGGGCATGCAGACRTTGGAAGAGGGTCT . .Other 3′ UTR . 858 TBXA2REX3 599 C 0.89 T 0.11 0.20CCCAGGCTGGAGTGYAGTGGCGCAATCTC . . Other 3′ UTR . 859 TBXA2REX3 701 C0.86 T 0.14 0.24 GGCGCGCGCCACCAYGCCCGGCTAATTTT . . Other 3′ UTR . 860TBXA2REX3 904 A 0.70 G 0.30 0.42 TGGAGTACAGTGGCRCGATCTCGGCTCAC . . Other3′ UTR . 861 TBXA2REX3 906 G 0.53 A 0.47 0.50GAGTACAGTGGCACRATCTCGGCTCACTG . . Other 3′ UTR . 862 TBXA2REX3 953 G0.39 C 0.61 0.47 TTCAAGCGATTCTCSTGCCTCAGCCTCCC . . Other 3′ UTR . 863TBXASEX10 61 G 0.97 T 0.03 0.06 CAGCCTCGAGGAAGKCCTGCCCTATCTGG GGC GTCNonsynonymous Gly Val 864 TBXASEX10 98 G 0.93 A 0.07 0.14ATTGCAGAGACGCTRAGGATGTACCCGCC CTG CTA Synonymous Leu Leu 865 TBXASEX11105 C 0.91 T 0.09 0.16 GTGCTAGAGATGGCYGTGGGTGCCCTGCA GCC GCT SynonymousAla Ala 866 TBXASEX11 152 C 0.99 A 0.01 0.03GCCAAGCCCGGAGAMCTTCAACCCTGAAA ACC AAC Nonsynonymous Thr Asn 867TBXASEX11 49 C 0.98 G 0.02 0.05 CACGGGAGGCAGCTSAGGACTGCGAGGTG CAG GAGSynonymous Gln Glu 868 TBXASEX11 73 C 0.99 T 0.01 0.02AGGTGCTGGGGCAGYGCATCCCCGCAGGC CGC TGC Nonsynonymous Arg Cys 869TBXASEX11 88 G 0.90 A 0.10 0.18 GCATCCCCGCAGGCRCTGTGCTAGAGATG GCT ACTNonsynonymous Ala Thr 870 TBXASEX12 46 C 0.98 A 0.02 0.04TCACGGCTGAGGCCMGGCAGCAGCACCGG CGG AGG Synonymous Arg Arg 871 TBXASEX13226 A 0.99 G 0.01 0.02 CCTGGCATGCAAGGRTAAGAGGTTCTTTT . . Other 3′ UTR .872 TBXASEX4 130 C 0.99 T 0.01 0.03 CCAACAGAATGGTAYGTAGTTTTCTTTCC . .Other Intron . 873 TBXASEX5 15 G 0.99 A 0.01 0.02CTGACCCTCTGCTTRTTACTTCCCAACAG . . Other Intron . 874 TBXASEX6 59 C 0.98A 0.02 0.04 AGCCAAGCCTGCGAMCTTCTCCTGGCTCA GAC GAA Synonymous Asp Asp 875TBXASEX8 110 A 0.89 G 0.11 0.20 ATGGCTTTTTTAACRAACTCATTAGGAAT AAA GAANonsynonymous Lys Asp 876 TBXASEX8 119 A 0.99 G 0.01 0.03TTAACAAACTCATTRGGAATGTGATTGCC AGG GGG Nonsynonymous Arg Gly 877 TBXASEX9156 C 0.96 A 0.04 0.07 CGAACCCTTCCCGGMAACACCAGCCCAGC CAA AAANonsynonymous Gln Lys 878 TBXASEX9 276 C 0.88 G 0.12 0.21CTTTTGCCACCTACSTACTGGCCACCAAC CTA GTA Nonsynonymous Leu Val 879 TRHREX156 G 0.44 C 0.56 0.49 TTCTGCAGAACTTASATGATAAGCAACGA . . Other Promoter .880 TRHREX1 84 T 0.98 C 0.02 0.04 ACAAAGCCAGCTGCYTCTAGACCCCTGGC . .Other Promoter . 881 TRHREX2 147 C 0.99 A 0.01 0.03GTCAGTGAACTGAAMCAAACACAGCTTCA AAC AAA Nonsynonymous Asn Lys 882 TRHREX2240 A 0.99 G 0.01 0.03 GGCCTGGGCATTGTRGGCAACATCATGGT GTA GTG SynonymousVal Val 883 TRHREX3 1161 T 0.58 C 0.42 0.49TCCCACATGATGGGYGGAAAAAGGCAAAA . . Other 3′ UTR . 884 TRHREX3 1231 T 0.98C 0.03 0.05 TTAAATTTGAAAAGYATAGTCAAGACAAA . . Other 3′ UTR . 885 TRHREX31540 T 0.97 A 0.03 0.06 TTCTTTTTTTGTTTWTCTCAAATGCTAGT . . Other 3′ UTR .886 TRHREX3 1786 A 0.99 T 0.01 0.03 GAATCTCCGAGGGCWAAAATTGCCCTTGG . .Other 3′ UTR . 887 TRHREX3 1846 T 0.94 C 0.06 0.12GTAGATCAAAAAAGYACCCATACCTTTAC . . Other 3′  UTR . 888 TRHREX3 2046 G0.98 A 0.02 0.04 CCTCATTCTAGAGTRCGCTTTTTTTTTTT . . Other 3′  UTR . 889TRHREX3 2175 A 0.97 G 0.03 0.06 ACCTGCATGACAGTRAGCAATCTATGTTA . . Other3′ UTR . 890 TRHREX3 2283 G 0.95 A 0.05 0.10ACAAGCACATGTGTRTTTATAAACACATA . . Other 3′ UTR , 891 TRHREX3 377 T 0.95C 0.05 0.10 GCCACAAAAGTGTCYTTTGATGACACCTG TCT TCC Synonymous Ser Ser 892TRHREX3 960 T 0.96 C 0.04 0.07 TAAGATTTTAGACAYACATGTTAACTGTA . . Other3′ UTR . 893

TABLE 2 Type of Base Ref Alt Hetero- Ref Alt amino Ref Alt SEQ Gene/Posi- Al- Freq Al- Freq zygosity Co- Co- acid amino amino ID ExOn tionlele (P) lele (Q) (H) Sequence Tag don don change acid acid NO: ACEEX13138 C 0.81 T 0.19 0.30 CCTCTGCTGGTCCCYAGCCAGGAGGCATC CCC CCT Synon- ProPro 894 ymous ACEEX17 52 A 0.20 G 0.80 0.32AATGTGATGGCCACRTCCCGGAAATATGA ACA ACG Synon- Thr Thr 895 ymous ADRB3EX1416 T 0.90 C 0.10 0.18 TCGTGGCCATCGCCYGGACTCCGAGACTC TGG CGC Nonsyn- TrpArg 896 onymous AGTEX2 644 C 0.86 T 0.14 0.24GCTGCTGCTGTCCAYGGTGGTGGGCGTGT ACG ATG Nonsyn- Thr Met 897 onymous AGTEX2827 T 0.10 C 0.90 0.18 TGGCTGCTCCCTGAYGGGAGCCAGTGTGG ATG ACT Nonsyn- MerThr 898 onymous AGTEXP1 173 C 0.71 T 0.29 0.41TGCTTGTGTGTTTTYCCCAGTGTCTATTA . . Other Pro- . 899 moter AGTEXP2 203 G0.86 A 0.14 0.24 CTCGACCCTGCACCRGCTCACTCTGTTCA . . Other Pro- . 900moter AGTEXP3 144 C 0.24 A 0.76 0.37 GCTATAAATAGGGCMTCGTGACCCGGCCA . .Other Pro- . 901 moter ANPEX3 120 T 0.91 C 0.09 0.16GTCTCTGCTGCATTYGTGTCATCTTGTTG . . Other 3′UTR . 902 ANPEX3 33 T 0.80 C0.20 0.32 TCTCTTTGCAGTACYGAAGATAACAGCCA TGA AGA Nonsyn- Stop Arg 903onymous AT1EX5 1138 A 0.93 G 0.07 0.13 AAGAAGCCTGCACCRTGTTTTGAGGTTGA CCACCG Synon- Pro Pro 904 ymous AT1EX5 1593 G 0.88 T 0.12 0.21AAAGTTTTCGTGCCKGTTTTCAGCTATTA . . Other 3′UTR . 905 AT1EX5 649 T 0.61 C0.39 0.47 CAAAATTCAACCCTYCCGATAGGGCTGGG CTT CTC Synon- Leu Leu 906 ymousMRLEX2 1504 C 0.89 T 0.11 0.20 CAAGAACCAGATGAYGGGAGCTATTACCC GAC GATSynon- Asp Asp 907 ymous MRLEX2 545 A 0.81 G 0.19 0.30GCGTCATGCGCGCCRTTGTTAAAAGCCCT ATT GTT Nonsyn- Ile Val 908 onymousNCX1EX12 3101 A 0.16 T 0.84 0.26 ACTCATTTTTTAGCWGTATTAGGAATGTC . . Other3′UTR . 909

TABLE 3 Gene/Exon Gene Name Table 1 AADD Alpha-Adducin ACE AngiotensinConverting Enzyme ADDB Beta Adducin ADDG Gamma Adducin ADORA2A A2aAdenosine Receptor ADRB3 Beta-3-Adrenergic Receptor ADROM (prepro)Adrenomedullin AE1 Anion Exchanger AGT Angiotensinogen ALDRED AldoseReductase ANPEX1 Atrial Natriuretic Factor APOA1 Apolipoprotein A-IAPOA2 Apolipoprotein A-II APOA4 Apolipoprotein A-IV APOC1EX1Apolipoprotein C-I APOC2 Apolipoprotein C-II APOC3 Apolipoprotein C-IIIAPOC4 Apolipoprotein C-IV APOER2 Apolipoprotein E Receptor 2 AT1Angiotensin II Receptor Type-1 AT2 Angiotensin II Receptor Type 2 AVPArginine Vasopressin AVPR2 Arginine Vasopressin Receptor Type II BIRBeta Inward Rectifier Subunit (Pancreatic K Channel) BKRB2 B2-BradykininReceptor BNP Brain Natriuretic Protein BRS3 Bombesin Receptor Subtype-3CAL/CGRP Calcitonin/Calcitonin Gene Related Peptide CHY Chymase CLCNKBChloride Channel (Human Kidney - B) CNP C-Type Natriuretic Peptide COX1Cyclooxygenase - 1 COX2 Cyclooxygenase - 2 CYP11B1 Cytochrome P-450 11Beta 1 CYP11B2 Cytochrome P-450 11 Beta 2 DBH Dopamine Beta-HydroxylaseDD1R Dopamine D1 Receptor EDNRA Endothelin Receptor Subtype A EDNRBEndothelin Receptor Subtype B ELAM1 Endothelial Leukocyte AdhesionMolecule I ENDOTHEL Endothelin-2 ET1 Endothelin-1 GALNR Galanin ReceptorGGR Glucagon Receptor GH1 Growth Hormone 1 GH2 Growth Hormone 2 GIPRGlucose Insulinotropic Peptide Receptor or Gastric InhibitoryPolypeptide Receptor GLUT2 Glucose Transporter 2 GLUT4 GlucoseTransporter 4 GLUT5 Glucose Transport-Like 5 GNB3 G-Protein Beta-3 ChainGSY1 Glycogen Synthetase HAPT Haptoglobin HSD11K HydroxysteroidDehydrogenase 11 Beta Kidney Isozyme HSTSCGENE Homo sapiensThiazide-Sensitive Cotransporter HUMAPNH1A Human Na/II AntiporterHUMGFAT Human Glutamine: Fructose-6-Phosphate Amidotransferase HUMGLTRNHuman Glucose Transporter HUMGUANCYC Human Guanylate Cyclase IAPP IsletAmyloid Polypeptide ICAM1 Intercellular Adhesion Molecule 1 ICAM2Intercellular Adhesion Molecule 2 INS Insulin KALST Kallistatin KLKKallikrein MRL Mineralocorticoid Receptor NCX1 Sodium-Calcium ExchangerNET Norepinephrine Transporter NPY Neuropeptide Y NPYR1 Neuropeptide YY1 Receptor PGIS Prostacyclin Synthase PLA2A Pancreatic PhospholipaseA-2 PNMT Phenylethanolamine N-Methyltransferase PPGLUC PreproglucagonPPTHR Preprothyrotropin-Releasing Hormone PTGER3 Prostaglandin EReceptor EP3 Subtype REN Renin SA SA Gene Acetyl-CoA SynthetaseHomologue ?? (a candidate gene for genetic hypertension) SCNN1GAmiloride-Sensitive Epithelial Sodium Channel Gamma Subunit TBXA2RThromboxane A2 Receptor THXASO Thromboxane Synthase TRHRThyrotropin-Releasing Hormone Receptor Table 2 ACE AngiotensinConverting Enzyme ADRB3 Beta-3-Adrenergic Receptor AGT AngiotensinogenANP Atrial Natriuretic Factor AT1 Angiotensin II Receptor Type-1 MRLMineralocorticoid Receptor NCX1 Sodium-Calcium Exchanger

909 1 29 DNA Artificial Sequence AADDEX1 305 1 acgggggcgg agccrgagccggagccgac 29 2 29 DNA Artificial Sequence AADDEX10 246 2 aagcttccgaggaakggcag aatggaagc 29 3 29 DNA Artificial Sequence AADDEX12 43 3gatccgagag cagawtttac aggacatta 29 4 29 DNA Artificial Sequence AADDEX13173 4 gaagcagaag ggctstgaag gtgagtgct 29 5 29 DNA Artificial SequenceAADDEX15 74 5 cctagtaagt accgygctgc ctccgctct 29 6 29 DNA ArtificialSequence AADDEX16 1071 6 attcctgtca taggraaggt atatcagga 29 7 29 DNAArtificial Sequence AADDEX16 1321 7 gccctggggc ccctygacat caccgtcat 29 829 DNA Artificial Sequence AADDEX16 1328 8 ggcccctcga catcrccgtcattgatgga 29 9 29 DNA Artificial Sequence AADDEX16 1478 9 cagcctgactaggtrcaggc aagcttgtg 29 10 29 DNA Artificial Sequence AADDEX16 691 10cagctttggc tgcasgtcac cctcctgag 29 11 29 DNA Artificial SequenceAADDEX16 995 11 tatgcatgtc tgacygacga tccctcgac 29 12 29 DNA ArtificialSequence AADDEX2 31 12 tttgattctg taggraccta gaaagattg 29 13 29 DNAArtificial Sequence AADDEX7 96 13 ttggagaagt ggctwatcat gactaccat 29 1429 DNA Artificial Sequence AADDEX9 173 14 attggtgagc aggawtttgaagccctcat 29 15 29 DNA Artificial Sequence ACEEX13 151 15 ccagccaggaggcaycccaa caggtgaca 29 16 29 DNA Artificial Sequence ACEEX13 202 16aggcaacaac cagcrgccag acaaccacc 29 17 29 DNA Artificial Sequence ACEEX15144 17 ctagaacggg cagcrctgcc tgcccagga 29 18 29 DNA Artificial SequenceACEEX17 19 18 ctcaagccat tcaamcccct accagatct 29 19 29 DNA ArtificialSequence ACEEX18 130 19 cagccactct acctsaacct gcatgccta 29 20 29 DNAArtificial Sequence ACEEX21 150 20 cttccatgag gccaytgggg acgtgctag 29 2129 DNA Artificial Sequence ACEEX22 19 21 agcatgacat caackttctg atgaagatg29 22 29 DNA Artificial Sequence ACEEX24 118 22 cagtccaagg aggcygggcagcgcctggg 29 23 29 DNA Artificial Sequence ACEEX24 16 23 tgctccaggtacttygtcag cttcatcat 29 24 29 DNA Artificial Sequence ACEEX26 154 24gggcctcagc cagcrgctct tcagcatcc 29 25 29 DNA Artificial Sequence ACEEX26174 25 tcagcatccg ccacmgcagc ctccaccgg 29 26 29 DNA Artificial SequenceACEEX26 205 26 ctcccacggg ccccmgttcg gctccgagg 29 27 29 DNA ArtificialSequence ACEEX26 224 27 ggctccgagg tggarctgag acactcctg 29 28 29 DNAArtificial Sequence ADDBEX10 81 28 ctcctggagc aggakaagca ccggcccca 29 2929 DNA Artificial Sequence ADDBEX15 68 29 gctctggtcc ggccrtgtgcgagttcttc 29 30 29 DNA Artificial Sequence ADDBEX15 85 30 tgcgagttcttcagygttgc cctccacat 29 31 29 DNA Artificial Sequence ADDBEX17 147 31gaggaaatcc tcagmaaagg cctgagcca 29 32 29 DNA Artificial Sequence ADDBEX3138 32 gcttctcaga ggacracccc gagtacatg 29 33 29 DNA Artificial SequenceADDBEX4 134 33 catggccagc acctsccacg cagtcttcc 29 34 29 DNA ArtificialSequence ADDBEX8 173 34 ccacctgcaa ggttrgctta gctcttctg 29 35 29 DNAArtificial Sequence ADDBEX9 69 35 gtagaggagg cattytacaa gatcttcca 29 3629 DNA Artificial Sequence ADDG 2087 36 tgacattgca catcyaaata ccacattta29 37 29 DNA Artificial Sequence ADORA2AEX1 429 37 ggtgtcactg gcggyggccgacatcgcag 29 38 29 DNA Artificial Sequence ADORA2AEX2 1230 38 tgcagaagcatctgkaagca ccaccttgt 29 39 29 DNA Artificial Sequence ADORA2AEX2 596 39ccgccagacc ttccrcaaga tcattcgca 29 40 29 DNA Artificial SequenceADORA2AEX2 741 40 ggagtgtggg ccaayggcag tgctcccca 29 41 29 DNAArtificial Sequence ADRB3EX1 1020 41 ggccccggtg gggaygtgcg ctccgcccg 2942 29 DNA Artificial Sequence ADRB3EX1 1354 42 tgcgccgccg cccgyccggccctcttccc 29 43 29 DNA Artificial Sequence ADRB3EX1 1445 43 ggtaggtaaccgggkcagag ggaccggcg 29 44 29 DNA Artificial Sequence ADRB3EX1 44 44gctactcctc ccccragagc ggtggcacc 29 45 29 DNA Artificial SequenceADRB3EX2 301 45 gtggtagtgt ccagstgccg tggagcagc 29 46 29 DNA ArtificialSequence ADRB3EX2 408 46 tggttccatt ccttytgcca cccaaaccc 29 47 29 DNAArtificial Sequence ADROMEX1 1197 47 tgggacgtct gagaytttct ccttcaagt 2948 29 DNA Artificial Sequence ADROMEX1 154 48 atgttacctt ccttkcctgactcaagggt 29 49 29 DNA Artificial Sequence ADROMEX1 723 49 gggctcttgctgttyttcgc caggaggct 29 50 29 DNA Artificial Sequence ADROMEX1 981 50gagcaggagc gcgcrtggct gaggaaaga 29 51 29 DNA Artificial SequenceADROMEX2 101 51 tcgctcgcct tcctmggcgc tgacaccgc 29 52 29 DNA ArtificialSequence ADROMEX3 81 52 ctgcggatgt ccagsagcta ccccaccgg 29 53 29 DNAArtificial Sequence ADROMEX4 1033 53 accgagtctc tgtayaatct atttacata 2954 29 DNA Artificial Sequence ADROMEX4 1292 54 tgtcctgggt gcgartcagggcttcgcgg 29 55 29 DNA Artificial Sequence ADROMEX4 1389 55 gcgagcctggactcycgggt tgcgcaacg 29 56 29 DNA Artificial Sequence ADROMEX4 388 56caagcatccc gctgstgcct cccgggacg 29 57 29 DNA Artificial SequenceADROMEX4 536 57 cgcttcctta gcctkgctca ggtgcaagt 29 58 29 DNA ArtificialSequence ADROMEX4 918 58 attttaagac gtgartgtct cagcgaggt 29 59 29 DNAArtificial Sequence AE1EX1 298 59 ggggcatgag tcagrggttt gcgagctgc 29 6029 DNA Artificial Sequence AE1EX1 80 60 tcaaaccttc atccmcaaag gaagagtca29 61 29 DNA Artificial Sequence AE1EX10 77 61 cgaggggagc tgctrcactccctagaggg 29 62 29 DNA Artificial Sequence AE1EX11 181 62 gtcatcttcatctaytttgc tgcactgtc 29 63 29 DNA Artificial Sequence AE1EX11 191 63tctactttgc tgcaytgtca cccgccatc 29 64 29 DNA Artificial Sequence AE1EX11228 64 cggcctcctg ggtcwgtgcc aatacctgt 29 65 29 DNA Artificial SequenceAE1EX12 70 65 gtgtcggagc tgctratctc cactgcagt 29 66 29 DNA ArtificialSequence AE1EX12 71 66 tgtcggagct gctgwtctcc actgcagtg 29 67 29 DNAArtificial Sequence AE1EX14 159 67 ccttcttctt tgccwtgatg ctgcgcaag 29 6829 DNA Artificial Sequence AE1EX15 107 68 ttcttcattc aggayacctacacccaggt 29 69 29 DNA Artificial Sequence AE1EX16 92 69 ggctgggtcatccayccact gggcttgcg 29 70 29 DNA Artificial Sequence AE1EX17 34 70cctacagtag gctgrttgtc agcaaacct 29 71 29 DNA Artificial Sequence AE1EX1740 71 gtaggctgat tgtcrgcaaa cctgagcgc 29 72 29 DNA Artificial SequenceAE1EX17 72 72 atggtcaagg gctcyggctt ccacctgga 29 73 29 DNA ArtificialSequence AE1EX19 132 73 tggccctgcc cttcrtcctc atcctcact 29 74 29 DNAArtificial Sequence AE1EX19 43 74 ggtgaagacc tggcrcatgc acttattca 29 7529 DNA Artificial Sequence AE1EX20 1007 75 aatcagtgga ctccraggggactgagaca 29 76 29 DNA Artificial Sequence AE1EX20 1213 76 atttgagagccattwtcctc aactccatc 29 77 29 DNA Artificial Sequence AE1EX20 1542 77aaaaatacaa aaatyagctg ggtgtctcg 29 78 29 DNA Artificial Sequence AE1EX201628 78 cccaggaggt ggagsttgca gtgagccaa 29 79 29 DNA Artificial SequenceAE1EX20 1679 79 ctgggcaaca gagcragacc ctgtctcaa 29 80 29 DNA ArtificialSequence AE1EX20 379 80 tcactgggga tcccrtgctg gaagactta 29 81 29 DNAArtificial Sequence AE1EX20 418 81 ctccctcttc ccagmacagg caggggtag 29 8229 DNA Artificial Sequence AE1EX20 991 82 ttactgaggg ccccrgaatcagtggactc 29 83 29 DNA Artificial Sequence AE1EX4 17 83 caatactaaccgacytctgg ttttcagct 29 84 29 DNA Artificial Sequence AE1EX4 36 84gttttcagct cacgmcaccg aggcaacag 29 85 29 DNA Artificial Sequence AE1EX489 85 acccgggtac ccacraggtg aggacccca 29 86 29 DNA Artificial SequenceAE1EX5 197 86 ctagagctgc gtagwgtctt caccaaggg 29 87 29 DNA ArtificialSequence AE1EX8 35 87 ttcccacagg gagayggggg cacagaagg 29 88 29 DNAArtificial Sequence AGTEX2 181 88 agagtacctg tgagyagctg gcaaaggcc 29 8929 DNA Artificial Sequence AGTEX2 354 89 gtcgggatgc tggcyaactt cttgggctt29 90 29 DNA Artificial Sequence AGTEX2 755 90 ggacttcaca gaackggatgttgctgctg 29 91 29 DNA Artificial Sequence AGTEX5 258 91 tggcaaggcctctgyccctg gcctttgag 29 92 29 DNA Artificial Sequence AGTEX5 376 92agctggaaag cagcsgtttc tccttggtc 29 93 29 DNA Artificial SequenceAGTEX5385 93 gcagccgttt ctccytggtc taagtgtgc 29 94 29 DNA ArtificialSequence AGTEX5 641 94 gccttcggtt tgtakttagt gtcttgaat 29 95 29 DNAArtificial Sequence AGTEXP1 101 95 ctggctgtgc tattsttggt gtttaacag 29 9629 DNA Artificial Sequence AGTEXP2 160 96 ggaaccttgg ccccractcctgcaaactt 29 97 29 DNA Artificial Sequence AGTEXP2 35 97 ccctctgcacctccrgcctg catgtccct 29 98 29 DNA Artificial Sequence AGTEXP3 158 98ctcgtgaccc ggccrgggga agaagctgc 29 99 29 DNA Artificial Sequence AGTEXP3173 99 ggggaagaag ctgcygttgt tctgggtac 29 100 29 DNA Artificial SequenceALDREDEX1 162 100 gcgccaagat gcccwtcctg gggttgggt 29 101 29 DNAArtificial Sequence ALDREDEX1 71 101 aaaggtacgc gccgsggcca aggccgcac 29102 29 DNA Artificial Sequence ALDREDEX10 150 102 ttgcaaatgt agtakggcctgtgtcactc 29 103 29 DNA Artificial Sequence ALDREDEX2 180 103 tgaagcgtgaggagstcttc atcgtcagc 29 104 29 DNA Artificial Sequence ALDREDEX2 204 104tcagcaaggt atcgktccgc ggtggggct 29 105 29 DNA Artificial SequenceALDREDEX2 88 105 cgtcgggtac cgccwcatcg actgtgccc 29 106 29 DNAArtificial Sequence ALDREDEX3 28 106 cctctcgctg gcttwgctgt ggtgcacgt 29107 29 DNA Artificial Sequence ALDREDEX4 101 107 aacattctgg acacrtgggcggtaagaca 29 108 29 DNA Artificial Sequence ALDREDEX6 87 108 actgccagtccaaargcatc gtggtgacc 29 109 29 DNA Artificial Sequence ALDREDEX9 67 109ccaggatatg accaycttac tcagctaca 29 110 29 DNA Artificial Sequence ANPEX1252 110 ccatgtacaa tgccrtgtcc aacgcagac 29 111 29 DNA ArtificialSequence ANPEX1 297 111 tagggccagg aaagygggtg cagtctggg 29 112 29 DNAArtificial Sequence ANPEX3 106 112 tcctgtcccc tgggktctct gctgcattt 29113 29 DNA Artificial Sequence ANPEX3 127 113 ctgcatttgt gtcaycttgttgccatgga 29 114 29 DNA Artificial Sequence APOA1 101 114 gccttgccccaggcygggcc tctgggtac 29 115 29 DNA Artificial Sequence APOA1 1016 115cgtaactggg caccmgtccc agctctgtc 29 116 29 DNA Artificial Sequence APOA11162 116 aggtgtcacc caggsctcac ccctgatag 29 117 29 DNA ArtificialSequence APOA1 1163 117 ggtgtcaccc agggytcacc cctgatagg 29 118 29 DNAArtificial Sequence APOA1 1401 118 tgcagcccta cctgsacgac ttccagaag 29119 29 DNA Artificial Sequence APOA1 1576 119 tgtggacgcg ctgcscacgcatctggccc 29 120 29 DNA Artificial Sequence APOA1 1643 120 cttgaggctctcaargagaa cggcggcgc 29 121 29 DNA Artificial Sequence APOA1 1757 121caaggcctgc tgccsgtgct ggagagctt 29 122 29 DNA Artificial Sequence APOA12007 122 ctccgtgccc agacwggacg tcttagggc 29 123 29 DNA ArtificialSequence APOA1 334 123 aaccatcggg gggcyttctc cctaaatcc 29 124 29 DNAArtificial Sequence APOA1 620 124 tttgaaggct ccgcyttggg aaaacagct 29 12529 DNA Artificial Sequence APOA1 771 125 ctggatggag aaacyggaat ggatctcca29 126 29 DNA Artificial Sequence APOA1 840 126 gggctgcccg atgcrtgatcacagagcca 29 127 29 DNA Artificial Sequence APOA2 1334 127 agattaggcttaaawtgcag agaaaaagt 29 128 29 DNA Artificial Sequence APOA2 1412 128aagaactggg ccttsaattt cagtctcta 29 129 29 DNA Artificial Sequence APOA21414 129 gaactgggcc ttgawtttca gtctctaga 29 130 29 DNA ArtificialSequence APOA2 1459 130 agcaaaggtc ttgaytctat tcctaccta 29 131 29 DNAArtificial Sequence APOA2 1672 131 aggctggaac ggaaytggtt aacttcttg 29132 29 DNA Artificial Sequence APOA2 249 132 tgcttcctgt tgcaytcaagtccaaggac 29 133 29 DNA Artificial Sequence APOA2 547 133 gacgctggctaggtmagata aggaggcaa 29 134 29 DNA Artificial Sequence APOA4 1228 134gaccaggtgg ccacrgtgat gtgggacta 29 135 29 DNA Artificial Sequence APOA41338 135 gggactacag tgtgyggtgg tgacgggga 29 136 29 DNA ArtificialSequence APOA4 1479 136 ccacatatgt aaacyggaag tttggaccg 29 137 29 DNAArtificial Sequence APOA4 1529 137 ttgctttgac gttcyagagt ttgacaaat 29138 29 DNA Artificial Sequence APOA4 1597 138 ggaggaaaat gtcaygtgagctgatttct 29 139 29 DNA Artificial Sequence APOA4 1617 139 ctgatttctaatacrtttca gaaagacag 29 140 29 DNA Artificial Sequence APOA4 1879 140gattctgaga caaastatgt gggagatcc 29 141 29 DNA Artificial Sequence APOA41961 141 ctgcaccacc atagrgaggg tgaactcgg 29 142 29 DNA ArtificialSequence APOA4 1998 142 agcactcacc tgtcytagca cgtgtgcat 29 143 29 DNAArtificial Sequence APOA4 2134 143 gaagtgaaca cttaygcagg tgacctgca 29144 29 DNA Artificial Sequence APOA4 2138 144 tgaacactta cgcargtgacctgcagaag 29 145 29 DNA Artificial Sequence APOA4 2140 145 aacacttacgcaggygacct gcagaagaa 29 146 29 DNA Artificial Sequence APOA4 2358 146gcgcacccag gtcarcacgc aggccgagc 29 147 29 DNA Artificial Sequence APOA42698 147 atctcggcca gtgcygagga gctgcggca 29 148 29 DNA ArtificialSequence APOA4 2764 148 ctgaggggca acacygaggg gctgcagaa 29 149 29 DNAArtificial Sequence APOA4 2806 149 ctgggtgggc acctrgacca gcaggtgga 29150 29 DNA Artificial Sequence APOA4 2837 150 agttccgacg ccggstggagccctacggg 29 151 29 DNA Artificial Sequence APOA4 2926 151 catgcgggggacgtkgaagg ccacttgag 29 152 29 DNA Artificial Sequence APOA4 3058 152cagcaggaac agcakcagga gcagcagca 29 153 29 DNA Artificial Sequence APOA4350 153 gccagcaggg cctcraggca tcagtcccg 29 154 29 DNA ArtificialSequence APOA4 637 154 tggcgatagg gagasagttt aaatgtctg 29 155 29 DNAArtificial Sequence APOA4 687 155 gttcccactg cagcrcaggt gagctctcc 29 15629 DNA Artificial Sequence APOC1EX1 1020 156 ttgtattttc agtakagacagggtttcac 29 157 29 DNA Artificial Sequence APOC1EX1 1044 157 ttcaccgtggtctcratctc ctgactttg 29 158 29 DNA Artificial Sequence APOC1EX1 1057 158cgatctcctg acttygtgat ccgcctgcc 29 159 29 DNA Artificial SequenceAPOC1EX1 1111 159 caggcgtgag ccacygcgtc cggccattc 29 160 29 DNAArtificial Sequence APOC1EX1 1376 160 gcacgcgcct gtagkcccag ctactcggg 29161 29 DNA Artificial Sequence APOC1EX1 1411 161 aggcaggaga atcasttgaacccgggagg 29 162 29 DNA Artificial Sequence APOC1EX1 432 162 aggctcttcctgtcrctccc ggtcctggt 29 163 29 DNA Artificial Sequence APOC1EX1 462 163gtggttctgt cgatsgtctt ggaaggtaa 29 164 29 DNA Artificial SequenceAPOC1EX1 496 164 ggatgggaga attgsggagt ttggagatt 29 165 29 DNAArtificial Sequence APOC1EX1 713 165 acctctggga ttggytgtcc tgcttcgac 29166 29 DNA Artificial Sequence APOC2 1084 166 tctgaggact caagkgccaagatggaggg 29 167 29 DNA Artificial Sequence APOC2 126 167 caggtctctggacaytatgg gcacacgac 29 168 29 DNA Artificial Sequence APOC2 13 168ctgggacacc gagcwcacac agagcagga 29 169 29 DNA Artificial Sequence APOC2472 169 cccagaacct gtacragaag acatacctg 29 170 29 DNA ArtificialSequence APOC2 553 170 tggcccatac caccractgc atccaggac 29 171 29 DNAArtificial Sequence APOC2 725 171 cccaggagtc caggycccca gaccctcct 29 17229 DNA Artificial Sequence APOC2 804 172 tgtgctttct ccccwgggac ttgtacagc29 173 29 DNA Artificial Sequence APOC2 819 173 gggacttgta cagcmaaagcacagcagcc 29 174 29 DNA Artificial Sequence APOC3 1148 174 ctggggactaagaawgttta tgaacacct 29 175 29 DNA Artificial Sequence APOC3 1322 175cacgggcttg aattrggtca ggtggggcc 29 176 29 DNA Artificial Sequence APOC31468 176 atacgcctga gctcmgcctc ctgtcagat 29 177 29 DNA ArtificialSequence APOC3 1519 177 ggagtgtgaa ccctrttgtg aactgcaca 29 178 29 DNAArtificial Sequence APOC3 1637 178 ggcccatgga aaaawtgtcc accacaaaa 29179 29 DNA Artificial Sequence APOC3 1722 179 aggaaaatgg ggccrggcgcagtggctcg 29 180 29 DNA Artificial Sequence APOC3 1728 180 atggggccaggcgcrgtggc tcatgcctg 29 181 29 DNA Artificial Sequence APOC3 1736 181aggcgcagtg gctcrtgcct gtaatccca 29 182 29 DNA Artificial Sequence APOC31774 182 gaggccgagg caggmggatc ccctgaggt 29 183 29 DNA ArtificialSequence APOC3 1817 183 caacctggcc aacayggtga aaccccatc 29 184 29 DNAArtificial Sequence APOC3 1931 184 ttgaacccgg gagayggagg ttgcagtga 29185 29 DNA Artificial Sequence APOC3 1975 185 ctgcactcca gcctrggtgacagagggag 29 186 29 DNA Artificial Sequence APOC3 2221 186 agggctaaaacggcrcggcc ctaggactg 29 187 29 DNA Artificial Sequence APOC3 2535 187gcgtgcttca tgtarccctg catgaagct 29 188 29 DNA Artificial Sequence APOC32854 188 ccctggggag gtggygtggc ccctaaggt 29 189 29 DNA ArtificialSequence APOC3 429 189 gcaacctaca ggggmagccc tggagattg 29 190 29 DNAArtificial Sequence APOC3 460 190 ggacccaagg agctsgcagg atggatagg 29 19129 DNA Artificial Sequence APOC3 636 191 taaatcagtc agggraagca acagagcag29 192 29 DNA Artificial Sequence APOC3 954 192 gtgcaaacag caccrcctggagttgcaca 29 193 29 DNA Artificial Sequence APOC4 1150 193 aagtgctaggattayaggcg tgagccact 29 194 29 DNA Artificial Sequence APOC4 1246 194aggctggtct tgaamtcctg acctcaggt 29 195 29 DNA Artificial Sequence APOC41281 195 cccgccttgg cctcycaaag tgctgggat 29 196 29 DNA ArtificialSequence APOC4 1287 196 ttggcctccc aaagygctgg gattacagg 29 197 29 DNAArtificial Sequence APOC4 1313 197 aggcatgagc caccrcgccc ggccatgta 29198 29 DNA Artificial Sequence APOC4 1406 198 acagggccag gcacrgtggctcatgcctg 29 199 29 DNA Artificial Sequence APOC4 1446 199 ctttcggaggccgargcggg tggatcgca 29 200 29 DNA Artificial Sequence APOC4 1587 200cgggaggctg aggcmggaga atcacttga 29 201 29 DNA Artificial Sequence APOC41782 201 ataaccctga ggtasatatt attaccccg 29 202 29 DNA ArtificialSequence APOC4 1794 202 tagatattat taccycgttc tacaaaagg 29 203 29 DNAArtificial Sequence APOC4 1842 203 caggataagt caccrgccaa ggcacacag 29204 29 DNA Artificial Sequence APOC4 1858 204 ccaaggcaca cagcyagctacatgtggcc 29 205 29 DNA Artificial Sequence APOC4 1875 205 ctacatgtggccccygcgtg acggctggt 29 206 29 DNA Artificial Sequence APOC4 2206 206tgaagagatg gcccrgccgg acggggtgg 29 207 29 DNA Artificial Sequence APOC42237 207 cacatctgta atccyagcat tttgggagc 29 208 29 DNA ArtificialSequence APOC4 2276 208 tggatcactt gaggycagga gttcgaggc 29 209 29 DNAArtificial Sequence APOC4 2345 209 attagccggg catgrtggca gatgcctgt 29210 29 DNA Artificial Sequence APOC4 2366 210 atgcctgtaa tcccwgctactcgggaggc 29 211 29 DNA Artificial Sequence APOC4 2767 211 aagatgagtcgctgragcct ggtgagggg 29 212 29 DNA Artificial Sequence APOC4 3027 212tcacagagag gagcrgataa atggggcag 29 213 29 DNA Artificial Sequence APOC43078 213 gcctccactg tgatstcctc tctcctgta 29 214 29 DNA ArtificialSequence APOC4 3162 214 ggacctgggt ccgckcacca aggcctggt 29 215 29 DNAArtificial Sequence APOC4 3252 215 tggggacaag gaccwgggtt aaaatgttc 29216 29 DNA Artificial Sequence APOC4 483 216 ctgagagtga agtgkgaatgtcacattgg 29 217 29 DNA Artificial Sequence APOC4 931 217 ccaggctggagtgcrgtggc gtgatcttg 29 218 29 DNA Artificial Sequence APOC4 968 218caagctccgc ctccygggtt cacgccatt 29 219 29 DNA Artificial SequenceAPOER2EX1 454 219 cgcggcaagg actcsgaggg ctgagacgc 29 220 29 DNAArtificial Sequence APOER2EX12 68 220 accaactgtc cagcmttgac ttcagtgga 29221 29 DNA Artificial Sequence APOER2EX13 55 221 cgaggccatt ttcastgcaaatcggctca 29 222 29 DNA Artificial Sequence APOER2EX14 162 222gaagaggtgc taccraggta agcagacct 29 223 29 DNA Artificial SequenceAPOER2EX17 55 223 tacctgatct ggagraactg gaagcggaa 29 224 29 DNAArtificial Sequence APOER2EX19 1005 224 agagtgctca gaaastcaag ataggatat29 225 29 DNA Artificial Sequence APOER2EX19 1060 225 taaagttcagctctytgagt aacttcttc 29 226 29 DNA Artificial Sequence APOER2EX19 1149226 tgccatcctt acagwgctaa gtggagacg 29 227 29 DNA Artificial SequenceAPOER2EX19 13 227 gttgtctccc cagcragtgg cattaagcc 29 228 29 DNAArtificial Sequence APOER2EX19 602 228 tttagagaag tgagrgtatt tatttttgg29 229 29 DNA Artificial Sequence APOER2EX19 931 229 ccatggctgctgtgmctcct accagggct 29 230 29 DNA Artificial Sequence APOER2EX9 116 230tgctcaagaa tgtcrtggca ctagatgtg 29 231 29 DNA Artificial SequenceAPOER2EX9 157 231 aatcgcatct actgstgtga cctctccta 29 232 29 DNAArtificial Sequence AT1EX5 1158 232 tgaggttgag tgacrtgttc gaaacctgt 29233 29 DNA Artificial Sequence AT1EX5 1226 233 tcctctgcag cactkcactaccaaatgag 29 234 29 DNA Artificial Sequence AT1EX5 1242 234 actaccaaatgagcmttagc tacttttca 29 235 29 DNA Artificial Sequence AT1EX5 1249 235aatgagcatt agctrctttt cagaattga 29 236 29 DNA Artificial Sequence AT1EX51473 236 cctgcttttg tcctrttatt ttttatttc 29 237 29 DNA ArtificialSequence AT2EX3 1355 237 gtttgtacaa gattktcatt ggtgagaca 29 238 29 DNAArtificial Sequence AT2EX3 1361 238 acaagatttt cattrgtgag acatattta 29239 29 DNA Artificial Sequence AT2EX3 562 239 tatatagttc ccctygtttggtgtatggc 29 240 29 DNA Artificial Sequence AT2EX3 807 240 ctatgggaagaacargataa cccgtgacc 29 241 29 DNA Artificial Sequence AT2EX3 844 241aagatggcag ctgcygttgt tctggcctt 29 242 29 DNA Artificial Sequence AVPEX2154 242 ggagaactac ctgcygtcgc cctgccagt 29 243 29 DNA ArtificialSequence AVPR2EX1 114 243 tcatggcgtc caccwcttcc ggtaaggct 29 244 29 DNAArtificial Sequence AVPR2EX2 109 244 acccgggacc cgctrctagc ccgggcgga 29245 29 DNA Artificial Sequence AVPR2EX2 129 245 ccgggcggag ctggygctgctctccatag 29 246 29 DNA Artificial Sequence AVPR2EX2 184 246 ggcctggtgctggckgccct agctcggcg 29 247 29 DNA Artificial Sequence AVPR2EX2 444 247ccgtcccatg ctggygtacc gccatggaa 29 248 29 DNA Artificial SequenceAVPR2EX3 112 248 tctttcagca gcagygtgtc ctcagagct 29 249 29 DNAArtificial Sequence AVPR2EX3 232 249 aaggacactt catcrtgagg agctgttgg 29250 29 DNA Artificial Sequence AVPR2EX3 252 250 agctgttggg tgtcytgcctctagaggct 29 251 29 DNA Artificial Sequence AVPR2EX3 46 251 gcgccctttgtgctrctcat gttgctggc 29 252 29 DNA Artificial Sequence BIR 1069 252caggactggc tggaygcaca gctctaggg 29 253 29 DNA Artificial Sequence BIR1142 253 ggtgagccag tcctraattg ggttgggag 29 254 29 DNA ArtificialSequence BIR 1185 254 ataacccagt acagkttcct gctgaggcc 29 255 29 DNAArtificial Sequence BIR 1265 255 ggaggctgag ctgargctgg cccagcctc 29 25629 DNA Artificial Sequence BIR 1295 256 caccaggccc tggcygggct acataccac29 257 29 DNA Artificial Sequence BIR 1441 257 aggggcccgc gggcygaggcgagggtcag 29 258 29 DNA Artificial Sequence BIR 1521 258 tgtgggcactttgayggtgt tgccaaact 29 259 29 DNA Artificial Sequence BIR 1729 259ggtgccaggt cgtasagtgg gctgttggc 29 260 29 DNA Artificial Sequence BIR1946 260 gcatgaagca gaggyggccg tggcgcagg 29 261 29 DNA ArtificialSequence BIR 1960 261 cggccgtggc gcagrgcgat caccgcatg 29 262 29 DNAArtificial Sequence BIR 2463 262 acggtacctg ggctyggcag ggtcctctg 29 26329 DNA Artificial Sequence BIR 2664 263 tgtgctggcc tcacytctga gataactcc29 264 29 DNA Artificial Sequence BIR 2894 264 tggtggtgcg cacckgtaatcccacctac 29 265 29 DNA Artificial Sequence BIR 2954 265 cccgagaggcggagsttgca gtgagccaa 29 266 29 DNA Artificial Sequence BIR 3174 266tcccgctaag agccyttctc cccgcccag 29 267 29 DNA Artificial Sequence BIR369 267 caacactgct ccaarggtcc aggcacggg 29 268 29 DNA ArtificialSequence BIR 510 268 ccttctggac aaagygagtg gcagccact 29 269 29 DNAArtificial Sequence BIR 657 269 cacagagccc tcacwgcacg aggccgatg 29 27029 DNA Artificial Sequence BIR 981 270 ttggagccac agacrcaaag cagcagccc29 271 29 DNA Artificial Sequence BKRB2EX1 55 271 ggtggggacg gtggkgacggtggggacat 29 272 29 DNA Artificial Sequence BKRB2EX3 1513 272 atctccaggagaacygccat ccagctttg 29 273 29 DNA Artificial Sequence BKRB2EX3 1833 273actcaagtgg gaacractgg gcactgcca 29 274 29 DNA Artificial SequenceBKRB2EX3 747 274 aaggagatcc agacrgagag gagggccac 29 275 29 DNAArtificial Sequence BNPEX1 343 275 tttcctggga ggtckttccc acccgctgg 29276 29 DNA Artificial Sequence BNPEX2 15 276 tgaggcttgg acgcscccattcattgcag 29 277 29 DNA Artificial Sequence BNPEX2 174 277 gtgggcaccgcaaawtggtc ctctacacc 29 278 29 DNA Artificial Sequence BNPEX2 37 278attgcaggag cagcrcaacc atttgcagg 29 279 29 DNA Artificial SequenceBRS3EX1 424 279 agaactgaag caaargagta tctggatgt 29 280 29 DNA ArtificialSequence BRS3EX1 730 280 gtgccatcta tattmcttat gctgtgatc 29 281 29 DNAArtificial Sequence BRS3EX1 879 281 ctaacttgtg tgccwgtgga tgcaactca 29282 29 DNA Artificial Sequence BRS3EX2 144 282 gctctacctg aggcwatattttcaaatgt 29 283 29 DNA Artificial Sequence BRS3EX2 80 283 ctccaatgccatccwgaaga cttgtgtaa 29 284 29 DNA Artificial Sequence BRS3EX3 173 284gccatgcatt tcatyttcac cattttctc 29 285 29 DNA Artificial SequenceCAL/CGREPEX1+2 1063 285 ccccagtcac aggckctggg agcaaagag 29 286 29 DNAArtificial Sequence CAL/CGREPEX1+2 940 286 gtgcgatcag ggacrgcgtctggagccca 29 287 29 DNA Artificial Sequence CAL/CGREPEX3 112 287ctgcactggt gcagractat gtgcagatg 29 288 29 DNA Artificial SequenceCAL/CGREPEX3 120 288 gtgcaggact atgtkcagat gaaggccag 29 289 29 DNAArtificial Sequence CAL/CGREPEX4 30 289 tgttttccct gcagmctgga cagccccag29 290 29 DNA Artificial Sequence CAL/CGREPEX5 309 290 atgtggttttaaaawatcca taagggaag 29 291 29 DNA Artificial Sequence CAL/CGREPEX5 433291 cagaccaaga aatayagatc ctgtttatt 29 292 29 DNA Artificial SequenceCAL/CGREPEX5 719 292 aaagagcaag tgagrtaata gatgttaag 29 293 29 DNAArtificial Sequence CHYEX1 158 293 ttgccttctg ggagwtataa aacccaaga 29294 29 DNA Artificial Sequence CHYEX1 65 294 tctaggggaa cttcygatcagaaacagcc 29 295 29 DNA Artificial Sequence CHYEX2 107 295 ttgtaacttccaacsgtccc tcaaaattt 29 296 29 DNA Artificial Sequence CHYEX2 168 296gctgacggct gctcrttgtg caggaaggt 29 297 29 DNA Artificial Sequence CHYEX326 297 ccttcttcct cacarcaggt ctataacag 29 298 29 DNA Artificial SequenceCHYEX4 83 298 ctccccttcc catcmcaatt caactttgt 29 299 29 DNA ArtificialSequence CHYEX5 274 299 tccctcagcc acaaycctaa gcctccaga 29 300 29 DNAArtificial Sequence CLCNKBEX10 33 300 ctctggccac cttgsttctc gcctccatc 29301 29 DNA Artificial Sequence CLCNKBEX13 12 301 ggaggagctg ctatygggcgcctctttgg 29 302 29 DNA Artificial Sequence CLCNKBEX15 64 302 actggccaaggacaygccac tggaggagg 29 303 29 DNA Artificial Sequence CLCNKBEX15 68 303gccaaggaca cgccrctgga ggaggtggt 29 304 29 DNA Artificial SequenceCLCNKBEX18 51 304 cctctttgtg acgtygcggg gcagagctg 29 305 29 DNAArtificial Sequence CLCNKBEX3 34 305 gggagattgg ggacmgccac ctgctccgg 29306 29 DNA Artificial Sequence CLCNKBEX3 96 306 gtctctttct cttcrggcttctctcagag 29 307 29 DNA Artificial Sequence CLCNKBEX4 19 307 ctggaatcccggagstgaag accatgttg 29 308 29 DNA Artificial Sequence CLCNKBEX4 70 308acctggatat caagmacttt ggggccaaa 29 309 29 DNA Artificial SequenceCLCNKBEX7 108 309 ttccggctcc tggcrgtctt caacagcga 29 310 29 DNAArtificial Sequence CNPEX1 1018 310 gcagcgccaa ctttmtgcct gtatgactt 29311 29 DNA Artificial Sequence CNPEX1 144 311 gccttcacgc ctggkgacagccactgcac 29 312 29 DNA Artificial Sequence CNPEX1 1457 312 gcagcactgggaccstgctc gccctgcag 29 313 29 DNA Artificial Sequence CNPEX1 578 313attgttccca cagarggagt tcaccagcg 29 314 29 DNA Artificial Sequence CNPEX1592 314 gggagttcac cagcrgagtc agaccccgg 29 315 29 DNA ArtificialSequence CNPEX2 1171 315 aacatcccag cctcwgacat tgacagtca 29 316 29 DNAArtificial Sequence CNPEX2 139 316 ggacaccaag tcgcrggcag cgtgggctc 29317 29 DNA Artificial Sequence CNPEX2 357 317 cccgccgccc agccrgccttcggaggcgc 29 318 29 DNA Artificial Sequence CNPEX2 41 318 gctgcgggcggcggycagaa gaagggcga 29 319 29 DNA Artificial Sequence COX1 1063 319tttcctgcag ctgaratttg acccagagc 29 320 29 DNA Artificial Sequence COX11314 320 acatggacca ccacrtcctg catgtggct 29 321 29 DNA ArtificialSequence COX1 1386 321 tcaatgagta ccgcragagg tttggcatg 29 322 29 DNAArtificial Sequence COX1 1428 322 ccttccagga gctcrtagga gagaaggag 29 32329 DNA Artificial Sequence COX1 1906 323 ggtgagtgtt ggggytgaca tttagaact29 324 29 DNA Artificial Sequence COX1 1948 324 attatctgga atatygtgattctgtttat 29 325 29 DNA Artificial Sequence COX1 2037 325 gtctgccagaatackgggtt cttagttga 29 326 29 DNA Artificial Sequence COX1 310 326tgccaccttc atccragaga tgctcatgc 29 327 29 DNA Artificial Sequence COX1626 327 ttcaaaactt ctggmaagat gggtcctgg 29 328 29 DNA ArtificialSequence COX1 696 328 tttatggaga caatmtggag cgtcagtat 29 329 29 DNAArtificial Sequence COX1 938 329 gacctgctga aggcygagca ccccacctg 29 33029 DNA Artificial Sequence COX2EX1 186 330 cgattttctc atttscgtgggtaaaaaac 29 331 29 DNA Artificial Sequence COX2EX1 358 331 gcgaccaattgtcakacgac ttgcagtga 29 332 29 DNA Artificial Sequence COX2EX10 156 332aaccatggta gaagytggag caccattct 29 333 29 DNA Artificial SequenceCOX2EX1 379 333 gcaagttctt cccgmtccgg actagatga 29 334 29 DNA ArtificialSequence COX2EX10 866 334 aaagtacttt tggtyatttt tctgtcatc 29 335 29 DNAArtificial Sequence COX2EX10 87 335 catcgatgct gtggrgctgt atcctgccc 29336 29 DNA Artificial Sequence COX2EX10 937 336 attagacatt accartaatttcatgtcta 29 337 29 DNA Artificial Sequence COX2EX3 166 337 attatgagttatgtsttgac atgtaagta 29 338 29 DNA Artificial Sequence COX2EX7 206 338aacagagtat gcgaygtgct taaacagga 29 339 29 DNA Artificial SequenceCOX2EX8 268 339 atattgctgg aacayggaat tacccagtt 29 340 29 DNA ArtificialSequence CYP11B1EX1 351 340 tgacgtgatc cctcycgaag gcaaggcac 29 341 29DNA Artificial Sequence CYP11B1EX1 525 341 aggacagtgc tgccstttgaagccatgcc 29 342 29 DNA Artificial Sequence CYP11B1EX1 542 342tgaagccatg ccccrgcgtc caggcaaca 29 343 29 DNA Artificial SequenceCYP11B1EX1 601 343 agcagggtta tgagsacctg cacctggaa 29 344 29 DNAArtificial Sequence CYP11B1EX2 184 344 gtggcgtgtt cttgytgtaa gcggcgagc29 345 29 DNA Artificial Sequence CYP11B1EX2 188 345 cgtgttcttgctgtragcgg cgagctgag 29 346 29 DNA Artificial Sequence CYP11B1EX2 36 346ccccacaggt acgayttggg aggagcagg 29 347 29 DNA Artificial SequenceCYP11B1EX2 78 347 atgctgccgg aggaygtgga gaagctgca 29 348 29 DNAArtificial Sequence CYP11B1EX3 114 348 aggttcctcc cgatsgtgga tgcagtggc29 349 29 DNA Artificial Sequence CYP11B1EX4 177 349 cctgtctcgctggaycagcc ccaaggtgt 29 350 29 DNA Artificial Sequence CYP11B1EX4 205350 tggaaggagc acttkgaggc ctgggactg 29 351 29 DNA Artificial SequenceCYP11B1EX4 247 351 ggtgaggcca gggasccggg cagtgctat 29 352 29 DNAArtificial Sequence CYP11B1EX5 103 352 accagcatcg tggcrgagct cctgttgaa29 353 29 DNA Artificial Sequence CYP11B1EX5 107 353 gcatcgtggcggagstcctg ttgaatgcg 29 354 29 DNA Artificial Sequence CYP11B1EX5 16 354tgagggctgc ctccygctcc ccggatagg 29 355 29 DNA Artificial SequenceCYP11B1EX5 55 355 atccagaaaa tctaycagga actggcctt 29 356 29 DNAArtificial Sequence CYP11B1EX5 72 356 ggaactggcc ttcarccgcc ctcaacagt 29357 29 DNA Artificial Sequence CYP11B1EX7 52 357 ctgtgggtct gtttytggagcgagtggcg 29 358 29 DNA Artificial Sequence CYP11B1EX8 144 358ccggcaggaa cttcyaccac gtgcccttt 29 359 29 DNA Artificial SequenceCYP11B1EX9 16 359 ccagatggaa acccsgcttc tgtcctagg 29 360 29 DNAArtificial Sequence CYP11B1EX9 274 360 agccccagca caaayggaac tcccgaggg29 361 29 DNA Artificial Sequence CYP11B1EX9 350 361 gctggggaagatctkgctga ccttgtccc 29 362 29 DNA Artificial Sequence CYP11B1EX9 459362 cctcgtgtgg ccatrcaagg gtgctgtgg 29 363 29 DNA Artificial SequenceCYP11B1EX9 592 363 tctagagtcc agtcmagttc cctcctgca 29 364 29 DNAArtificial Sequence CYP11B1EX9 62 364 gtggagacac taacycaaga ggacataaa 29365 29 DNA Artificial Sequence CYP11B1EX9 657 365 ctctgaaagt tgtcrccctggaatagggt 29 366 29 DNA Artificial Sequence CYP11B1EX9 786 366atcgtgtcag cctcrtgccc ctggcctca 29 367 29 DNA Artificial SequenceCYP11B1EX9 835 367 gttccaggag tgggygttgg gtcctctgc 29 368 29 DNAArtificial Sequence CYP11B1EX9 879 368 ctggggaagg tcccraggat gctgtcagg29 369 29 DNA Artificial Sequence CYP11B2EX1 163 369 tcctgggtgagataraagga tttgggctg 29 370 29 DNA Artificial Sequence CYP11B2EX3 138370 gtggccaggg acttytccca ggccctgaa 29 371 29 DNA Artificial SequenceCYP11B2EX3 152 371 ctcccaggcc ctgargaaga aggtgctgc 29 372 29 DNAArtificial Sequence CYP11B2EX3 20 372 caagctctgc cctgscctct gtaggaatg 29373 29 DNA Artificial Sequence CYP11B2EX3 243 373 ggtgtgggcc atgcrggaaggtccagccc 29 374 29 DNA Artificial Sequence CYP11B2EX4 177 374cctgtctcgc tggaycagcc ccaaggtgt 29 375 29 DNA Artificial SequenceCYP11B2EX4 250 375 gaggccaggg acccrggcag tgctatggg 29 376 29 DNAArtificial Sequence CYP11B2EX4 99 376 ttctgccagc ctgamcttcc tccatgccc 29377 29 DNA Artificial Sequence CYP11B2EX5 103 377 acaggcatcg tggcrgagctcctgttgaa 29 378 29 DNA Artificial Sequence CYP11B2EX5 121 378ctcctgttga aggcrgaact gtcactaga 29 379 29 DNA Artificial SequenceCYP11B2EX5 55 379 atccagaaaa tctaycagga actggcctt 29 380 29 DNAArtificial Sequence CYP11B2EX5 72 380 ggaactggcc ttcarccgcc ctcaacact 29381 29 DNA Artificial Sequence CYP11B2EX6 195 381 tcaaggagac cttgmggtgggtgctggct 29 382 29 DNA Artificial Sequence CYP11B2EX6 91 382 cgacgtgcagcagaycctgc gccaggaga 29 383 29 DNA Artificial Sequence CYP11B2EX7 52 383ctgtgggtct gtttytggag cgagtggtg 29 384 29 DNA Artificial SequenceCYP11B2EX7 56 384 gggtctgttt ttggwgcgag tggtgagct 29 385 29 DNAArtificial Sequence CYP11B2EX7 65 385 tttggagcga gtggygagct cagacttgg 29386 29 DNA Artificial Sequence CYP11B2EX7 78 386 gtgagctcag acttrgtgcttcagaacta 29 387 29 DNA Artificial Sequence CYP11B2EX8 132 387acatcagggg ctccrgcagg aacttccac 29 388 29 DNA Artificial SequenceCYP11B2EX8 18 388 tgatccctgc tctgyaccgt ccgcagaca 29 389 29 DNAArtificial Sequence CYP11B2EX8 182 389 atgcgccagt gcctygggcg gcgcctggc29 390 29 DNA Artificial Sequence CYP11B2EX8 37 390 tccgcagacattggwacagg ttttcctct 29 391 29 DNA Artificial Sequence CYP11B2EX9 224391 gtcttctctc ccacrtgcac agcttcctg 29 392 29 DNA Artificial SequenceCYP11B2EX9 90 392 agatggtcta cagcktcata ttgaggcct 29 393 29 DNAArtificial Sequence DBHEX1 152 393 gggccagcct gcccrgcccc agcatgcgg 29394 29 DNA Artificial Sequence DBHEX3 153 394 agttgccctc agacrcgtgcaccatggag 29 395 29 DNA Artificial Sequence DBHEX3 239 395 aaggagcttccaaasggctt ctctcggca 29 396 29 DNA Artificial Sequence DBHEX3 257 396ttctctcggc accayattat caaggtacg 29 397 29 DNA Artificial Sequence DBHEX363 397 cgttccggtc actgsaggcc atcaacggc 29 398 29 DNA Artificial SequenceDBHEX4 12 398 cctcctcaca gtacsagccc atcgtcacc 29 399 29 DNA ArtificialSequence DBHEX4 132 399 ccaagatgaa acccraccgc ctcaactac 29 400 29 DNAArtificial Sequence DBHEX5 37 400 agaggaagcc ggccytgcct tcgggggtc 29 40129 DNA Artificial Sequence DBHEX5 39 401 aggaagccgg ccttkccttc gggggtcca29 402 29 DNA Artificial Sequence DD1R 122 402 cctattccct gcttrggaacttgaggggt 29 403 29 DNA Artificial Sequence DD1R 1521 403 ctgaactcgcagatraatcc tgccacaca 29 404 29 DNA Artificial Sequence DD1R 278 404tgctcatcct gtccmcgctc ctggggaac 29 405 29 DNA Artificial Sequence DD1R279 405 gctcatcctg tccasgctcc tggggaaca 29 406 29 DNA ArtificialSequence DD1R 310 406 ctggtctgtg ctgcsgttat caggttccg 29 407 29 DNAArtificial Sequence DD1R 319 407 gctgccgtta tcagkttccg acacctgcg 29 40829 DNA Artificial Sequence DD1R 76 408 gcaaagtgct gcctrgtggg gaggactcc29 409 29 DNA Artificial Sequence DD1R 764 409 atgccatctc atcckctgtaataagcttt 29 410 29 DNA Artificial Sequence EDNRAEX6 124 410 actgtgtataacgaratgga caagaaccg 29 411 29 DNA Artificial Sequence EDNRAEX6 88 411tggttccctc ttcayttaag ccgtatatt 29 412 29 DNA Artificial SequenceEDNRAEX8 1157 412 ttttcagatg attcrgaaat tttcattca 29 413 29 DNAArtificial Sequence EDNRAEX8 1380 413 acgattcttc acttyttggg gttttcagt 29414 29 DNA Artificial Sequence EDNRAEX8 1687 414 ttgtgccaaa gtgcrtagtctgagctaaa 29 415 29 DNA Artificial Sequence EDNRAEX8 228 415 caaggcaactgtgastccgg gaatctctt 29 416 29 DNA Artificial Sequence EDNRAEX8 295 416aagaaatgct ttccraaacc gcaaggtag 29 417 29 DNA Artificial SequenceEDNRAEX8 622 417 acaatatggg ctcargtcac ttttatttg 29 418 29 DNAArtificial Sequence EDNRAEX8 655 418 gtcatttggt gccartattt tttaactgc 29419 29 DNA Artificial Sequence EDNRAEX8 788 419 ctatttattt ttttraaacacaaattcta 29 420 29 DNA Artificial Sequence EDNRAEX8 950 420 gaacatgttttgtaygttaa attcaaaag 29 421 29 DNA Artificial Sequence EDNRAEX8 985 421ttcaatcaga tagtyctttt tcacaagtt 29 422 29 DNA Artificial SequenceEDNRBEX1 33 422 gccgcctcca agtcwgtgcg gacgcgccc 29 423 29 DNA ArtificialSequence EDNRBEX1 347 423 tgtcctgcct tgtgktcgtg ctggggatc 29 424 29 DNAArtificial Sequence EDNRBEX1 62 424 tggttgcgct ggttyttgcc tgcggcctg 29425 29 DNA Artificial Sequence EDNRBEX2 78 425 atacagaaag cctcygtgggaatcactgt 29 426 29 DNA Artificial Sequence EDNRBEX2 87 426 gcctccgtgggaatyactgt gctgagtct 29 427 29 DNA Artificial Sequence EDNRBEX3 144 427ttttgatata attaygatgg actacaaag 29 428 29 DNA Artificial SequenceEDNRBEX4 122 428 gttgagaaag aaaartggca tgcagattg 29 429 29 DNAArtificial Sequence EDNRBEX4 39 429 aaagattggt ggctrttcag tttctattt 29430 29 DNA Artificial Sequence ELAM1EX1 143 430 tctttgacct aaatratgaaagtcttaaa 29 431 29 DNA Artificial Sequence ELAM1EX1 209 431 ttattgcactagtgkccttt gcccaaaat 29 432 29 DNA Artificial Sequence ELAM1EX10 107 432cattagcacc atttytcctc tggcttcgg 29 433 29 DNA Artificial SequenceELAM1EX12 54 433 agccttgaat cagayggaag ctaccaaaa 29 434 29 DNAArtificial Sequence ELAM1EX13 1004 434 cagaaatatg tggtktccac gatgaaaaa29 435 29 DNA Artificial Sequence ELAM1EX13 1158 435 gatgtttgtcagatrtgata tgtaaacat 29 436 29 DNA Artificial Sequence ELAM1EX13 1549436 tgaacactgg caacracaaa gccaacagt 29 437 29 DNA Artificial SequenceELAM1EX13 967 437 actgaatgga aggtytgtat attgtcaga 29 438 29 DNAArtificial Sequence ELAM1EX2 382 438 aatgatgaga ggtgsagcaa gaagaagct 29439 29 DNA Artificial Sequence ELAM1EX3 152 439 gtaagtctgg ttctygcctctttcttcac 29 440 29 DNA Artificial Sequence ELAM1EX3 53 440 ccaatacatcctgcmgtggc cacggtgaa 29 441 29 DNA Artificial Sequence ELAM1EX5 197 441ggaattggga caacragaag ccaacgtgt 29 442 29 DNA Artificial SequenceELAM1EX5 55 442 gatgctgtga caaayccagc caatgggtt 29 443 29 DNA ArtificialSequence ELAM1EX7 199 443 ggggagtggg acaaygagaa gcccacatg 29 444 29 DNAArtificial Sequence ELAM1EX7 200 444 gggagtggga caacsagaag cccacatgt 29445 29 DNA Artificial Sequence ELAM1EX8 152 445 agggatttga attayatggatcaactcaa 29 446 29 DNA Artificial Sequence ELAM1EX8 22 446 agtgctctctcgtgygttcc agctgtgag 29 447 29 DNA Artificial Sequence ENDOTHELIN2 440447 cccctgcaga cgtgytccag actggcaag 29 448 29 DNA Artificial SequenceENDOTHELIN2 556 448 atgcgggagc ctcgrtccac acattccag 29 449 29 DNAArtificial Sequence ENDOTHELIN2 976 449 agccagccct ggagrctgga tggctcccc29 450 29 DNA Artificial Sequence ET1EX3 114 450 gcaacagacc gtgaraatagatgccaatg 29 451 29 DNA Artificial Sequence ET1EX5 90 451 aagctgaaaggcaakccctc cagagagcg 29 452 29 DNA Artificial Sequence GALNREX1 1052 452ctgcccacct gggtkctggg cgccttcat 29 453 29 DNA Artificial SequenceGALNREX1 325 453 ggtgcagcac gcagscgctc cgggagcca 29 454 29 DNAArtificial Sequence GALNREX1 327 454 tgcagcacgc agccsctccg ggagccagg 29455 29 DNA Artificial Sequence GALNREX1 553 455 tctctcagaa ggtcscggcgcaaagacgg 29 456 29 DNA Artificial Sequence GALNREX1 887 456 atcttcgcgctgggygtgct gggcaacag 29 457 29 DNA Artificial Sequence GALNREX3 298 457tgatactaaa gaaartaaaa gtcgaatag 29 458 29 DNA Artificial SequenceGALNREX3 322 458 aatagacacc ccacyatcaa ccaattgta 29 459 29 DNAArtificial Sequence GALNREX3 388 459 agtttccata taagyggacc agacacaga 29460 29 DNA Artificial Sequence GALNREX3 418 460 acaaacagaa tgagstagtaagcgatgct 29 461 29 DNA Artificial Sequence GALNREX3 523 461 taggaaattcctagktctag tgagaatta 29 462 29 DNA Artificial Sequence GALNREX3 650 462tccatatata tgttyaactc ttcatagat 29 463 29 DNA Artificial SequenceGALNREX3 799 463 atgtatttta aaatrtgatc atggacaca 29 464 29 DNAArtificial Sequence GGREX1 125 464 ctgctgttgc tgctrctgct ggcctgcca 29465 29 DNA Artificial Sequence GGREX11 57 465 cacgaagtgg tcttygccttcgtgacgga 29 466 29 DNA Artificial Sequence GGREX4 68 466 gaccccgggggcagscttgg cgtgatgcc 29 467 29 DNA Artificial Sequence GGREX5 71 467ctgtccctgg gggcsctgct cctcgcctt 29 468 29 DNA Artificial Sequence GGREX929 468 tgacaacatg ggctkctggt ggatcctgc 29 469 29 DNA Artificial SequenceGH1EX4 144 469 cctctgacag caacrtctat gacctccta 29 470 29 DNA ArtificialSequence GH2EX3 126 470 caacaccttc caacwgggtg aaaacgcag 29 471 29 DNAArtificial Sequence GIPREX2 72 471 cttcgccgcc ctcasgatga ctacctctc 29472 29 DNA Artificial Sequence GIPREX7 51 472 cattgcacta gaaaytatatccacatcaa 29 473 29 DNA Artificial Sequence GIPREX8 180 473 gctactacctgctcstcggc tggggtgag 29 474 29 DNA Artificial Sequence GLUT2EX1 137 474ccacagcact aattmtctgt ggagcagag 29 475 29 DNA Artificial SequenceGLUT2EX1 164 475 agtgcagtgt gcctyccatg ctccacagc 29 476 29 DNAArtificial Sequence GLUT2EX1 237 476 aaagatttct ctttycaccg gctcccaat 29477 29 DNA Artificial Sequence GLUT2EX1 242 477 tttctctttt caccrgctcccaattactg 29 478 29 DNA Artificial Sequence GLUT2EX10 161 478 gaattccaaaagaaragtgg ctcagccca 29 479 29 DNA Artificial Sequence GLUT2EX10 87 479tcctggcctt taccstgttt acatttttt 29 480 29 DNA Artificial SequenceGLUT2EX10 92 480 gcctttaccc tgttyacatt ttttaaagt 29 481 29 DNAArtificial Sequence GLUT2EX3 250 481 agttggtgga atgaytgcat cattctttg 29482 29 DNA Artificial Sequence GLUT2EX4A 153 482 tcaggactat attgyggtaagtctcacac 29 483 29 DNA Artificial Sequence GLUT2EX4A 162 483 tattgtggtaagtcwcacac acacacaca 29 484 29 DNA Artificial Sequence GLUT2EX4A 164 484ttgtggtaag tctcwcacac acacacaca 29 485 29 DNA Artificial SequenceGLUT2EX4B 127 485 ctggccatcg tcacrggcat tcttattag 29 486 29 DNAArtificial Sequence GLUT2EX5 78 486 atctgtggca catcytgctt ggcctgtct 29487 29 DNA Artificial Sequence GLUT2EX6 15 487 tgtttcaacc tgatyattttcttggacag 29 488 29 DNA Artificial Sequence GLUT2EX8 21 488 taatttctttaaaaytgtcc taggtattc 29 489 29 DNA Artificial Sequence GLUT2EX8 38 489tcctaggtat tcctygtgga gaaggcagg 29 490 29 DNA Artificial SequenceGLUT4EX1 1002 490 cgttgtggga acggmatttc ctggccccc 29 491 29 DNAArtificial Sequence GLUT4EX1 1051 491 agcatgtcgc ggacycttta aggcgtcat 29492 29 DNA Artificial Sequence GLUT4EX1 1228 492 tctcaggccg ctggwgtttccccggggca 29 493 29 DNA Artificial Sequence GLUT4EX1 1632 493 cagccccgctccacmagatc cgcgggagc 29 494 29 DNA Artificial Sequence GLUT4EX1 1662 494ccactgctct ccggrtcctt ggcttgtgg 29 495 29 DNA Artificial SequenceGLUT4EX1 1683 495 gcttgtggct gtggstccca tcgggcccg 29 496 29 DNAArtificial Sequence GLUT4EX1 1691 496 ctgtgggtcc catcrggccc gccctcgca 29497 29 DNA Artificial Sequence GLUT4EX1 368 497 acaggaggaa tcgarcctgacttctacca 29 498 29 DNA Artificial Sequence GLUT4EX1 560 498 gcggaaaggcgagaratagt gggttgaga 29 499 29 DNA Artificial Sequence GLUT4EX1 615 499tcgctcgccc tccargtggc agcacaacc 29 500 29 DNA Artificial SequenceGLUT4EX1 91 500 caggaggttt tgttyactct gaaaaggga 29 501 29 DNA ArtificialSequence GLUT4EX1 966 501 ctgaaagaca ggacmaagca gcccggcca 29 502 29 DNAArtificial Sequence GLUT4EX10 19 502 tccaccctcc ctgtstggcc cctaggagc 29503 29 DNA Artificial Sequence GLUT4EX11 1005 503 gtgctgggat tacargcgtgagccaccgc 29 504 29 DNA Artificial Sequence GLUT4EX11 1099 504gaaagtatgt gcccmtgtgt ggcaagatg 29 505 29 DNA Artificial SequenceGLUT4EX11 791 505 cgagtgcagt ggcgygatct tgcttcact 29 506 29 DNAArtificial Sequence GLUT4EX11 827 506 gtctcccagg ttcaygccat tctcctgcc 29507 29 DNA Artificial Sequence GLUT4EX11 872 507 ctgggactac aggcrcatgccaccacacc 29 508 29 DNA Artificial Sequence GLUT4EX11 874 508 gggactacaggcgcmtgcca ccacacctg 29 509 29 DNA Artificial Sequence GLUT4EX11 884 509gcgcatgcca ccacrcctgg ctaatttat 29 510 29 DNA Artificial SequenceGLUT4EX11 897 510 cacctggcta atttwttttg tatttttag 29 511 29 DNAArtificial Sequence GLUT4EX11 930 511 tacgcggttt caccrtgtta gccagaatg 29512 29 DNA Artificial Sequence GLUT4EX11 935 512 ggtttcacca tgttrgccagaatggtctc 29 513 29 DNA Artificial Sequence GLUT4EX11 941 513 accatgttagccagratggt ctcgatctc 29 514 29 DNA Artificial Sequence GLUT4EX11 963 514cgatctcctg acctygtgat ctgcctgcc 29 515 29 DNA Artificial SequenceGLUT4EX3 112 515 tccaggcacc ctcascaccc tctgggccc 29 516 29 DNAArtificial Sequence GLUT4EX4 96 516 atgggcctgg ccaaygctgc tgcctccta 29517 29 DNA Artificial Sequence GLUT4EX7 19 517 tcaggcctga ccttyccttctccaggtct 29 518 29 DNA Artificial Sequence GLUT4EX7 227 518 atgctgtatgtgtgsagcag cctccaggc 29 519 29 DNA Artificial Sequence GLUT5EX1 184 519aaaaggaggt gagcrgcact ctgcccttc 29 520 29 DNA Artificial SequenceGNB3EX1 184 520 gacagatggg gaacmctgtg cctccctga 29 521 29 DNA ArtificialSequence GNB3EX1 201 521 gtgcctccct gaacrgaaat ggcagggga 29 522 29 DNAArtificial Sequence GNB3EX1 328 522 gccaggggcc agtcragtgt atcacagat 29523 29 DNA Artificial Sequence GNB3EX10 144 523 agagcatcat ctgcrgcatcacgtccgtg 29 524 29 DNA Artificial Sequence GNB3EX10 155 524 tgcggcatcacgtcygtggc cttctccct 29 525 29 DNA Artificial Sequence GNB3EX11 129 525cttcctcaaa atctkgaact gaggaggct 29 526 29 DNA Artificial SequenceGNB3EX11 254 526 ccactaagct ttctyctttg agggcagtg 29 527 29 DNAArtificial Sequence GNB3EX11 536 527 tatggctctg gcacyactag ggtcctggc 29528 29 DNA Artificial Sequence GSY1EX10 46 528 ggagccttcc cgacrtgaacaagatgctg 29 529 29 DNA Artificial Sequence GSY1EX12 152 529 ccttggggctacacrccggg tgagtgtag 29 530 29 DNA Artificial Sequence GSY1EX12 163 530cacaccgggt gagtrtagtg ggcagggga 29 531 29 DNA Artificial SequenceGSY1EX15 75 531 ccaaggcctt tccasagcac ttcacctac 29 532 29 DNA ArtificialSequence GSY1EX16 152 532 ccgctggagg aagayggcga gcgctacga 29 533 29 DNAArtificial Sequence GSY1EX16 210 533 gcaacatccg tgcascagag tggccgcgc 29534 29 DNA Artificial Sequence GSY1EX16 65 534 cggccagcct cggtrccaccgtcgccctc 29 535 29 DNA Artificial Sequence GSY1EX2 219 535 ctgcaaggtgggacrtggcc cagcccagg 29 536 29 DNA Artificial Sequence GSY1EX3 117 536ccctggagcg ctggraggga gagctctgg 29 537 29 DNA Artificial SequenceGSY1EX3 134 537 ggagagctct gggayacctg caacatcgg 29 538 29 DNA ArtificialSequence GSY1EX3 149 538 acctgcaaca tcggrgtgcc gtggtacga 29 539 29 DNAArtificial Sequence GSY1EX3 53 539 gggcgctggc tgatsgaggg aggccctct 29540 29 DNA Artificial Sequence GSY1EX3 53 540 acagtggccc tgtcyctgttgcccacagt 29 541 29 DNA Artificial Sequence GSY1EX5 44 541 ttcaacgtggacaargaagc aggggagag 29 542 29 DNA Artificial Sequence GSY1EX6 54 542ccccaatggg ctgartgtga agaagtttt 29 543 29 DNA Artificial SequenceGSY1EX7 114 543 ggtgctgacg tcttyctgga ggcattggc 29 544 29 DNA ArtificialSequence GSY1EX7 16 544 gctttaccgt gcctkgtggg ttctttagg 29 545 29 DNAArtificial Sequence GSY1EX7 17 545 ctttaccgtg ccttstgggt tctttaggc 29546 29 DNA Artificial Sequence GSY1EX8 43 546 ggtgaacggc agcgrgcagacagtggttg 29 547 29 DNA Artificial Sequence HAPTEX1 135 547 gataaagagacagaytgatg gttcctgcc 29 548 29 DNA Artificial Sequence HAPTEX1 188 548gatttcagga aataytttgg caggtttgt 29 549 29 DNA Artificial SequenceHAPTEX1 239 549 cttgggattt gtaakagaac atcacaaga 29 550 29 DNA ArtificialSequence HAPTEX1 326 550 actggaaaag atagwgacct taccagggc 29 551 29 DNAArtificial Sequence HAPTEX1 329 551 ggaaaagata gtgascttac cagggccaa 29552 29 DNA Artificial Sequence HAPTEX1 369 552 acaggaatta cgaamtggagaagggggag 29 553 29 DNA Artificial Sequence HAPTEX1 375 553 attacgaaatggagragggg gagaagtga 29 554 29 DNA Artificial Sequence HAPTEX4 34 554tttgtttcag gagtrtacac cttaaatga 29 555 29 DNA Artificial SequenceHAPTEX6 34 555 tttgtttcag gagtrtacac cttaaacaa 29 556 29 DNA ArtificialSequence HAPTEX7 1331 556 catgctgttg cctcytcaaa gtgaattag 29 557 29 DNAArtificial Sequence HAPTEX7 367 557 gtgtctgtta atgaragagt gatgcccat 29558 29 DNA Artificial Sequence HAPTEX7 610 558 cacaccttct gtgcyggcatgtctaagta 29 559 29 DNA Artificial Sequence HAPTEX7 673 559 gcctttgccgttcaygacct ggaggagga 29 560 29 DNA Artificial Sequence HSD11KEX2 232 560accaaggccc acacmaccag caccggtca 29 561 29 DNA Artificial SequenceHSD11KEX3 139 561 aatttctttg gcgcrctcga gctgaccaa 29 562 29 DNAArtificial Sequence HSD11KEX5 951 562 actgtacttc ccaawtgcca cattttaaa 29563 29 DNA Artificial Sequence HSTSCGENE 1392 563 atcttcgggg ccacyctctcctctgccct 29 564 29 DNA Artificial Sequence HSTSCGENE 1881 564gccctcagct actcrgtggg cctcaatga 29 565 29 DNA Artificial SequenceHSTSCGENE 2139 565 tcggatgtca ttgcygagga cctccgcag 29 566 29 DNAArtificial Sequence HSTSCGENE 2595 566 cgtgtgttcg taggyggcca gattaacag29 567 29 DNA Artificial Sequence HSTSCGENE 3269 567 ggtcttgtgtttatrggcta gagaaatag 29 568 29 DNA Artificial Sequence HSTSCGENE 3660568 ctgcaacctc ctccygggtt caagcattt 29 569 29 DNA Artificial SequenceHSTSCGENE 3710 569 tagctgggat tacasgcacc tgccatcac 29 570 29 DNAArtificial Sequence HSTSCGENE 3727 570 acctgccatc acacsagcta atttttgta29 571 29 DNA Artificial Sequence HSTSCGENE 3838 571 cccaaagtgctgggrttaca ggcctgagc 29 572 29 DNA Artificial Sequence HUMAPNH1A 3057572 agggcatctc tgagygtctc tgcctggag 29 573 29 DNA Artificial SequenceHUMGFAT 2930 573 atctcctaaa agtgkttttt atttccttg 29 574 29 DNAArtificial Sequence HUMGLUTRN 2110 574 ggctatggcc acccsttctg ctggcctgg29 575 29 DNA Artificial Sequence HUMGLUTRN 933 575 gatgatgcgggagamgaagg tcaccatcc 29 576 29 DNA Artificial Sequence HUMGUANCYC 2388576 attgtcactg aataytgtcc tcgtgggag 29 577 29 DNA Artificial SequenceHUMGUANCYC 2571 577 cgttttgtgc tcaaratcac agactatgg 29 578 29 DNAArtificial Sequence HUMGUANCYC 2643 578 gccctctatg ccaaraagct gtggactgc29 579 29 DNA Artificial Sequence HUMGUANCYC 2787 579 gagggcctggacctsagccc caaagagat 29 580 29 DNA Artificial Sequence HUMGUANCYC 2905580 agcgatgttg ggctsaggac ccagctgag 29 581 29 DNA Artificial SequenceHUMGUANCYC 3300 581 gacaactttg atgtstacaa ggtggagac 29 582 29 DNAArtificial Sequence HUMGUANCYC 3663 582 cttcgggggg atgtrgaaat gaagggaaa29 583 29 DNA Artificial Sequence IAPPEX1-2 199 583 tttatttagagaaaygcaca cttggtgtt 29 584 29 DNA Artificial Sequence IAPPEX1-2 358 584gactgtatca ataamaattt tgatccttg 29 585 29 DNA Artificial SequenceIAPPEX3 1050 585 taaagtctat tgttygttgt gcttgctgg 29 586 29 DNAArtificial Sequence IAPPEX3 1076 586 tggtactaag aggcwattta aaagtataa 29587 29 DNA Artificial Sequence IAPPEX3 1184 587 tttaagtggc tttcmgcaaacctcagtca 29 588 29 DNA Artificial Sequence IAPPEX3 296 588 tgcccttttcatctycagtg tgaatatat 29 589 29 DNA Artificial Sequence IAPPEX3 848 589ctccagcctg ggtgrcagag tgagactcg 29 590 29 DNA Artificial SequenceIAPPEX3 959 590 ttcctttttg cagtrtattt ctgaaatga 29 591 29 DNA ArtificialSequence ICAM1EX1 683 591 agagttgcaa cctcmgcctc gctatggct 29 592 29 DNAArtificial Sequence ICAM1EX2 115 592 ctgtgaccag cccawgttgt tgggcatag 29593 29 DNA Artificial Sequence ICAM1EX3 151 593 ctccgtgggg agaasgagctgaaacggga 29 594 29 DNA Artificial Sequence ICAM1EX4 115 594 tgttccctggacggkctgtt cccagtctc 29 595 29 DNA Artificial Sequence ICAM1EX4 238 595gtgaccgcag aggaygaggg cacccagcg 29 596 29 DNA Artificial SequenceICAM1EX5 47 596 ttccggcgcc caacrtgatt ctgacgaag 29 597 29 DNA ArtificialSequence ICAM1EX6 18 597 catgtcatct catcrtgttt ttccagatg 29 598 29 DNAArtificial Sequence ICAM1EX6 254 598 gggaggtcac ccgcraggtg accgtgaat 29599 29 DNA Artificial Sequence ICAM1EX6 39 599 tccagatggc ccccractggacgagaggg 29 600 29 DNA Artificial Sequence ICAM1EX7 304 600 gcagctacacctacyggccc tgggacgcc 29 601 29 DNA Artificial Sequence ICAM1EX7 869 601tggcaaaaag atcaratggg gctgggact 29 602 29 DNA Artificial SequenceICAM1EX7 929 602 gagtgatttt tctaycggca caaaagcac 29 603 29 DNAArtificial Sequence ICAM2EX1 300 603 gagatgtcct ctttyggtta caggaccct 29604 29 DNA Artificial Sequence ICAM2EX2 63 604 ggccaaagaa gctgrcggttgagcccaaa 29 605 29 DNA Artificial Sequence ICAM2EX3 281 605 ggacttgatgtctcrcggtg gcaacatct 29 606 29 DNA Artificial Sequence INSEX1 233 606cagccctgcc tgtcwcccag atcactgtc 29 607 29 DNA Artificial Sequence INSEX1247 607 tcccagatca ctgtycttct gccatggcc 29 608 29 DNA ArtificialSequence INSEX1 453 608 cagggtgagc caacygccca ttgctgccc 29 609 29 DNAArtificial Sequence INSEX2 14 609 gaacctgctc tgcgyggcac gtcctggca 29 61029 DNA Artificial Sequence KALSTEX1 133 610 ctgctcctcc tgctkgttggactactggc 29 611 29 DNA Artificial Sequence KALSTEX1 511 611 catgggctggaaacrcgcgt gggcagtgc 29 612 29 DNA Artificial Sequence KALSTEX2 318 612gtaatcagtg tgctwtgggg gctgaatct 29 613 29 DNA Artificial SequenceKALSTEX2 79 613 actcccaaag acttytatgt tgatgagaa 29 614 29 DNA ArtificialSequence KALSTEX3 17 614 aatgttctaa ctcartgccc ctttcagga 29 615 29 DNAArtificial Sequence KALSTEX3 91 615 ctggctccta tgtaytagat cagattttg 29616 29 DNA Artificial Sequence KLKEX1 105 616 agggcattct gaagkccaaggcttatatt 29 617 29 DNA Artificial Sequence KLKEX3 253 617 tggagttgcccaccsaggaa cccgaagtg 29 618 29 DNA Artificial Sequence KLKEX3 50 618gctctggctg ggtcrccaca acttgtttg 29 619 29 DNA Artificial Sequence KLKEX4110 619 ccacgtccag aaggwgacag acttcatgc 29 620 29 DNA ArtificialSequence KLKEX4 88 620 ctaatgatga gtgcraaaaa gcccacgtc 29 621 29 DNAArtificial Sequence KLKEX5 318 621 ccccagctgt gtcartctca tggcctgga 29622 29 DNA Artificial Sequence MRLEX1B 156 622 ccgatcagcc aataytggacttgctggtg 29 623 29 DNA Artificial Sequence MRLEX1B 16 623 gggcgggtgcccgcstcccc ctctgcgcg 29 624 29 DNA Artificial Sequence MRLEX2 1338 624ctcttttaaa gggamtccaa cagtaaacc 29 625 29 DNA Artificial Sequence MRLEX21405 625 gatgataaag actaytattc cctatcagg 29 626 29 DNA ArtificialSequence MRLEX2 1617 626 aatatcttta tcacratcgg ctagagacc 29 627 29 DNAArtificial Sequence MRLEX2 1668 627 ctttcctcct gtcartactt tagtggagt 29628 29 DNA Artificial Sequence MRLEX2 1696 628 tcatggaaat cacayggcgacctgtcgtc 29 629 29 DNA Artificial Sequence MRLEX2 1720 629 tcgtctagaagaagygatgg gtatccggt 29 630 29 DNA Artificial Sequence MRLEX9 1326 630ggaatgacac actgyggtgt ctgcagctc 29 631 29 DNA Artificial Sequence MRLEX91572 631 gttaaagatc agctrttccc ttctgatct 29 632 29 DNA ArtificialSequence MRLEX9 1670 632 ggcccatctt ggcarggttc agtctgaat 29 633 29 DNAArtificial Sequence MRLEX9 1964 633 aatcttttaa aaatratgat aatcatcag 29634 29 DNA Artificial Sequence MRLEX9 247 634 acctgttttt aacaygtgatggttgattc 29 635 29 DNA Artificial Sequence MRLEX9 2551 635 ccaaattgtctgtcygctct tatttttgt 29 636 29 DNA Artificial Sequence MRLEX9 2635 636tcatataatt taaaraaaca ctaaattag 29 637 29 DNA Artificial Sequence MRLEX9869 637 tttgctgtgc tgtasattac tgtatgtat 29 638 29 DNA ArtificialSequence MRLEX9 916 638 aataaggtat aaggmtcttt tgtaaatga 29 639 29 DNAArtificial Sequence NCX1EX12 1135 639 agattcccag gaacrtgcaa aatcctttc 29640 29 DNA Artificial Sequence NCX1EX12 1190 640 tgattggcaa ggtcyttcttccagcattc 29 641 29 DNA Artificial Sequence NCX1EX12 1298 641 ataaccccattcaaraagca catcatcgt 29 642 29 DNA Artificial Sequence NCX1EX12 1366 642cgttgcttgg gattstctgt cagttttat 29 643 29 DNA Artificial SequenceNCX1EX12 1407 643 ccatggcttg cacartcctg ttccagtca 29 644 29 DNAArtificial Sequence NCX1EX12 1841 644 acccattaat tcagsaaggc caaggagaa 29645 29 DNA Artificial Sequence NCX1EX12 2099 645 gaaagaagcc agggygaccaacgggcctt 29 646 29 DNA Artificial Sequence NCX1EX12 2123 646 gcctttaaaagtgttgtctc ctctactta 29 647 29 DNA Artificial Sequence NCX1EX12 2614 647tgtgattact atttycatga gtaaaagtg 29 648 29 DNA Artificial SequenceNCX1EX12 2810 648 tttatctttg accgrcttgc agataaata 29 649 29 DNAArtificial Sequence NCX1EX12 2832 649 ataaatatat ctctscattt taaaccaag 29650 29 DNA Artificial Sequence NCX1EX12 3079 650 taaacattag aaaamtttttgcactcatt 29 651 29 DNA Artificial Sequence NCX1EX12 3193 651 ttgaaagctttttgstttgt ttgcttttt 29 652 29 DNA Artificial Sequence NCX1EX12 664 652tctctccagg ttgayaaatc cttaaggct 29 653 29 DNA Artificial SequenceNCX1EX12 709 653 ttggttttgt tttcrgtgga gctggggag 29 654 29 DNAArtificial Sequence NCX1EX12 948 654 agcatgtctt catcrtatta ccaaagttc 29655 29 DNA Artificial Sequence NCX1EX4 59 655 tagaatattt gaccrtgaggaatatgaga 29 656 29 DNA Artificial Sequence NCX1EX9 66 656 actgaccagcaaagwggaag aggagaggc 29 657 29 DNA Artificial Sequence NETEX11 123 657cgtcagtcct gcctkcctcc tggtgtgta 29 658 29 DNA Artificial SequenceNETEX12 81 658 tcacctacga cgacyacatc ttcccgccc 29 659 29 DNA ArtificialSequence NETEX13 50 659 gcctatggca tcacrccaga gaacgagca 29 660 29 DNAArtificial Sequence NETEX14 29 660 tgtctttctc tgcasttgca acactggct 29661 29 DNA Artificial Sequence NETEX5 121 661 ctccaatggc atcamtgcctacctgcaca 29 662 29 DNA Artificial Sequence NETEX5 175 662 cacggtcagtgctcrgtgac caccaagcc 29 663 29 DNA Artificial Sequence NETEX5 83 663ttcgtgctcc tggtscatgg cgtcacgct 29 664 29 DNA Artificial Sequence NETEX7112 664 tccttggtta catgscccat gaacacaag 29 665 29 DNA ArtificialSequence NETEX7 131 665 tgaacacaag gtcarcattg aggatgtgg 29 666 29 DNAArtificial Sequence NETEX7 73 666 gtatcaccag cttcstctct gggttcgcc 29 66729 DNA Artificial Sequence NETEX8 17 667 tgatgaggtc cttgmtgttt cttacagga29 668 29 DNA Artificial Sequence NETEX9 157 668 gttctgcata accarggtgagtaggggct 29 669 29 DNA Artificial Sequence NETEX9 56 669 gaggctgtcatcacrggcct ggcagatga 29 670 29 DNA Artificial Sequence NPYEX1 112 670gcgctggccg aggcrtaccc ctccaagcc 29 671 29 DNA Artificial Sequence NPYEX1178 671 gccagatact actcrgcgct gggacacta 29 672 29 DNA ArtificialSequence NPYEX1 92 672 ccctgctcgt gtgcmtgggt gcgctggcc 29 673 29 DNAArtificial Sequence NPYEX2 45 673 tatggaaaac gatcyagccc agagacact 29 67429 DNA Artificial Sequence NPYE3 100 674 cctattttca gcccrtattt catcgtgta29 675 29 DNA Artificial Sequence NPYEX3 78 675 gagacttgct ctctkgccttttcctattt 29 676 29 DNA Artificial Sequence NPYR1EX2 144 676 aacatactgtccatktgtct aaaataatc 29 677 29 DNA Artificial Sequence NPYR1EX3 451 677agtcgcattt aaaamaatca acaacaatg 29 678 29 DNA Artificial SequencePGISEX1 196 678 gcatataatc tcttmcttcc tgtaaatcc 29 679 29 DNA ArtificialSequence PGISEX1 396 679 tgcggggagc agggkttctc ccagagcgc 29 680 29 DNAArtificial Sequence PGISEX1 419 680 gagcgccccg gtccracccc tgcggacct 29681 29 DNA Artificial Sequence PGISEX1 568 681 ccccgccagc cccgycagccccgccagcc 29 682 29 DNA Artificial Sequence PGISEX1 636 682 cactgttgctgctgytgcta ctgagccgc 29 683 29 DNA Artificial Sequence PGISEX10 1255 683ttctgcattc acagygsctc ctggrcctg 29 684 29 DNA Artificial SequencePGISEX10 149 684 gctaccgcat ccgcycatga cacagggag 29 685 29 DNAArtificial Sequence PGISEX10 1500 685 cctggccaac atggygaaac cccgtctct 29686 29 DNA Artificial Sequence PGISEX10 1505 686 ccaacatggc gaaaycccgtctctactaa 29 687 29 DNA Artificial Sequence PGISEX10 1521 687 ccgtctctactaaamataaa aaaattagt 29 688 29 DNA Artificial Sequence PGISEX10 1525 688ctctactaaa catamaaaaa ttagtcagg 29 689 29 DNA Artificial SequencePGISEX10 1544 689 attagtcagg tgtgscggtg ccgtgcctg 29 690 29 DNAArtificial Sequence PGISEX10 1760 690 ttatgatgct atttktatta atataaagt 29691 29 DNA Artificial Sequence PGISEX10 1776 691 attaatataa agtcytgtttattgagacc 29 692 29 DNA Artificial Sequence PGISEX10 1852 692 cagcatctctatgargagaa ggagggttg 29 693 29 DNA Artificial Sequence PGISEX10 2474 693cgcaggctgc aaccytggtg tgctgggcg 29 694 29 DNA Artificial SequencePGISEX10 2636 694 actcaaggaa aagaygtgct cccaccagg 29 695 29 DNAArtificial Sequence PGISEX10 270 695 gctagcatta ccacytccct gcttttctc 29696 29 DNA Artificial Sequence PGISEX10 2967 696 ttgagatgga gtctygctctgctgcccag 29 697 29 DNA Artificial Sequence PGISEX10 2974 697 ggagtctcgctctgytgccc aggctagag 29 698 29 DNA Artificial Sequence PGISEX10 3009 698ggcgtgatct cggcycactg caagctctg 29 699 29 DNA Artificial SequencePGISEX10 3022 699 ctcactgcaa gctcygcctc ccgtgttca 29 700 29 DNAArtificial Sequence PGISEX10 3061 700 ctgcctcagc ctccygagta gctgggact 29701 29 DNA Artificial Sequence PGISEX10 308 701 tgggtccagg ggagkgaaaagctaagagg 29 702 29 DNA Artificial Sequence PGISEX10 3082 702 ctgggactacaggcrcccgc caccacacc 29 703 29 DNA Artificial Sequence PGISEX10 3139 703tgggatttca ccgtrttagc caggatggt 29 704 29 DNA Artificial SequencePGISEX10 3140 704 gggatttcac cgtaytagcc aggatggtc 29 705 29 DNAArtificial Sequence PGISEX10 3186 705 tgatctgccc gcctyggcct cccaaagtg 29706 29 DNA Artificial Sequence PGISEX10 3214 706 gctgggatta caggygtgagccaccgcgc 29 707 29 DNA Artificial Sequence PGISEX10 3217 707 gggattacaggtgtragcca ccgcgccca 29 708 29 DNA Artificial Sequence PGISEX10 3244 708cagccaagaa taaamtactc ttaagttga 29 709 29 DNA Artificial SequencePGISEX10 3339 709 gtttaccaaa tattytcctt taaacagac 29 710 29 DNAArtificial Sequence PGISEX10 3419 710 gcccaggctg gagtrcaatg gcacgatct 29711 29 DNA Artificial Sequence PGISEX10 3540 711 caactggttt ttgtwtttttagtagagac 29 712 29 DNA Artificial Sequence PGISEX10 3651 712 gattacaggcatgarccacc atgcccggc 29 713 29 DNA Artificial Sequence PGISEX10 3663 713gagccaccat gcccrgccta aactttgtt 29 714 29 DNA Artificial SequencePGISEX10 3774 714 atgaaaaata aattygctgg ggaaggggg 29 715 29 DNAArtificial Sequence PGISEX10 3840 715 tctctgttac aaaaygagat aagcaagtr 29716 29 DNA Artificial Sequence PGISEX10 400 716 tcaggctttg tctgytcccaattcacctc 29 717 29 DNA Artificial Sequence PGISEX10 4074 717 gattttaatgattaraaaga ataaacaca 29 718 29 DNA Artificial Sequence PGISEX10 454 718aaatgctatt cagayaaggc agaactagg 29 719 29 DNA Artificial SequencePGISEX10 573 719 ggatgctggc cacakaaagg ccactcagg 29 720 29 DNAArtificial Sequence PGISEX10 578 720 ctggccacag aaagrccact caggatgtc 29721 29 DNA Artificial Sequence PGISEX10 948 721 ctccttagac tgatmaagccaaaaaagaa 29 722 29 DNA Artificial Sequence PGISEX3 165 722 cattacagccccagwgatga aaaggccag 29 723 29 DNA Artificial Sequence PGISEX3 69 723tcctacgacg cggtkgtgtg ggagcctcg 29 724 29 DNA Artificial SequencePGISEX4 143 724 acttctccta cagcytcctg ctcaggtga 29 725 29 DNA ArtificialSequence PGISEX4 93 725 gggcgatgct acagmagcag gcagtggct 29 726 29 DNAArtificial Sequence PGISEX5 79 726 caggcccagg accgygtcca ctcagctga 29727 29 DNA Artificial Sequence PGISEX6 35 727 gcagtgtcaa aagtygcctgtggaagctg 29 728 29 DNA Artificial Sequence PGISEX6 52 728 ctgtggaagctgctrtcccc agccaggct 29 729 29 DNA Artificial Sequence PGISEX6 97 729cggagcaaat ggctrgagag ttacctgct 29 730 29 DNA Artificial SequencePGISEX8 102 730 ccatggcaga cgggmgagaa ttcaacctg 29 731 29 DNA ArtificialSequence PGISEX9 42 731 ttcctgaacc ctgayggatc agagaagaa 29 732 29 DNAArtificial Sequence PLA2AEX1 302 732 ccccgcagtc tcaawtcgag gttcccagt 29733 29 DNA Artificial Sequence PLA2AEX2 118 733 gggagtgacc ccttyttggaatacaacaa 29 734 29 DNA Artificial Sequence PLA2AEX2 42 734 agtggccgccgccgmcagcg gcatcagcc 29 735 29 DNA Artificial Sequence PLA2AEX3 103 735atttctgctg gacamcccgt acacccaca 29 736 29 DNA Artificial SequencePLA2AEX3 104 736 tttctgctgg acaamccgta cacccacac 29 737 29 DNAArtificial Sequence PLA2AEX3 131 737 acctattcat actcrtgctc tggctcggc 29738 29 DNA Artificial Sequence PLA2AEX3 59 738 catgacaact gctaygaccaggccaagaa 29 739 29 DNA Artificial Sequence PNMTEX3 181 739 gcttggaggctgtgwgccca gatcttgcc 29 740 29 DNA Artificial Sequence PNMTEX3 251 740gcctgggggg caccwcctcc tcatcgggg 29 741 29 DNA Artificial SequencePNMTEX3 269 741 cctcatcggg gcccwggagg agtcgtggt 29 742 29 DNA ArtificialSequence PNMTEX3 380 742 ggtccgggac ctccrcacct atatcatgc 29 743 29 DNAArtificial Sequence PNMTEX3 445 743 gcgtcttctt cgccwgggct cagaaggtt 29744 29 DNA Artificial Sequence PNMTEX3 554 744 aaataatacc ctgcygctgcggtcagtgc 29 745 29 DNA Artificial Sequence PNMTEX3 75 745 cgagccagggtgaarcgggt cctgcccat 29 746 29 DNA Artificial Sequence PPGLUCEX1 133 746caggtattaa atccrtagtc tcgaactaa 29 747 29 DNA Artificial SequencePPGLUCEX1 44 747 atgaaaagca tttaytttgt ggctggatt 29 748 29 DNAArtificial Sequence PPGLUCEX1 560 748 aagtactcaa aattyctctg tccaaagaa 29749 29 DNA Artificial Sequence PPGLUCEX1 635 749 acgtaaactg tacawaaatatctcttggc 29 750 29 DNA Artificial Sequence PPGLUCEX2 196 750 agaggaacaggtaaragtct aagcctggc 29 751 29 DNA Artificial Sequence PPGLUCEX3 119 751tttggaaggc caagytgcca aggaattca 29 752 29 DNA Artificial SequencePPGLUCEX4 447 752 aaatgaaaca tgggwaatgt tacatcatt 29 753 29 DNAArtificial Sequence PPGLUCEX4 571 753 tagtgagaac tggayaccga aaaatactt 29754 29 DNA Artificial Sequence PPGLUCEX4 615 754 gattttttaa taatyattcataattgttt 29 755 29 DNA Artificial Sequence PPGLUCEX4 672 755 aaataatctttaaaygaaaa tattttaag 29 756 29 DNA Artificial Sequence PPTHREX1 106 756ccccggatcc cggasccatc ctgtggagc 29 757 29 DNA Artificial SequencePPTHREX1 36 757 agagggctcg gcagscgccc ggggtcctc 29 758 29 DNA ArtificialSequence PPTHREX2 19 758 aacccagacg ccgcratgcc cggcccttg 29 759 29 DNAArtificial Sequence PPTHREX2 41 759 gcccttggtt gctgstcgct ctggctttg 29760 29 DNA Artificial Sequence PPTHREX2 79 760 ctgaccggtg tcccsggcggccgtgctca 29 761 29 DNA Artificial Sequence PPTHREX3 1234 761 taatgataataaaasctgca tccagataa 29 762 29 DNA Artificial Sequence PPTHREX3 185 762tcatggtcag tcgaygtaac ccagcacaa 29 763 29 DNA Artificial SequencePPTHREX3 401 763 ccctgtgggc cccarggagc ctatggtca 29 764 29 DNAArtificial Sequence PPTHREX3 425 764 ggtcaagcgg gcctyctgct ggggctcct 29765 29 DNA Artificial Sequence PPTHREX3 512 765 gcagcctggg tcagrgagcccctggagga 29 766 29 DNA Artificial Sequence PPTHREX3 576 766 ctaaggatgtcttgrgccct gtgtgcccc 29 767 29 DNA Artificial Sequence PPTHREX3 895 767agcccctggg agggmagcca gtgagggtg 29 768 29 DNA Artificial SequencePPTHREX3 963 768 cccctcccca acctsgcagg attctccat 29 769 29 DNAArtificial Sequence PTGER3EX1 232 769 tgcggctctc tggaygccat cccctcctc 29770 29 DNA Artificial Sequence PTGER3EX1 371 770 gcgcggggca acctsacgcgccctccagg 29 771 29 DNA Artificial Sequence PTGER3EX1 765 771 ggtatgcgagccacwtgaag acgcgtgcc 29 772 29 DNA Artificial Sequence PTGER3EX1 878 772cagtggcccg ggacktggtg cttcatcag 29 773 29 DNA Artificial SequencePTGER3EX10 206 773 acatgttttt gtacytttac tatatctac 29 774 29 DNAArtificial Sequence PTGER3EX10 281 774 gcgtatacat tatcrtatgt aaaatttgc29 775 29 DNA Artificial Sequence PTGER3EX2 1293 775 actaaaatgtttttyctaca gtctacatg 29 776 29 DNA Artificial Sequence PTGER3EX2 1295776 taaaatgttt tttcyacagt ctacatgaa 29 777 29 DNA Artificial SequencePTGER3EX2 1393 777 gcacttctta aaaaygtctc cccaccaaa 29 778 29 DNAArtificial Sequence PTGER3EX2 1403 778 aaaatgtctc cccamcaaac atagtaatc29 779 29 DNA Artificial Sequence PTGER3EX2 1614 779 taaagaattaatttygatag gtacaatat 29 780 29 DNA Artificial Sequence PTGER3EX2 1719780 tggagacaaa atctsttgag agtgcttat 29 781 29 DNA Artificial SequencePTGER3EX2 2153 781 agtccatcag gctgrtaaag tgaattatt 29 782 29 DNAArtificial Sequence PTGER3EX2 2517 782 taggcattcg ttagyatggg gaaacctga29 783 29 DNA Artificial Sequence PTGER3EX2 3069 783 tagtgctgtatataycccaa gatatttta 29 784 29 DNA Artificial Sequence PTGER3EX2 3101784 aaatgtaagt gtttratcat gccagattt 29 785 29 DNA Artificial SequencePTGER3EX2 326 785 atatcgctaa acctwactgt gaatttagg 29 786 29 DNAArtificial Sequence PTGER3EX2 3282 786 actaaaaact ggcaracagt attttaata29 787 29 DNA Artificial Sequence PTGER3EX2 3382 787 tttttataattttgytcttt ttgactcca 29 788 29 DNA Artificial Sequence PTGER3EX2 557 788tataaatgat cttgktctat tggggagcg 29 789 29 DNA Artificial SequencePTGER3EX2 628 789 aaccacatac atcaytgaag acaagggat 29 790 29 DNAArtificial Sequence PTGER3EX2 769 790 gtataatgta tttawaatat tcatcgata 29791 29 DNA Artificial Sequence PTGER3EX2 787 791 attcatcgat accaktattcaaatattgc 29 792 29 DNA Artificial Sequence PTGER3EX2 805 792 tcaaatattgctcamtacag caaattagc 29 793 29 DNA Artificial Sequence PTGER3EX2 850 793tttaagttta cttgrattga taattaggt 29 794 29 DNA Artificial SequencePTGER3EX2 852 794 taagtttact tggawtgata attaggttt 29 795 29 DNAArtificial Sequence PTGER3EX2 855 795 gtttacttgg attgwtaatt aggtttact 29796 29 DNA Artificial Sequence PTGER3EX3 76 796 ctccacctcc ttacyctgccagtgttcct 29 797 29 DNA Artificial Sequence PTGER3EX3 80 797 acctccttaccctgycagtg ttcctcaac 29 798 29 DNA Artificial Sequence PTGER3EX4 719 798tctaagcttt tgatkacaaa ggagtgatg 29 799 29 DNA Artificial SequencePTGER3EX4 94 799 tttgcatatt tcttyccacc tgagaagga 29 800 29 DNAArtificial Sequence PTGER3EX6 197 800 gagtgctgtg ttttraaaaa gcaagctcc 29801 29 DNA Artificial Sequence PTGER3EX6 300 801 gagattacca gcaarccaggtcatttccg 29 802 29 DNA Artificial Sequence PTGER3EX6 387 802 ccaatttagacttawagtaa gaatagcac 29 803 29 DNA Artificial Sequence PTGER3EX7 85 803ttggtgcagt tctcrtgata gtgagtgag 29 804 29 DNA Artificial SequencePTGER3EX8 116 804 gatttgtcct ttccygccat gtcttcatc 29 805 29 DNAArtificial Sequence PTGER3EX9 16 805 tgcctatcac ataayaggag aaccctgca 29806 29 DNA Artificial Sequence RENEX1 80 806 ggaagcatgg atggwtggagaaggatgcc 29 807 29 DNA Artificial Sequence RENEX2 135 807 atgaagaggctgacmcttgg caacaccac 29 808 29 DNA Artificial Sequence RENEX4 151 808gacatcatca ccgtragttg ggccgccct 29 809 29 DNA Artificial Sequence RENEX4165 809 aagttgggcc gccckaggtc atctgcccc 29 810 29 DNA ArtificialSequence RENEX9 138 810 ttcaggtgag gttcragtcg gccccctcg 29 811 29 DNAArtificial Sequence SAEX1 167 811 gttttgggcc agtcytgctc ctccggatt 29 81229 DNA Artificial Sequence SAEX1 76 812 attacctgta agagkaaccg ctgggagtc29 813 29 DNA Artificial Sequence SAEX11 143 813 agagcagatg atgtyatattatcctctgg 29 814 29 DNA Artificial Sequence SAEX2 54 814 ctctgtgcaaatccygagtg ctaaagctt 29 815 29 DNA Artificial Sequence SAEX3 109 815gagttttgag gaacygggat ctctgtcca 29 816 29 DNA Artificial Sequence SAEX4187 816 cactccaagc tgatygtatc agagaactc 29 817 29 DNA ArtificialSequence SAEX5 182 817 tggaaggtat acttycacaa aagtgcagc 29 818 29 DNAArtificial Sequence SAEX8 111 818 aaatggagaa acaasacggg cctggatat 29 81929 DNA Artificial Sequence SAEX9 101 819 ccttctcctg ctttygatgt taaggtttg29 820 29 DNA Artificial Sequence SCNN1GEX1 167 820 ggtggcccaggaagrcgcag cgcggccgg 29 821 29 DNA Artificial Sequence SCNN1GEX1 236 821tgaagtcgtg gccckctccg ggcggtctc 29 822 29 DNA Artificial SequenceSCNN1GEX1 498 822 tggagcggat gccgrgcgcc agggcgtcg 29 823 29 DNAArtificial Sequence SCNN1GEX1 552 823 gagccagcat cagcsggtgg cggcttccc 29824 29 DNA Artificial Sequence SCNN1GEX1 553 824 agccagcatc agccrgtggcggcttcccg 29 825 29 DNA Artificial Sequence SCNN1GEX12 1016 825agatcagagt gccgwggtgg aggtctggg 29 826 29 DNA Artificial SequenceSCNN1GEX12 1085 826 caggagatgg atttrgttat tcaattttg 29 827 29 DNAArtificial Sequence SCNN1GEX12 407 827 atgctggatg agctstgagg cagggttga29 828 29 DNA Artificial Sequence SCNN1GEX12 454 828 gaccaccagccatgktctaa ggacatgga 29 829 29 DNA Artificial Sequence SCNN1GEX12 485829 gggtgccccc agacrtgtgc acaggggac 29 830 29 DNA Artificial SequenceSCNN1GEX12 569 830 cgcaagatgg ggcckgggca tgcgcagga 29 831 29 DNAArtificial Sequence SCNN1GEX12 646 831 ataaatcccg ggacytgaac tattagcac29 832 29 DNA Artificial Sequence SCNN1GEX12 678 832 actagagactgggarccgag gcagtggtg 29 833 29 DNA Artificial Sequence SCNN1GEX12 982833 gagaactggc ccagrgccct tggagtgtt 29 834 29 DNA Artificial SequenceSCNN1GEX2 219 834 tcgtggtgtc ccgckgccgt ctgcgccgc 29 835 29 DNAArtificial Sequence SCNN1GEX2 26 835 tcttctttgc ccctscagca cgcccgtcc 29836 29 DNA Artificial Sequence SCNN1GEX2 43 836 gcacgcccgt cctcrgagtcccgtcctca 29 837 29 DNA Artificial Sequence SCNN1GEX3 186 837 ttctcccaccggatyccgct gctgatctt 29 838 29 DNA Artificial Sequence SCNN1GEX3 259 838ggaagcggaa agtcrgcggt agcatcatt 29 839 29 DNA Artificial SequenceSCNN1GEX3 261 839 aagcggaaag tcggyggtag catcattca 29 840 29 DNAArtificial Sequence SCNN1GEX3 301 840 atgtcatgca catcragtcc aagcaagtg 29841 29 DNA Artificial Sequence SCNN1GEX3 99 841 ctgaagtccc tgtayggctttccagagtc 29 842 29 DNA Artificial Sequence SCNN1GEX4 47 842 tcaaatgacacctcygactg tgccaccta 29 843 29 DNA Artificial Sequence SCNN1GEX7 142 843ggtaacagat tggcrggggc acccagccc 29 844 29 DNA Artificial SequenceTBXA2REX1 518 844 gctgggcccg ccccwggtca cagccagac 29 845 29 DNAArtificial Sequence TBXA2REX1B 130 845 ctcagcctcc cgagyagctg ggattacag29 846 29 DNA Artificial Sequence TBXA2REX2 292 846 tcctcaccttcctcwgcggc ctcgtcctc 29 847 29 DNA Artificial Sequence TBXA2REX2 329 847cctggggctg ctggwgaccg gtaccatcg 29 848 29 DNA Artificial SequenceTBXA2REX2 333 848 gggctgctgg tgacyggtac catcgtggt 29 849 29 DNAArtificial Sequence TBXA2REX2 371 849 cgccgcgctc ttcgwgtggc acgccgtgg 29850 29 DNA Artificial Sequence TBXA2REX2 390 850 cacgccgtgg acccwggctgccgtctctg 29 851 29 DNA Artificial Sequence TBXA2REX2 525 851 ccggcggtcgcctcrcagcg ccgcgcctg 29 852 29 DNA Artificial Sequence TBXA2REX2 568 852tggtgtgggc ggccrcgctg gcgctgggc 29 853 29 DNA Artificial SequenceTBXA2REX2 617 853 gggtcgctac accgwgcaat acccggggt 29 854 29 DNAArtificial Sequence TBXA2REX2 739 854 tcctgctgaa cacgrtcagc gtggccacc 29855 29 DNA Artificial Sequence TBXA2REX2 852 855 atcatggtgg tggcmagcgtgtgttggct 29 856 29 DNA Artificial Sequence TBXA2REX3 145 856 gacccctgggtgtayatcct gttccgccg 29 857 29 DNA Artificial Sequence TBXA2REX3 358 857ggggtgctgg atggrcagtg ggcatcagc 29 858 29 DNA Artificial SequenceTBXA2REX3 528 858 aagggcatgc agacrttgga agagggtct 29 859 29 DNAArtificial Sequence TBXA2REX3 599 859 cccaggctgg agtgyagtgg cgcaatctc 29860 29 DNA Artificial Sequence TBXA2REX3 701 860 ggcgcgcgcc accaygcccggctaatttt 29 861 29 DNA Artificial Sequence TBXA2REX3 904 861 tggagtacagtggcrcgatc tcggctcac 29 862 29 DNA Artificial Sequence TBXA2REX3 906 862gagtacagtg gcacratctc ggctcactg 29 863 29 DNA Artificial SequenceTBXA2REX3 953 863 ttcaagcgat tctcstgcct cagcctccc 29 864 29 DNAArtificial Sequence TBXASEX10 61 864 cagcctcgag gaagkcctgc cctatctgg 29865 29 DNA Artificial Sequence TBXASEX10 98 865 attgcagaga cgctraggatgtacccgcc 29 866 29 DNA Artificial Sequence TBXASEX11 105 866 gtgctagagatggcygtggg tgccctgca 29 867 29 DNA Artificial Sequence TBXASEX11 152 867gccaagcccg gagamcttca accctgaaa 29 868 29 DNA Artificial SequenceTBXASEX11 49 868 cacgggaggc agctsaggac tgcgaggtg 29 869 29 DNAArtificial Sequence TBXASEX11 73 869 aggtgctggg gcagygcatc cccgcaggc 29870 29 DNA Artificial Sequence TBXASEX11 88 870 gcatccccgc aggcrctgtgctagagatg 29 871 29 DNA Artificial Sequence TBXASEX12 46 871 tcacggctgaggccmggcag cagcaccgg 29 872 29 DNA Artificial Sequence TBXASEX13 226 872cctggcatgc aaggrtaaga ggttctttt 29 873 29 DNA Artificial SequenceTBXASEX4 130 873 ccaacagaat ggtaygtagt tttctttcc 29 874 29 DNAArtificial Sequence TBXASEX5 15 874 ctgaccctct gcttrttact tcccaacag 29875 29 DNA Artificial Sequence TBXASEX6 59 875 agccaagcct gcgamcttctcctggctca 29 876 29 DNA Artificial Sequence TBXASEX8 110 876 atggcttttttaacraactc attaggaat 29 877 29 DNA Artificial Sequence TBXASEX8 119 877ttaacaaact cattrggaat gtgattgcc 29 878 29 DNA Artificial SequenceTBXASEX9 156 878 cgaacccttc ccggmaacac cagcccagc 29 879 29 DNAArtificial Sequence TBXASEX9 276 879 cttttgccac ctacstactg gccaccaac 29880 29 DNA Artificial Sequence TRHREX1 56 880 ttctgcagaa cttasatgataagcaacga 29 881 29 DNA Artificial Sequence TRHREX1 84 881 acaaagccagctgcytctag acccctggc 29 882 29 DNA Artificial Sequence TRHREX2 147 882gtcagtgaac tgaamcaaac acagcttca 29 883 29 DNA Artificial SequenceTRHREX2 240 883 ggcctgggca ttgtrggcaa catcatggt 29 884 29 DNA ArtificialSequence TRHREX3 1161 884 tcccacatga tgggyggaaa aaggcaaaa 29 885 29 DNAArtificial Sequence TRHREX3 1231 885 ttaaatttga aaagyatagt caagacaaa 29886 29 DNA Artificial Sequence TRHREX3 1540 886 ttcttttttt gtttwtctcaaatgctagt 29 887 29 DNA Artificial Sequence TRHREX3 1786 887 gaatctccgagggcwaaaat tgcccttgg 29 888 29 DNA Artificial Sequence TRHREX3 1846 888gtagatcaaa aaagyaccca tacctttac 29 889 29 DNA Artificial SequenceTRHREX3 2046 889 cctcattcta gagtrcgctt ttttttttt 29 890 29 DNAArtificial Sequence TRHREX3 2175 890 acctgcatga cagtragcaa tctatgtta 29891 29 DNA Artificial Sequence TRHREX3 2283 891 acaagcacat gtgtrtttataaacacata 29 892 29 DNA Artificial Sequence TRHREX3 377 892 gccacaaaagtgtcytttga tgacacctg 29 893 29 DNA Artificial Sequence TRHREX3 960 893taagatttta gacayacatg ttaactgta 29 894 29 DNA Artificial SequenceACEEX13 138 894 cctctgctgg tcccyagcca ggaggcatc 29 895 29 DNA ArtificialSequence ACEEX17 52 895 aatgtgatgg ccacrtcccg gaaatatga 29 896 29 DNAArtificial Sequence ADRB3EX1 416 896 tcgtggccat cgccyggact ccgagactc 29897 29 DNA Artificial Sequence AGTEX2 644 897 gctgctgctg tccayggtggtgggcgtgt 29 898 29 DNA Artificial Sequence AGTEX2 827 898 tggctgctccctgaygggag ccagtgtgg 29 899 29 DNA Artificial Sequence AGTEXP1 173 899tgcttgtgtg ttttycccag tgtctatta 29 900 29 DNA Artificial SequenceAGTEXP2 203 900 ctcgaccctg caccrgctca ctctgttca 29 901 29 DNA ArtificialSequence AGTEXP3 144 901 gctataaata gggcmtcgtg acccggcca 29 902 29 DNAArtificial Sequence ANPEX3 120 902 gtctctgctg cattygtgtc atcttgttg 29903 29 DNA Artificial Sequence ANPEX3 33 903 tctctttgca gtacygaagataacagcca 29 904 29 DNA Artificial Sequence AT1EX5 1138 904 aagaagcctgcaccrtgttt tgaggttga 29 905 29 DNA Artificial Sequence AT1EX5 1593 905aaagttttcg tgcckgtttt cagctatta 29 906 29 DNA Artificial Sequence AT1EX5649 906 caaaattcaa ccctyccgat agggctggg 29 907 29 DNA ArtificialSequence MRLEX2 1504 907 caagaaccag atgaygggag ctattaccc 29 908 29 DNAArtificial Sequence MRLEX2 545 908 gcgtcatgcg cgccrttgtt aaaagccct 29909 29 DNA Artificial Sequence NCX1EX12 3101 909 actcattttt tagcwgtattaggaatgtc 29

What is claimed is:
 1. A nucleic acid of between 10 and 100 basescomprising at least 10 contiguous nucleotides including a polymorphicsite from a sequence shown in Table 1, column 8 or the complementthereof, wherein the sequence is selected from the group consisting ofSEQ ID NOS: 2, 3, 4, 13, 15, 16, 20, 21, 25, and
 26. 2. The nucleic acidof claim 1 that is DNA.
 3. The nucleic acid of claim 1 that is RNA. 4.The nucleic acid of claim 1 that is less than 50 bases.
 5. The nucleicacid of claim 1 that is less than 20 bases.
 6. The nucleic acid of claim1, wherein the polymorphic form occupying the polymorphic site is areference base shown in Table 1, column
 3. 7. The nucleic acid of claim1, wherein the polymorphic form occupying the polymorphic site is analternative base shown in Table 1, column
 5. 8. The nucleic acid ofclaim 7, wherein the alternative base correlates with hypertension orsusceptibility thereto.
 9. The nucleic acid of claim 1, which is from agene encoding alpha-adducin.
 10. The nucleic acid of claim 1, which isfrom a gene encoding an angiotensin converting protein.
 11. Anallele-specific oligonucleotide of no more than 100 bases thathybridizes to a sequence including a polymorphic site shown in Table 1or the complement thereof, wherein the sequence is selected from thegroup consisting of SEQ ID NOS: 2, 3, 4, 13, 15, 16, 20, 21, 25, and 26.12. The allele-specific oligonucleotide of claim 11 that is a probe. 13.An isolated nucleic acid comprising a sequence of Table 1, column 8 orthe complement thereof, wherein the polymorphic site within the sequenceor its complement is occupied by a base other than the reference baseshown in Table 1, column 3, and wherein the sequence is selected fromthe group consisting of SEQ ID NOS: 2, 3, 4, 13, 15, 16, 20, 21, 25, and26.